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Abstract 
Eve Bunni 
Differences in Phenotypic Features and Hormone Responsiveness between Healthy 
Eutopic Endometrium and Tubal Epithelium in Women– Functional Relevance in 
Gynaecological Disease. 
Introduction: We recently reported a unique phenotypic profile for the epithelial 
cells of the basalis compartment of the human endometrium, from where the 
functionalis is regenerated after menstrual shedding. As the human fallopian tube 
shares the same embryonic origin as the uterus and has the capacity to undergo 
changes according to the menstrual cycle including regeneration, we wondered 
whether this unique phenotype was shared with the fallopian tube.  Recently it has 
been thought that the distal fallopian tubal mucosa may also contain a stem cell 
population - it was found that cells were expressing markers that were known to be 
stem cell markers in other tissues.  This suggested that the distal mucosa may be 
equivalent to the stem-cell rich stratum basalis of the endometrium.  Endometrial 
expression of steroid receptors vary throughout the menstrual cycle in response to 
the fluctuating steroid hormones in the circulation.  Although some evidence exists 
on steroid receptor presence in human fallopian tube, detailed examination of both 
the distal and proximal parts of the tube has not been studied.  Furthermore even 
though the androgen receptor has been identified in the human endometrium, the 
effect of androgens on fallopian tube and endometrial mucosa has not been studied 
to date. 
Aim: To examine the differential expression of phenotypic markers and hormone 
responsiveness between the endometrium and fallopian tubal epithelium in healthy 
women across the menstrual cycle and in the postmenopausal period. 
Methods: A prospective study examining 22 full-thickness endometrium and 
matched tubes for the basal endometrial epithelial markers (SOX9, SSEA1, nuclear 
β-Catenin, BCAM), Sialylated SSEA-1, Steroid receptors and the proliferative marker 
KI67 with immunohistochemistry and analysed using a modified-Quickscore. 
Secondary confirmation of data by RT-PCR.  Explant cultures of matched 
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endometrial and fallopian tube tissue (n=3) were treated with DHT for 24 hours and 
expression of SOX9, AR and Ki67 was assessed with IHC/RT-PCR. 
Main results: Trends were observed in the sample populations. The proliferative 
activity and phenotypic marker expression of distal tubal epithelium correlated with 
that of the endometrial basalis epithelium.  SSEA-1, SOX9 and cytoplasmic beta 
catenin increased after the menopause in both endometrial and fallopian tubal 
epithelia.  Steroid hormonal expression however, showed a unique pattern in tubal 
epithelial cells which may play a role in preventing cyclical regeneration in the tube.  
Proximal and distal portions of the tube had different responses to ER alpha and 
beta throughout the menstrual cycle indicating a unique function in the isthmic 
region of the tube in the premenopausal population. Short-term explant culture, 
DHT treatment up-regulated AR expression with an increase in KI67 in tubal 
epithelium, but no difference was observed in the matched endometrial epithelium.  
Increased AR and KI67 expression was observed in the endometrial stroma. 
Messenger-RNA expression of SOX9 was reduced after DHT treatment. IHC results 
were confirmed by RT-PCR.  
Conclusion: The Tubal Epithelium and Endometrial Mucosa share a phenotypic 
profile consistent with their shared embryonic origin.  Explant analysis suggests a 
unique role for androgens in the tube.  After menopause, it is evident that the tubal 
epithelia and endometrial glands exist as a continuum.  Proximal and distal tubal 
epithelia have different patterns of steroid receptor expression throughout the 
menstrual cycle suggesting a unique steroid hormone response in the proximal tube 
possibly separating these organs and preventing cyclical regeneration in the tube.  
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Chapter 1 Introduction 
 
The fallopian tube and endometrium derives from the same embryological origin.1 
Recent studies investigating endometrial mucosa have revealed that particular 
markers are strongly expressed in the basalis region of the endometrium.  The 
markers identified were SOX9, SSEA-1 and beta catenin.2  The presence of these 
markers has been identified in tissues with regenerative abilities with a 
subpopulation of progenitor cells residing in these regions.  It is thought that 
progenitor cells give the endometrium the capacity to regenerate and proliferate 
every month and can thus be found in the basalis region of the endometrium – the 
regenerative layer.3  Recently, it has been thought that the distal fallopian tubal 
mucosa may also contain a stem cell population.4  The characterisation of the 
epithelial layer of the fallopian tube is yet to be fully understood.   
Endometrium is the main target organ for ovarian steroid hormones. These 
hormones induce their effects on the endometrium via hormone receptors. The 
steroid hormone receptors are: Oestrogen receptor (ER), progesterone receptor 
(PR) and androgen receptor (AR). Endometrial expression of the steroid hormone 
receptors has been investigated in some detail.  Expression of the steroid receptors 
vary throughout the menstrual cycle in response to the fluctuating steroid 
hormones in the circulation.   
Although the general consensus is that the steroid receptor expression in the 
endometrium is fully characterised, the existing evidence is very limited for the 
details of steroid receptor expression in functionally very different stratum basalis 
and functionalis, also no conclusive studies on comparisons of healthy pre and post-
menopausal endometrium. For these reasons, from the existing data, it is difficult to 
conclude on the normal pattern of steroid receptor expression in healthy human 
endometrium.  
Detailed examination of steroid receptor expression in both distal and proximal 
parts of the tube, across the menstrual cycle of premenopausal women and in 
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postmenopausal women, is yet to be compared with matched normal endometrial 
steroid receptor expression - to my knowledge has not been conclusively reported. 
Since steroid receptors regulate endometrial and possibly tubal function and their 
regenerative process hence are implicated in normal function and in many 
pathological conditions, understanding the above is of significant importance. This 
thesis therefore provides data, to fill these existing gaps in current knowledge and 
explore the similarities and differences in the expression of a panel of phenotypical 
markers and steroid receptors between the endometrium and tubal epithelium 
examining their differential response to one of the ovarian hormones, androgen. 
1.1 Structure and function of human uterus, endometrium and 
fallopian tube. 
1.1.1 Macroscopic structure of the female reproductive system. 
The female reproductive system is divided into the internal and external genitalia.  
The internal genitalia are those that are within the true pelvis.  The external 
genitalia are found outside of the true pelvis.5 
Table 1-1 – Table of the different organs in the female reproductive system 
Internal Genitalia External Genitalia 
Vagina Perineum 
Cervix Mons Pubis 
Uterus  Clitoris 
Fallopian tubes (Right and left). Urethral Meatus 
Ovaries Labia Majora 
 Labia Minora 
 Vestibule 
 Vestibular Bulbs 
 Bartholin’s Glands 
 Skene Glands 
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Figure 1-1 - The external genitalia6 
1.1.1.1 The Vagina 
The vagina connects the cervix to the outside environment.  It is a muscular tube of 
approximately 6.5-7cm in length anteriorly and 9cm posteriorly.  It is situated 
anterior to the rectum and posterior to the urinary bladder. The vagina is lined with 
mucosal folds called rugae.  In-between a layer of erectile tissue can be found with 
a large venous plexus within it.  The vaginal portion of the cervix is found towards 
the apex of the vagina.  It protrudes into the vagina leaving a recess surrounding it 
called the anterior, posterior and lateral fornices.7 The vaginal arteries supply the 
vagina; these branch off the internal iliac artery. 
 Its function is a reservoir for sperm; to facilitate their ascent towards the uterus 
and up towards the fallopian tubes to fertilise an oocyte.  It is also the canal in 
which the neonate descends during labour and delivery. 
1.1.1.2 The Cervix 
This is the most inferior portion of the uterus separating the vagina from the uterus.  
There is an opening to allow sperm to enter the cervical canal called the external os.  
The sperm exit the canal, into the uterine cavity via the internal os.  Branches of the 
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descending uterine arteries supply the cervix.  The nerve supply to the cervix is via 
the parasympathetic nervous system (S2-S4).  Lymphatic drainage is complex.1 
1.1.1.3 The Uterus 
The uterus is a pear-shaped, hollow, muscular organ lying between the urinary 
bladder and the rectum.  It begins with the cervix most inferiorly then becomes the 
body; in which the blastocyst implants.  Superiorly the fallopian tubes project 
laterally either side of the organ – the lumen is continuous with the endometrial 
lining.  The fallopian tubes, most distally, then open adjacently to the ovaries in the 
peritoneal cavity.  The uterus expands enormously during the pregnant-state of the 
female.8  The uterine arteries supply the main body of the uterus.  As they enter the 
myometrium they branch to become the arcuate arteries.  They then branch further 
as they enter the endometrial layer, becoming the spiral arteries.  The venous 
system usually runs below the arteries.  The nervous system supplying the body of 
the uterus is via sympathetic nerve fibres originating from thoracic vertebrae 11 
and 12 (T11, 12).  Lymphatic drainage eventually drains into the internal iliac, 
external iliac and sacral groups.9 
1.1.1.4 The Fallopian Tubes 
The fallopian tubes (also referred to as; uterine tubes and oviducts) exit the uterus 
bilaterally via the cornua and are considered a link between the endometrium and 
the peritoneal cavity.  There are three parts to the tube each believed to have 
different, important roles.  The most proximal part is named the Isthmus.  This is 
thought to be a reservoir for sperm as they enter the oviduct.10  The middle part is 
called the Ampulla.  This is the main site of fertilisation.  The most distal part of the 
fallopian tube is called the Infundibulum where finger-like projections called 
fimbriae can be found.  These fimbriae receive the oocyte that is released during 
ovulation from the ovary.   The arterial supply to the fallopian tube originates from 
the ovarian and uterine arteries.  The nerve supply comes from thoracic and lumbar 
vertebrae (T11-L1) via sympathetic and parasympathetic fibres.11 Lymphatic 
drainage is into to the external iliac and lateral aortic nodes.12  The main function of 
the fallopian tube is to facilitate fertilisation by promoting contact between the 
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sperm and the oocyte.  After successful fertilisation, the fallopian tube enables the 
transport of the fertilised zygote toward the endometrium for subsequent 
implantation. 
1.1.1.5 The Ovaries 
 
The ovaries are approximately 3-5cm in length.  They are located either side of the 
uterus and lie within the ovarian fossa.  The ovarian fossa is a shallow depression 
encased by the external iliac arteries superiorly, the obliterated umbilical artery 
anteriorly, and posterior is the ureter.13  The ovaries are held within the broad 
ligament which also covers the anterior aspect of the uterus.  The ovaries have an 
uneven surface and contain 1-3 million immature oocytes, of which only 0.01% will 
mature and be released at ovulation.  The main purpose of the ovary is to house the 
ova so that under the influence of pituitary hormones FSH and LH, a follicle can 
develop and an oocyte can mature and be released for the purpose of fertilising 
with a spermatozoa. During the menstrual cycle the ovary produces steroid 
hormones; oestrogen and progesterone (see 1.1.5 for full explanation).  The blood 
supply to the ovary is via the ovarian artery originating directly from the descending 
aorta.  The venous drainage is slightly different in that the left ovarian vein empties 
into the left renal vein and the right ovarian vein drains directly into the vena cava.  
Lymphatic drainage is into the aortic nodes as well as some of the iliac nodes.  The 
nerve supply is via the ovarian, hypogastric and aortic plexuses and runs with the 
vessels into the hilum of the ovary in the suspensory ligament.   
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Figure 1-2 - The female reproductive system14 
 
1.1.2 Histology of The Uterus 
The uterus has three layers: 
-  The endometrium 
- The myometrium 
- The perimetrium 
The endometrium or mucosa of the uterus is the innermost part of the uterus.  It is 
divided into two zones:  the functional layer (stratum funtionale) and the basal layer 
(stratum basale).  The functional layer proliferates and then sloughs off during 
menstruation.  The basal layer is thought to be the source of regeneration of the 
functional layer; it remains constant throughout the female menstrual cycle.  The 
endometrium builds up during the menstrual cycle to prepare for implantation of 
the blastocyst.  The endometrium is lined by simple columnar epithelium made up 
of a mixture of secretory and ciliated cells.  The endometrial tissue is made up of 
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stroma and glands. The glands are lined also by columnar epithelium. The stroma 
contains many cells and bears a resemblance to mesenchyme.   
The myometrium is a thick muscular layer in the uterus.  There is a thick middle 
layer consisting of smooth muscle bundles arranged in a circular and spiral pattern 
with large numbers of blood and lymphatic vessels running through it.  This layer is 
called the vascular layer (stratum vasculare).  The inner and outer layers 
surrounding this are also made up of smooth muscle bundles that run in parallel to 
the uterine axis.  These smooth muscle cells undergo massive hypertrophy in the 
pregnant-state.  They begin at 50 micrometres and enlarge to 500 micrometres.  
The myometrial fibres are arranged randomly for the very important reason that 
during uterine contraction, the layers of musculature can work together to expel 
material through the very narrow cervical lumen. 
The microvasculature of the endometrium is abundant.  The uterine artery divides 
into the arcuate arteries in the myometrium.  These further divide and become the 
radial arteries which then enter the basal layer of the endometrium - the radial 
arteries branch to become straight arteries supplying the stratum basale of the 
endometrium.  The radial arteries coil when they enter the functional layer and 
become the spiral arteries.  The spiral arteries anastomose and make a richly 
vascularised functional endometrium. 
The perimetrium is the peritoneal outer-lining of the uterus.  This becomes 
continuous with the abdominal peritoneum.  It is comprised of mesothelium, 
connective tissue and some elastic tissue.  The perimetrium covers the uterus 
posteriorly and partially anteriorly.15 
1.1.3 Histology of the Uterine Tube 
The fallopian tubes have three layers, histologically.  The innermost layer is the 
luminal epithelium, the middle layer is the muscularis layer and the outermost layer 
is the serosal layer.  Starting most distally, the infundibulum has a row of ciliated 
columnar epithelium coating the fimbriae.  This helps to capture the oocyte as it is 
released from the ovary and sweep it along the tube.  The ampulla has numerous 
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longitudinal folds with a layer of epithelial cells comprising of ciliated, secretory and 
peg cells that are claimed to be more abundant around day 14 of the menstrual 
cycle, the time of ovulation.16  The isthmus – the most proximal part, is small in 
diameter and an increased proportion of secretory cells are seen in the epithelium. 
The muscularis layer surrounding the epithelium gradually increases more 
proximally.  The smooth muscle layer is made up of circular, oblique and 
longitudinal fibres and is thought to be involved in the movement of the oocyte 
towards the uterus through regular peristaltic movements.  It is also thought that 
the infundibular muscular layer relaxes and distends towards the ovary to facilitate 
oocyte capture.  The outer layer, the serosa is made up of mesothelium and is 
continuous with the broad ligament.17 
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1.1.4 Embryology of the Fallopian Tube 
In the second month of embryologic development the genital tract begins to 
develop.  It begins with a pair of genital ducts: the mesonephric (Wolffian) ducts 
and paramesonephric (Mullerian) ducts. The Wolffian duct regresses and the 
mullerian ducts are what form the female reproductive tract.18  After meeting in the 
midline, the most superior part of the paramesonephric ducts are what form the 
fallopian tubes.19  These open into the coelomic cavity.  The caudal part of these 
ducts fuse together forming the uterus and upper vagina. Tissue lateral to the 
middle portion forms the broad ligament.20   
 
 
 
 
 
 
 
 
 
Figure 1-3 - Reproductive System Development Overview21 
 
1.1.5 The Human Menstrual Cycle 
The female menstrual cycle typically lasts 28 days.  It begins on the first day of a 
menstrual bleed, this process is termed menstruation.  Bleeding will slow and 
eventually stop after 3-7 days and proliferative/follicular phase will begin.  During 
this phase, the endometrial lining builds up or proliferates to create a hospitable 
environment for an embryo to implant.  Follicular growth occurs in the ovary in 
response to a rise in circulating gonadotrophin, FSH.  At around day 14 of the 
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menstrual cycle another phase begins, the ovulatory phase.  The follicle releases the 
matured oocyte into the fallopian tube ready to be fertilised by spermatozoa.  After 
follicular rupture, a corpus luteum remains hence marking the beginning of the 
luteal phase of the menstrual cycle.  The corpus luteal hormones help to maintain 
the endometrium for the arrival of the embryo.  If fertilisation does not take place, 
the corpus luteum breaks down and the lining of the uterus, no longer being 
maintained, is shed.  This marks the beginning of the next cycle.   
1.1.5.1 Hormonal regulation during the menstrual cycle  
Beginning in the follicular phase, follicle-stimulating hormone (FSH) is released by 
the anterior pituitary gland.  The rise in FSH levels causes the development of antral 
ovarian follicles.  It also causes proliferation of oestrogen-secreting granulosa cells 
and stimulates expression of luteinising hormone (LH) receptors.  As oestrogen 
levels inevitably rise, this stimulates release of gonadotropin-releasing hormone 
(GnRH).   GnRH increases the production of LH.  At this stage, LH stimulates 
proliferation and generation of follicular thecal cells and induces androgen synthesis 
by these cells. 
Serum oestrogen levels rise during this phase promoting growth and proliferation of 
the endometrium and myometrium in the uterus.  They also promote progesterone 
receptor production in preparation for the luteal phase.  2-3 days before the LH 
surge; one or occasionally two follicles emerge as dominant. Oestrogen levels then 
continue to rise from the follicle.  As well as causing endometrial changes, 
oestrogen stimulates mucus production in the crypts of the cervix.  This provides a 
less acidic and hence more hospitable environment for sperm in the vagina. 
Mid-cycle there is a surge in LH levels.  This causes completion of the first meiotic 
division of the oocyte.  About 30 hours after the beginning of the LH surge, 
ovulation occurs.  There is also a spike in FSH causing cumulus expansion just before 
ovulation.  After ovulation the corpus luteum is formed – this is stimulated by FSH 
and LH.  During the luteal phase of the cycle the main hormone that is produced by 
the corpus luteum is progesterone.  Progesterone plays a key role in making the 
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endometrium receptive to the implantation of the blastocyst.  It also causes a rise in 
basal body temperature. 
Oestrogen is also produced by the corpus luteum.  There is usually a “secondary 
oestrogen surge” a few days after ovulation, this can lower basal body temperature 
and create fertile cervical mucus. 
The corpus luteal hormones suppress production of LH and FSH.  The fall of these 
hormones causes the death of the corpus luteum.  With the death of the corpus 
luteum, levels of progesterone and oestrogen fall.  The subsequent lack of 
suppression of the pituitary hormones (LH and FSH) causes a rise in FSH levels 
stimulating follicular growth – the next cycle begins. 
In the event of fertilisation and implantation – the embryo produces human 
chorionic gonadotropin (hCG).   This hormone is structurally similar to LH.  With 
that, hCG can maintain the corpus luteum and prevent its breakdown.  The corpus 
luteum will then continue to produce progesterone for up to 12 weeks, until the 
placenta functionally takes over. 
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Figure 1-4 - The Human Menstrual Cycle22 
1.1.5.2 Histological Change throughout the Menstrual Cycle 
It is known that the endometrium undergoes typical histological changes 
throughout the menstrual cycle.  In the early proliferative phase, endometrial 
glands are small and straight.  During the late proliferative phase; the glands of the 
endometrium are described as adopting a “tortuous” appearance owing to the fact 
that they are undergoing considerable proliferation.  The functional endometrial 
layer is typically thin, glands are short and stroma is tight and compact.  Towards 
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the end of the proliferative phase the glands become longer with 
pseudostratification and the functionalis layer increases in size. 
 
Around the ovulatory phase it has been calculated that 50% of glands contain 
subnuclear vacuoles.   
 
During the secretory phase the functionalis layer ceases to proliferate and begins its 
secretory activity.  This layer is thick and full of long coiled glands.  There are greater 
than 50% subnuclear vacuoles seen during this phase and arterioles thicken.  As the 
menstrual phase approaches, shedding of the functional layer occurs.  Micrographic 
images show glandular and stromal breakdown with necrosis and haemorrhage. 
23   
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Figure 1-5 - Structural changes throughout the menstrual cycle24 
 
1.1.6 The Human Menopause 
In women approximately aged 51 years, their menstrual periods typically become 
irregular and eventually cease. This is due to ovarian shutdown. This phase of a 
female’s life is commonly called the menopause.  Ovulation stops and mature 
oocytes are no longer released from developing follicles.  Concentrations of ovarian 
steroid hormones fall causing a rise in pituitary hormones, LH and FSH due to the 
loss of negative feedback.  Post-menopause, androgens continue to be produced by 
the adrenal gland at low levels.  Oestrogens are subsequently synthesised by the 
aromatisation of androgens by adipocytes.25  The histological pattern of the normal 
postmenopausal endometrium has been described as atrophic.  This indicates that 
there is a thin endometrium with scarce glands and an inactive phenotype.  The 
blood supply is low, with capillaries bearing no resemblance to spiral arteries. It is 
also very common for postmenopausal females to have endometrium that appears 
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to have a cystic glandular appearance.  The glands are dilated and the epithelial 
cells are flattened with loose surrounding stroma.  In a study by McBride J, 
Histological examination of 206 postmenopausal endometrial specimens showed 
that the largest proportion of females had an inactive cystic glandular pattern with 
a single polyp; closely followed by atrophic-type endometrium.26  In a study on post-
menopausal fallopian tubes transmission and scanning electron microscopy 
evaluation described fallopian tube epithelial cell structure and change over the 
peri-menopausal and post-menopausal period.  They reported fused microvilli, 
microplicae-like structures developing over time and low mitotic activity of cells.  
They also concluded that the epithelium becomes more non-secretory in nature.27 
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1.2 The Reproductive Steroid Receptors 
The steroid hormone receptors are transcription factors affecting cellular 
proliferation and differentiation in specific tissues.28  Steroid receptors have been 
studied in great detail in human endometrial tissue but there is only a small amount 
of evidence about the presence of these in human fallopian tubes; the functional 
relevance of the presence of these receptors remains unclear. 
1.2.1 Androgen Receptor 
The androgen receptor (or AR) mediates the physiological effects of androgens.  The 
AR gene is located on chromosome Xq 11-12.  By binding to certain DNA sequences; 
it activates transcription of androgen-responsive genes. The androgen hormone 
usually binds in the cytoplasm and translocates to the nucleus.  It has been said to 
be most closely related to the progesterone receptor.29     
1.2.1.1 Androgen Receptor in the Endometrium 
Expression of AR is present in normal human endometrium.  Although there has 
been detection of this receptor there is conflicting evidence.  Some studies suggest 
that there is cyclical changes throughout showing a particularly high stromal 
expression during the proliferative phase.  Other studies suggest that androgen 
receptor expression remains relatively constant throughout.30  Various studies have 
reported that the androgen receptor is localised predominantly to the stromal cells 
of the endometrium (barely detectable in the glands), with an abundance of 
receptor expression during the proliferative, early and mid-secretory phases.31  
After the menopause, AR persists in the stromal nuclei.32 In females total and free 
testosterone and androstenedione have a mid-cycle peak and are relatively higher 
during the luteal phase.33   The high AR expression in the secretory phase reflects 
the circulating levels of androgens suggesting that the androgen receptor is up-
regulated in the presence of free androgens.   
1.2.1.2 Androgen Receptor in the Fallopian Tube 
There is very little evidence on the expression of this receptor in human fallopian 
tubes, an article in 2010 mentions the expression of this receptor in benign and 
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malignant fallopian tube samples and states that it is mostly nuclear.  Normal 
fallopian tube samples were analysed to compare to a population with epithelial 
ovarian carcinoma (EOC).  The authors claimed that a reduction in AR expression 
was observed in EOC cases. 34 This however, was not compared to endometrium.  
Cyclical changes in expression in premenopausal women were not evaluated and 
neither was postmenopausal expression of AR. 
 
 
Figure 1-6 - Steroidogenesis in the ovaries, adrenal glands and peripheral tissue related to female sexual function.35 
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1.2.2 Progesterone Receptor 
The physiological effects of progesterone are mediated through its interaction 
with the progesterone receptor.  The progesterone receptor has two isoforms 
progesterone receptor-A (PR-A) and progesterone receptor-B (PR-B). They are 
both derived from the same gene. The genes controlled by PR have a role in cell 
cycle control.  They moderate transcription of genes that regulate the cell cycle.36 
Since their discovery, extensive controversy exists around the contribution of each 
of the receptors to the physiological function of progesterone.37  Progesterone 
receptors are known to be present in the endometrium.  Evidence exists that 
shows that there are indirect (paracrine) and direct (endocrine) routes of action of 
progesterone on the endometrium.38  Progesterone plays a vital role in the human 
endometrium.  The endometrium is most receptive to embryo implantation 
around days 20-24 – this is normally the time when serum levels of progesterone 
are at a peak.  If the corpus luteum does not detect chorionic gonadotrophin (CG) 
from an embryo after fertilisation; programmed cell death occurs of the corpus 
luteum and eventually the endometrium, leading to menstruation.  It is also 
known that the removal of the corpus luteum less than 5 weeks after implantation 
causes loss of pregnancy due to early decline of progesterone levels.39  
1.2.2.1 Progesterone Receptor in the endometrium 
A review in 2003 by Lessey, looks at the two pathways of progesterone in human 
endometrium.  The author comments on the evidence that progesterone 
receptors vary throughout the menstrual cycle. The receptor can be found in the 
glandular epithelia and stromal compartments of the endometrium.  Epithelial 
expression tends to be higher in the proliferative phase and reduced around the 
mid-secretory phase – which is usually the optimum time of implantation.  Stromal 
expression remains constant throughout however.40  The two different pathways 
involve a direct epithelial endocrine pathway or an indirect paracrine pathway 
involving the stromal compartment inducing specific gene products.  This evidence 
comes from a study that suggests that heparin-binding EGF could be one of the 
paracrine factors induced by progesterone in stroma; other proteins in the 
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endometrium rely on HB-EGF for their stimulation, like the beta 3 integrin subunit.  
They concluded that progesterone has two functions on the endometrium; one of 
stimulating stromal paracrine factors and the other of inhibiting oestrogen and 
progesterone receptors.41 
1.2.2.2 Progesterone Receptor in the Fallopian Tube 
More recently, evidence has shown the presence of this receptor in human 
fallopian tube.  In a study by Shao et al., using immunofluorescence imaging, they 
revealed the presence of both PR A and B in the nuclei of fallopian tubal epithelia.  
The authors also discovered that both receptors were low in the mid-secretory 
phase of the menstrual cycle consistent with studies of the endometrium.42  
Another study by Horne et al. also described the presence of both PR A and B in 
the nuclei of the fallopian tube cells and showed reduced mRNA expression of PR 
A and B in the secretory phase – consistent with the previous study.  In addition, 
they found that in vitro treatment with progesterone caused down regulation of 
both receptors.43 
1.2.3 Oestrogen Receptor 
Oestrogen controls many cellular processes in the female reproductive system.  Its 
main targets are ovaries, uterus, vagina and mammary glands.  It is also 
responsible for the growth and maintenance of the skeleton.  Most of oestrogen’s 
actions are carried out through binding to the oestrogen receptors.  These 
receptors are known to be ligand-binding transcription factors.  To date, two 
oestrogen receptors are known; oestrogen receptor alpha and beta:  
1.2.3.1 Oestrogen Receptor Alpha 
This receptor is a nuclear hormone receptor.  Oestradiol (E2) and its receptors are 
involved in gene expression which have an effect on proliferation and 
differentiation in tissues.  Nuclear transactivation is ligand- dependent with either 
direct homodimer bonding to a palindromic oestrogen response element (ERE) 
sequence or interactions with other DNA-binding transcription factors.44 The ESR1 
gene encodes for this protein. 
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1.2.3.2 Oestrogen Receptor Beta 
This receptor has a similar affinity to oestrogen receptor alpha and can form a 
heterodimer with oestrogen receptor alpha.  This receptor is similar in the DNA and 
ligand binding domains however differs in the N-terminal transactivation domain. 
The ESR2 gene encodes for this receptor.  Isoforms Beta-1 and 2 are expressed in 
the ovary and at a lower level in the uterus.  Beta-3 is not present in the female 
reproductive tract.  Beta-4 is expressed at a low level in the ovary and uterus and 
Beta-5 has low expression in the uterus.45 
1.2.3.3 Oestrogen Receptors in the endometrium 
After the discovery of oestrogen receptor beta (ER Beta) studies looked into the 
presence of this and the ER alpha in human endometrium and any cyclical changes 
in its expression to indicate its functional relevance.  A study in 1999 by Matsuzaki 
et al. looked at mRNA expression particularly. They discovered that there was 
mRNA expression in all uterine cell types including the glandular epithelial cells and 
stromal cells of the endometrium.  They found that ER alpha was expressed more 
prominently throughout the menstrual cycle than ER beta.  They also found that ER 
beta protein expression is predominantly glandular in the proliferative phase 
whereas ER alpha is expressed in both glands and stroma.  They also noted that 
both receptors are weaker during the secretory phase.  The conclusions drawn from 
the findings suggest that oestrogenic effects occur mostly through ER alpha; 
however ER beta will play a role in this particularly in glandular epithelial cells 
throughout the menstrual cycle.46  Another study by Brandenburger et al. found 
that these receptors upregulate the progesterone receptor.  The oestrogen 
receptors are also present in endometrioma tissue.47  A study in 2000 by Taylor et 
al. attempted to immunolocalise ER beta in many human tissues.  The authors 
reported the presence of ER alpha and beta in endometrial tissue and fallopian 
tubal epithelia.  Interestingly they reported a very low if not negligible expression of 
ER beta in the nuclei of glandular epithelia but presence within the cytoplasm of 
some of these cells. Stromal and luminal nuclei were positive for ER beta.  This lack 
of ER Beta in the glandular epithelia could have been as a result of the samples 
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being in late secretory phase of the menstrual cycle, which would then support the 
previous evidence.  ER Beta expression in the fallopian tube seemed to be 
particularly strong in the nuclei of epithelial cells48 Moderate oestrogen receptor 
expression was observed in an immunohistochemical study in 1992 in the glandular 
epithelia and stroma of postmenopausal women.  This study did not distinguish 
between ER-alpha and beta, however.49 
1.2.3.4 Oestrogen Receptors in the Fallopian Tube 
The presence of ER alpha and beta in the fallopian tube has been confirmed by Shao 
et al.  Both receptors are most abundant during the secretory phase of the 
menstrual cycle, according to this study.  ER alpha was found in the lamina propria 
whereas beta was not.42 Horne et al.  Found that ER alpha was down regulated in 
vitro with treatment of progesterone.  This conflicts with evidence from the former 
study because the author claims that the ER are most abundant during the 
secretory phase when progesterone is higher.43  More research is necessary to 
confirm the ER status throughout the menstrual cycle.  Another study by Shao et al. 
found that ER beta was mainly found in the ciliated cells of the fallopian tube in 
rodents – confirmation in humans would need human tissue samples to be tested.50 
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1.3 Stem Cells 
Stem cells are unspecialised cells that are capable of self-renewal even after long 
periods of quiescence.  There are two umbrella terms for stem cells: embryonic 
stem cells and somatic (adult) stem cells.  Embryonic stem cells are derived from 
the embryo from a fertilised ovum.  A somatic stem cell is an undifferentiated cell 
found amongst differentiated cells in an organ.  Somatic stem cells have the ability 
to divide (by mitosis) and differentiate into mature cell types that have specialised 
functions in tissues and organs. They provide a repair mechanism for the body and 
replenish tissues.51  The differentiation capacity of a stem cell is called its potency: 
Totipotency – a stem cell that can differentiate into embryonic and extra-embryonic 
cell types.  These have the ability to create an organism.  These cells are created 
after the fusion of a sperm and an egg up until the first few divisions.52 
Pluripotency- these stem cells have the ability to divide into almost all cells i.e. 
these are derived from the three germ layers. 
Multipotency – stem cells that can differentiate into a closely related cell types. 
Oligopotency – can differentiate into a few cell types. 
Unipotency – can produce their own one cell type and self-renew.53 
1.3.1 Identifying the side population cells and Fluorescence Activated Cell 
Sorting (FACS)  
As described previously, it has been suggested that progenitor cells can be 
identified in the basalis layer of human endometrium and distal fallopian tube but a 
specific marker for identifying these is yet to be found.  One way of identifying 
potential progenitor cells from differentiated somatic cells (i.e. the undifferentiated 
proportion of cells) in a tissue is to perform side population analysis.54  The side 
population is a proportion of cells that that show different characteristics to the 
main population for example; stem-like properties.  They are identified by particular 
markers that demonstrate their phenotype. 
Hoechst side population analysis is a flow cytometry technique to identify 
undifferentiated cells in a variety of tissues.  After the tissue is digested, cells are 
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sorted and suspended in a single cell suspension; Hoechst 33342 DNA dye is added 
to this to be taken up by live cells.  ATP-Binding Cassette (ABC) transporters are 
present in stem and early progenitor cells and they are able to pump this DNA dye 
out of the cell.  This is unlike differentiated cells which incorporate the dye into 
their DNA.  This can be analysed using a flow cytometer with a UV laser.  A minor 
cell population is observed with low fluorescence (the side population) due to the 
ABCG2 transporters pumping the dye out of the cell and a large proportion of 
differentiated cells retain the dye, resulting in a bright fluorescent signal. 
Confirmation of identification of the side population can be achieved by incubation 
of an inhibitor of the ABC pump (e.g. verapamil). After Hoechst is introduced, the 
side population phenotype is lost due to pump inhibition and this confirms the 
presence of these cells – this can be used as the control for this technique.55  
 
Figure 1-7 - Side Population Analysis and Sorting55 
Once the side population is identified immunocytochemistry can be performed to 
analyse the phenotype of these cells in comparison to the non-side population cells. 
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1.4 The Fallopian Tube and The Endometrium 
1.4.1 Stem-like Cells in the distal reproductive tract 
It is known that the embryological origin of the fallopian tube and the endometrium 
is the same.1 Like the basalis endometrium, recent evidence in the last few years 
has revealed the presence of stem-like cells in the distal fallopian tube, with 
pluripotent stem cell properties. 
Paik et al. In 2012 revealed that, fallopian tube stem cells are more concentrated at 
the distal end of the fallopian tube and after histological observation after 
Fluorescence Activated Cell sorting (FACS); the authors identified that the so-called 
peg cells in the tube are basally located and undifferentiated.  These cells were 
positive for CD44, a known marker for stem cells with migratory properties.4  
Up until very recently little has been known about the existence of this cell-type in 
the reproductive system of females and it has been speculated that stem cells could 
be implicated in many pathological, gynaecological conditions such as 
endometriosis and malignancies.  In 2012 a study performed by Wang et al. 
searched for quiescent stem-like cells in the female reproductive system using a 
mouse model.56  They did this by performing an in vivo pulse-chase experiment 
using histone 2B-green fluorescent protein (2B-GFP).  This was to try to identify 
long-term label retaining cells (LT-LRCs) which would suggest that these were 
quiescent stem-like cells.  Using transgenic 2B-GFP mice they administered 
doxycycline in the drinking water of the mice, to express the 2B-GFP protein and 
then withdrew this after a specified amount of time.  Actively cycling cells would 
reduce the expression of GFP over time, whereas quiescent cells would retain the 
GFP for longer.  The expression was monitored for up to 47 weeks after the pulse 
(doxycycline).  Methods used for analysis in the study were immunohistochemistry, 
flow cytometry for sorting of cells, in vitro cell culture with a self-renewal assay and 
differentiation assay of the sorted cells. 
Using IHC techniques and immunofluorescence imaging; uterine cells were found to 
express H2B-GFP labelling particularly in the epithelial compartment.  Proximal and 
distal oviductal cells also had positive labelling.  During the chase period it was 
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found that uterine cells and proximal oviductal cells lost the GFP signal early on (<12 
weeks).  An interesting finding was that cells in the distal oviduct retained their GFP 
signal for at least 12 weeks and some cells were labelled after 47 weeks.  Cells were 
termed long-term label retaining cells if they persisted for more than 12 weeks after 
labelling.  LT-LRCs were isolated from the distal oviduct ex-vivo and were found to 
be able to form spheroids at a higher rate than GFP negative cells.  Specific analysis 
of individual LT-LRCs showed initial formation of an unstructured organoid and 
subsequent growth of an epithelial-like outer layer.  If the spheroids were exposed 
to serum morphological changes were observed.  The spheroids were observed to 
spread out and budding of hollow tube-like structures occurred.  IHC staining of the 
spheroids to determine any differentiation into specific cell lineages showed that, if 
allowed to differentiate, the spheroids stained positive for ER alpha and CD44 – 
similar to the distal oviductal cells.  If allowed to differentiate even further the 
spheroids stained positive for ER alpha, CD44, PR and PAEP; an expression pattern 
similar to cells of the proximal oviduct and endometrium.  A conclusion was made 
that upon differentiation, spheroids derived from LT-LRCs express markers that are 
characteristic of cells found in the proximal oviduct and endometrium.  
The author thus hypothesised that quiescent stem-like LT-LRCs in the distal oviduct 
lead to the production of progenitor cells for the epithelial layer of the proximal 
oviduct and endometrium.  The hypothesis suggests that there is migration of cells 
from the distal oviduct towards the endometrium.  The author speculated that the 
only way to confirm this would be lineage tracing studies, however.  This hypothesis 
creates a link between distal oviduct endometrial epithelium.  Studies on the 
expression of other markers typical of endometrial epithelia need to be tested on 
fallopian tubal epithelia to confirm this link. 
Identification of LT-LRCs in the distal oviduct could open up suggestions into the 
pathogenesis of ovarian cancer, due to recent evidence that serous ovarian 
carcinoma originates in the fallopian tube.  The author also hypothesises that tissue 
injury in the distal oviduct could activate otherwise quiescent cells and cause 
compartmental expansion and differentiation.   
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In 2013 a study performed by Indumathi et al. compared the biomarkers of stem 
cells in the endometrium and fallopian tubes to bone marrow due to their special 
remodelling and regenerative properties.  The authors noticed however biomarkers 
to identify these stem cells were poorly understood.  Isolated cells from the 
endometrium and fallopian tubes were characterised for a wide range of 
biomarkers by flowcytometry and many of these were positive, like bone marrow.  
The stem cells were collectively positive for markers of pluripotency (SSEA4 and 
OCT4), cell adhesion molecules (CD 13, 29, 44, 54 and 166) perivascular (CD140b 
and 146) and mesenchymal stem cells (CD 73, 90 and 105).  The positivity of these 
particular markers indicated that these stem cells were involved in tissue 
regeneration and repair.1  
1.4.2 Stem cell presence in the endometrium 
Unlike tube, there is much evidence around suggesting there are progenitor cells 
in the endometrium.  Back in 2007, a study by Kato et al.  Was the first to Identify 
side-population cells in human endometrium.  They studied the phenotype of 
these cells and found that they could repopulate and produce gland and stroma-
like cells.3  This supports the theory that progenitor cells in the endometrium have 
the capacity to differentiate and regenerate as described in the study above.  A 
study then came out in 2008 by Tsuji et al.  Describing this side-population of cells 
but followed on by revealing that the side-population cells expressed endothelial 
cell markers, epithelial cell markers and mesenchymal cell markers.  The 
researchers also confirmed that these cells were side-population cells by staining 
for ABCG2 in the endometrium.  Interestingly, they found that these cells were 
strongly stained in the vascular endothelial and basal layer compartments.57 With 
the knowledge that the basalis layer regenerates the functionalis layer every 
month the accumulation of these cells in the basalis suggests that they could be 
the reason for this regeneration.  Supporting this, a study in 2010 revealed that 
the side population cells were enriched with stem cells that cause physiological 
regeneration of the endometrium every month and also claimed that they could 
be implicated in the pathogenesis of endometriosis due to their capability to 
migrate and cause angiogenesis in a mouse kidney model.58 
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In 2012, Nguyen et al. studied the Wnt pathway in pre and postmenopausal 
endometrial cells.  The Wnt pathway has been associated with endometrial 
development and stem cell regulation.  With expression of Wnt associated genes 
in premenopausal and postmenopausal endometrium and a similar gene profile of 
premenopausal basalis endometrium and postmenopausal endometrium suggests 
that progenitor cells reside mainly in the basalis layer.  These findings show that 
under the correct hormonal signal (i.e. premenopausal state) these cells could be 
the source of monthly regeneration for the functionalis layer.59  A recent study in 
2013 suggested that mesenchymal cells play an important role in endometrial 
regeneration through mesenchymal to epithelial transition.  This was due to 
transitional cells being found expressing epithelial cell and stromal cell markers 
predominantly in the regeneration zone; the mesometrial part of the 
endometrium.  This finding could also implicate the proliferative diseases of the 
endometrium.60 
1.4.3 Endometrial Ablation and Regrowth of the Endometrium 
Women with the common problem of menorrhagia (loss of > 80 ml of blood per 
menstrual cycle) undergo the procedure of endometrial ablation to alleviate this 
issue.  Endometrial ablation is the process of destroying the whole endometrial 
layer of the uterine cavity leaving behind myometrium only.  Since the early 90’s 
global endometrial ablation devices (GEA’s) have been introduced, which 
eliminate the endometrium in all areas of the uterine cavity.61  With the basalis 
layer of the endometrium destroyed, the monthly regeneration and shedding of 
the functionalis endometrium cannot occur, thus supporting the recent evidence 
that any regenerative cells in the basalis would also theoretically be eliminated.  
Although endometrial ablation has a high success rate short term, it has frequently 
been reported all over the world that after five years the success rates drop 
dramatically with at least one in four women undergoing hysterectomy.  A 
prospective randomised control trial by Silva-Filho et al. compared women who 
received a levonorgestrel-releasing intrauterine system (LR-IUS) with women who 
underwent thermal balloon ablation (TBA) five years post-insertion/operation.  
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Hysterectomy rates and menstrual blood loss were significantly higher in patients 
undergoing TBA compared with the LR-IUS revealing that the IUS had higher 
overall satisfaction rates.62  This leads on to the question – where is the 
endometrium coming from to cause this blood loss?  Re-growth from the cornua 
of the uterus has previously been described; however with the newer devices 
today, this should reduce if not stop this risk.  Failure rates have still remained 
high.  A theory could be that the stem cells in the distal fallopian tube migrate 
towards the uterus and differentiate into endometrial-like cells, eventually 
repopulating the endometrial cavity.  A photo taken of a patient’s endometrial 
cavity with symptoms of menstrual blood loss following ablation shows this re-
growth coming from the fundus bilaterally near the tubal junctions (see below).  
This theory is supported by the evidence from the study of the label retaining cells 
in the mouse model described in section 1.4.1.    
 
Figure 1-8 – Photo of uterine cavity. Patient had hysterectomy due to ablation failure.  Fundal area of cavity 
lined with endometrium (red) and inferior portion atrophic (yellow). 
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1.4.4 Characterisation of the Basalis Endometrium 
As mentioned in part 1.4.2 it is thought that endometrial progenitor cells reside in 
the basalis compartment of the endometrium.  Even though side population cells 
have been located – it seems that markers for these cells are yet to be identified.  
Schwab in 2004 investigated the side population in stromal tissue of the 
endometrium.  They identified that CD90 differentiates basalis stroma from 
functionalis stroma, however potential stem cell markers were unidentifiable.63 
Before understanding the stem cell component of the endometrium, it is important 
to characterise the compartments of endometrium to be able to understand the 
phenotypic differences between the glandular and stromal basalis and glandular, 
stromal and luminal functionalis. 
Recently, epithelial cell markers have been discovered distinguishing the basalis 
from the functionalis layer of the endometrium.  In 2013 it was hypothesised that 
the epithelial cell markers SOX9 and nuclear beta catenin may distinguish the 
basalis layer of endometrium from the functionalis with the rationale that these 
markers are found in abundance in the regenerative intestinal crypts where the 
progenitor cells reside.  Authors found that the basalis endometrium expressed 
SOX9 and a subpopulation of cells were positive for nuclear beta catenin.  They also 
found that the embryonic stem cell-surface marker SSEA-1 was positive in the 
basalis region more abundantly than the functionalis.  Isolated SSEA-1+ cells showed 
higher telomerase activity and gland-like spheroid growth. With these findings and 
markers distinguishing the basalis from the functionalis, further studies into the 
analysis of stem cell activity can be made.64 With this in mind, if the basalis 
endometrium exhibits particular phenotypic features and the tubal epithelium is 
hypothesised to contribute to this mucosa – are there phenotypic similarities 
between fallopian tubal epithelium and endometrial epithelium? 
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1.5 Markers to Characterise and Compare The Fallopian Tube and 
Endometrium 
1.5.1 Basalis Markers 
1.5.1.1 BCAM 
Basal cell adhesion molecule has a wide tissue distribution being highest in 
intensity in the pancreas and lowest in the brain.  It is a marker for the basal 
surface of epithelial cells and also for the endothelium of blood vessel walls.  Its 
gene encodes for Lutheran blood group antigen which is known to be a member of 
the immunoglobulin superfamily.  BCAM is a receptor for laminin.65  Laminins are 
an integral component of all basement membranes, 66  and have many cellular 
functions including roles in:  adhesion, motility, growth, differentiation and 
apoptosis.67  BCAM has been found to be present in some epithelial cells in human 
tissue.  Positive expression of this molecule has been found in hepatic epithelial 
cells, haematopoietic cells, chorionic villi of the placenta and the glomeruli, 
arterial cells and tubules of the kidney.68  BCAM has also been found on hair 
follicles and in areas of inflammatory epidermis.69  Presence of BCAM is found 
solely in erythrocytes of the blood.70  BCAM has also shown up-regulation in some 
epithelial cell cancers.71  On immunostaining; BCAM is localised to the basal 
surfaces of epithelial cells of tissues.  Strong cytoplasmic and membranous 
staining has been observed in certain tissues of which fallopian tube was one – no 
studies have been published fully describing BCAM expression in the human 
fallopian tube and its functional relevance remains unclear in this tissue.72 
1.5.1.2 SOX9  
SOX9 or SRY (sex determining region Y)-Box 9 is a transcription factor. Its gene has 
been located in 17q24. The protein recognises the sequence CCTTGAG and various 
other HMG-box class DNA binding proteins. 73   SOX9 insufficiency has been 
associated with campomelic dyplasia, skeletal malformations and XY sex reversal (Bi 
W et al).   With steroidogenic factor-1, SOX9 regulates/stimulates levels of anti 
Mullerian hormone (AMH) expression74 thus playing an essential role in male sexual 
development. Previous studies have shown rich SOX9 presence in basal epithelial 
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cells. The transcription factor SOX9 has been located in basal epithelia of the 
prostate, the intestinal crypts and the outer root sheath of hair follicles.  Progenitor 
cells are all thought to reside in these particular regions.75  As mentioned in section 
1.4.4 SOX9 has been strongly detected in the basal glandular epithelia of the 
endometrium. This is also a region in which progenitor cells are thought to reside.64 
This has yet to be investigated in tubal epithelia and could give an indication as to 
whether these cells exhibit a basal epithelial cell phenotype. 
1.5.1.3 SSEA-1 
Stage specific embryonic antigen-1, also known as Lewis X and CD 15 - has a 
significant role in the adhesion and migration of the preimplantation embryo in 
murine pluripotent stem cells.76 It is synthesised by fucosyltransferase 4 (FUT4) 
and also by FUT9.  It is a cell-surface marker that has previously been found to be 
expressed in the human basalis endometrium and in ectopic endometrial lesions. 
Studies in our lab discovered that SSEA-1 marked the glandular epithelia in the 
stratum basalis of the endometrium.  The study used magnetic activated cell 
sorting to isolate SSEA-1+ cells and these were grown in 3D culture.  The SSEA-1+ 
cells were found to produce a higher number of endometrial gland-like spheroids 
in comparison to the untreated group.2 Immunohistochemical staining for SSEA-1 
in adult murine oviducts shows positivity, however human fallopian tube 
expression of SSEA-1 is yet to be studied.77 
1.5.1.4 Beta Catenin 
Beta catenin protein or cadherin-associated protein with gene name CTNNB1 has 
many roles.  Some of the key functions of this protein are; cell adhesion with 
bridges formed between cadherins in the cell junction and also in the cytoskeleton 
with actin.  It is also believed that beta catenin plays a role in gene expression in the 
canonical Wnt signalling pathway.78  In the absence of Wnt, ubiquitination of beta 
catenin occurs - signalling its degradation via the proteasome.  In the presence of 
Wnt however, beta catenin accumulates in the nucleus where it then acts as a co-
activator for transcription factors belonging to the TCF/LEF family, leading to the 
subsequent activation of Wnt-responsive target genes.79 Studies have shown that 
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the Wnts activate intracellular cascades that regulate cellular proliferation, 
differentiation, migration, and polarity.80 
1.5.2 Luminal Surface Marker 
1.5.2.1 Sialylated SSEA-1 
The sialylated SSEA-1 or sialylated Lewis X antigen is a tetrasaccharide 
carbohydrate molecule on the surface of cells.  It attaches to the endothelial 
adhesion molecule E-selectin.  This antigen plays a significant role in inflammatory 
response, being that it is expressed on activated leucocytes and causes attraction 
of these to local sites of inflammation or injury.  It is also involved in cell to cell 
recognition and recent evidence has shown that it plays a vital role in the 
fertilisation process.  It has been shown to be the means by which the oocyte 
attracts the sperm; with subsequent binding and fertilisation.81  
 Sialylated SSEA-1 has been identified on human endometrial luminal epithelial 
cells.  It is associated with markers that are known to promote adhesion for 
implantation of an embryo.82 A study claimed that sialylated SSEA-1 is a specific 
tumour marker and reported a high percentage of antigen positivity in patients 
with ovarian cancer (72.3%) and endometriosis (75 %).  There was also low 
positive expression in other gynaecological malignancies such as endometrial 
cancer and cancer of fallopian tubes.  This study suggested that sialylated SSEA-1 
is a specific tumour marker for gynaecological malignancy, particularly ovarian 
cancer.83 
1.5.3 Marker of Proliferation 
1.5.3.1 KI67 
Expression of KI67 protein in cells indicates that they are proliferating.  KI67 is 
therefore considered a marker of proliferation in a cell.  The antigen has been 
detected in the nucleus of cells and has been proven to disappear during the 
resting phase (G0) period of the cell cycle.  KI67 has also been studied in diagnosis 
and prediction of prognosis in tumour cells.84  Studies measuring the so-called 
“KI67 Index” in breast cancer have found a significant increase in index score in 
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higher grade malignancies and lower overall survival rates.85  KI67 protein 
expression has been detected in endometrial glandular epithelia and has been 
shown to significantly increase in the proliferative phase of the menstrual cycle 
and diminish dramatically during the secretory phase, when the cells are in a more 
quiescent state.86 
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Chapter 2 Aims and Hypotheses 
 
     2.1 Primary Hypothesis 
Markers preferentially found in the endometrial basalis layer are also found in the 
distal tubal epithelium.  This region of the fallopian tube may be phenotypically 
similar to the basalis layer of the endometrium. 
Rationale: As described in the introduction the tubal mucosa exists as a continuum 
with endometrial mucosa, although endometrial and tubal epithelium have 
separately been characterised.  There is yet to be a comparison of tubal and 
endometrial mucosa.  Recent novel findings suggest a pooling of progenitor cells 
exist in the distal fallopian tube.  Side-population analysis has revealed that the 
basalis endometrium contains the majority of cells phenotypically suggestive of 
progenitor cells in this region.  It is commonly thought that these undifferentiated 
cells have the capacity to differentiate under particular conditions and are the 
source of the basalis layer’s monthly regeneration of the functionalis layer.  Latest 
characterisation of the basalis layer of the endometrium has revealed the presence 
of particular markers that are usually found in abundance in stem cell-rich areas.  
Comparison of the tubes with the endometrium by testing for the presence of the 
markers previously found in the basalis compartment is necessary to directly 
compare the phenotype of the tubal epithelium with the basal glandular epithelium.   
2.2 Secondary Hypotheses 
2.2.1 The endometrium undergoes cyclical changes every month by shedding and 
regenerating the functionalis layer under the influence of steroids.  The fallopian 
tube has a distinct hormonal response and cyclical pattern of receptor expression 
reflects this.  
Rationale: This hypothesis aims to investigate whether the tube undergoes the 
monthly changes that the endometrium experiences.  This is to be determined by 
studying the changes in expression of steroid receptors throughout the menstrual 
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cycle in the tube and comparing this with matched endometrium.  Changes in 
proliferation will also be determined throughout the menstrual cycle to consider 
whether the fallopian tubal mucosa undergoes phenotypic changes similar to the 
character of the endometrium which sheds and regenerates each month.  
2.2.2 Fallopian tubal epithelia respond to androgens in a unique way. 
Rationale: Androgens have been shown to up-regulate their receptors in the 
endometrial glandular epithelium and receptors are strongly expressed in the 
endometrial stroma but no such investigation has been carried out in the fallopian 
tubes.  Both tissues have shown changes in receptor expression under the influence 
of oestrogen and progesterone treatment in explant culture.  There is no evidence to 
date, looking at the effects of treatment of fallopian tubal mucosa with androgens 
in explant culture.  Investigating the influence of this steroid on the androgen 
receptor, its cellular location and markers of proliferation could give an insight into 
the function of this steroid in the fallopian tubes.    
2.2.3 The endometrial and fallopian tubal mucosa are in an atrophic state in 
postmenopausal females. 
Rationale:  The postmenopausal state of the endometrium is when the cells are of a 
basalis phenotype with a lack of the monthly changing functional layer.  
Concentrations of progenitor cells are found in this mucosal layer.  Is the tubal 
epithelium expressing/ not expressing markers that suggest that it is in a quiescent 
state similar to that found in the endometrium? After the menopause – most 
pathological change occurs in the female reproductive tract including diseases such 
as endometrial and ovarian cancer.  If expression of markers in the fallopian tube 
and endometrium are similar; this would suggest a continuum between the two 
tissues.  Recent theories suggest that there may be migration and differentiation of 
cells from the tube towards the uterus. With this and the suggestion that the tissues 
are in a continuum – it could be quite possible that the fallopian tubal cells play a 
part in the development of diseases throughout the reproductive tract.  In particular, 
the diseases that involve change in vulnerable cells for example; progenitor cells 
undergoing neoplastic formation.  Not only would this support the evidence 
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suggesting that high grade serous ovarian carcinoma begins in the distal fallopian 
tube, but also tubal cells could be implicated in endometrial cancer and benign, 
migratory diseases such as endometriosis.   
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Chapter 3 Materials and Methods 
3.1 Ethics 
Ethical approval for the collection of fresh human endometrial and fallopian tube 
samples was obtained by the Local Research Ethics Committee (Collection of human 
endometrium was approved by Liverpool Adult Ethics committee (REC references; 
09/H1005/55 and 11/H1005/4). Full written and informed consent was taken prior 
to the collection of these samples using a standard consent form for the collection 
of specimens appropriate for the study (see appendix). 
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3.2 Sample Collection and Processing 
Patients were carefully selected according to the inclusion and exclusion criteria 
specified during this study - on theatre lists performed in the Liverpool Women’s 
Hospital.  Researchers who consented and collected samples were required to 
attend the Good Clinical Practice course (GCP). 
3.2.1 Inclusion and Exclusion Criteria 
Table 3-1 - Inclusion and Exclusion Criteria 
Premenopausal Population Postmenopausal Population  
Inclusion Criteria 
Normal cycling female. 
Undergoing hysterectomy for non-
endometrial pathology. 
Bilateral salpingoophorectomy. 
Hormone treatment-free for at least 3 
months prior to operation. 
Must be able to give valid informed 
written consent 
Inclusion Criteria 
Female. 
Patient’s last menstrual period at least 
one year previous to operation. 
Hysterectomy for non-cancerous 
pathology. 
Bilateral salpingoophorectomy. 
Hormone treatment-free. 
Must be able to give valid informed 
written consent 
Exclusion Criteria 
Any female on hormone treatment or 
in the past 3 months. 
Known endometriosis. 
Cancer of any type. 
Hyperplasia. 
Pregnancy. 
Salpingitis/other fallopian tubal 
pathology. 
Mirena intrauterine system (IUS). 
Exclusion Criteria 
Females on HRT. 
Abnormal postmenopausal bleeding. 
Cancer. 
Hyperplasia. 
Fallopian tubal pathology. 
Proliferating endometrium on 
histological examination.  
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Full thickness sample sections (all endometrial layers through to myometrium) were 
collected and small sections of fallopian tube were dissected after the uterus was 
extracted during hysterectomy and bilateral salpingoophorectomy.  If the patients 
were undergoing salpingectomy operations, pipelle samples were taken to obtain 
endometrial tissue.  The acquirement of tissue did not affect the patient’s 
treatment during surgery and no additional procedures were performed. 
For full thickness endometrial sections obtained after hysterectomy: the uterus was 
transferred to a clean trolley, opened anteriorly and a small slice of full thickness 
uterine tissue was dissected using a sterile scalpel.   
A small section of the tissue was transferred into 15ml neutral-buffered formalin 
(NBF) for paraffin embedding for immunohistochemistry. A small section was also 
transferred into 500 microliters RNA later, stored at 4⁰C overnight, the solution was 
then removed and tissue was frozen at -70⁰C – it is ready to be RNA extracted.  
Another small section was transferred into collection media for explant culture on 
the day of collection:  
Table 3-2 - Ingredients in Collection Media 
Collection Media for Fallopian 
Tube 
Collection Media for 
Endometrium 
Supplier  
Dulbecco’s Modified Eagle 
Medium (DMEM/F12) (Phenol-
Red Free) 
DMEM DMEM/F12 – Life 
Technologies 
DMEM - SIGMA 
Primocin (Antibiotic) Primocin (Antibiotic) InvivoGen, though 
Source BioScience 
 1% Fetal Bovine 
Serum (FBS)  
Biosera Ltd 
 
Fallopian tube sections were dissected from the isthmic and fimbrial ends of the 
tube in a cross-section so that the lumen would be left intact.  These were 
transferred into the same solutions as the endometrium described above and 
transported back to the lab for processing.  
61 
 
A pipelle is a single use, sterile suction curette for a biopsy of the endometrial tissue 
in the uterine cavity.  The pipelle is passed through the cervix into the uterine cavity 
and the piston within the sheath should be withdrawn towards the proximal end to 
create a negative pressure so that mucosal tissue is drawn into the opening at the 
distal end of the sheath.  By rotating and twirling the sheath several times within 
the cavity the maximal amount of tissue can be retrieved in the pipelle.87  The 
collected specimen was dispensed into the appropriate solutions for processing – as 
mentioned earlier NBF, RNA later and collection media. 
3.3 Immunohistochemistry 
The technique used throughout this project was a two-step immunohistochemical 
staining technique; using The Vector immPRESS TM reagent kit, horseradish 
peroxidase (HRP).   
In the body; a set of proteins called antibodies are produced by B cells to attach to 
and destroy antigens that have entered body tissues and cause cell damage.  This 
technique can be applied, in the lab on tissue samples to detect certain protein 
expression properties in particular cells.  This procedure is called 
immunohistochemistry.   
If a human antigen is injected into a particular animal (for example – a rabbit) the 
animal produces antibodies in defence against that specific antigen.  If the 
antibodies are subsequently collected and applied to human tissue – these will 
attach to the antigen of interest. This allows precise location of the antigen within 
the cell.88  
During this project the indirect method of immunohistochemistry was followed.  
This is where a primary, unlabelled antibody is added to the tissue and then a 
secondary labelled antibody is added to react with the primary antibody.  The 
secondary antibody is produced by adding immunoglobulin of the host of the 
primary antibody to another animal.  A number of the secondary antibodies will 
detect and build on the primary, attached antibody therefore amplifying the signal 
detection.  The second antibody is labelled with a peroxidase enzyme.89  Finally, 
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Diaminobenzidine (DAB) is added – in the presence of peroxidase, an insoluble 
substrate is formed producing a brown-coloured stain that can be seen under a light 
microscope.  
 
Figure 3-1 - Indirect method, using ImmPRESS system immunohistochemistry 90 
3.3.1 Tissue Processing and Paraffin Embedding 
Samples must be preserved for long-term maintenance of tissue and cutting fine 
sections so that they can be stained easily.  Fresh tissue samples were stored in 
neutral-buffered formalin for 24 hours before processing.  The processing 
procedure took place using the Shandon Citadel 1000 processing machine and 
involved formalin fixed tissue undergoing dehydration, clearing then impregnation 
with paraffin wax.  The processing schedule was as follows: 
Table 3-3 - Processing Procedure 
4% Formalin in neutral buffer 45 minutes 
60% Ethanol 1 hour 
70% Ethanol 1 hour 
90% Ethanol 1 hour 
100% Ethanol 1 hour 
100% Ethanol 1 ½ hours 
100% Ethanol 2 hours 
Xylene 1 1 hour 
Xylene 2 1 ½ hours  
Xylene 3 2 hours 
Wax 1 2 ½ hours 
Wax 2 3 ½ hours 
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Embedding of samples into paraffin blocks took place in the Shandon Histocentre 3.  
Here processed samples were transferred into wax-filled moulds to create a paraffin 
block for cutting.   
3.3.2 Cutting Paraffin Sections 
Once the samples were embedded they needed to be cut into 3 micrometre thick 
sections and transferred onto glass slides for undergoing immunohistochemistry.  
The sections were cut using the Microm HM335 rotary microtome.  Excess wax was 
trimmed to expose the tissue then the microtome blade was fed through the wax 
block cutting a ribbon of 3 micrometre thick sections.  This ribbon was floated onto 
a warm water bath using forceps.  The water bath was warmed to 41⁰C. Once the 
ribbon was separated, individual sections were floated onto aminopropyl triethoxy 
silane (APES) coated slides and left to dry for several hours. 
3.3.3 Preparation of Slides 
To ensure that tissue sections adhered properly to the glass slides they were heated 
prior to the immunohistochemical procedure.   
Tubes and matched eutopic endometrium were prepared for the 
immunohistochemical procedure by baking at 37⁰C overnight or at 60⁰C for one 
hour. 
3.3.4 De-waxing 
For the sections to be ready to stain the tissue needed to be deparaffinised with 
xylene and subsequently rehydrated with alcohol. 
Using a slide rack; the tissue samples were placed in a staining dish containing 
xylene for 10 minutes.  They were then progressively transferred through another 
dish of xylene, two containers of 100% ethanol, 90% ethanol, 70% ethanol and 
finally into a dish of distilled water.  The tissue samples were ready for antigen 
retrieval. 
Table 3-4 - Dewaxing procedure 
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Dewaxing Chemical Time 
Xylene 1 10 minutes 
Xylene 2 10 minutes 
100% Ethanol 1 5 minutes 
100% Ethanol 2 5 minutes 
90% Ethanol 1 minute 
70% Ethanol 1 minute 
 
3.3.5 Antigen Retrieval 
The tissue sample underwent formalin-fixation to stabilise the tissue proteins.  
Whilst stabilising the tissue for processing; this modified the antigen’s epitopes and 
electrostatic charges.  Antigen retrieval is a process that enables the restoration of 
the tissue sample’s epitopes.  By restoring these; the antigen can react with the 
antibody and produce a stronger, more visible stain. 
This was achieved by preparing a 10mM, pH 6.0 solution of citrate buffer for 
heating in a pressure cooker.  For SSEA-1 antibody, Tris-EDTA buffer was used in 
antigen retrieval.  10mM of Tris, in 1mM of EDTA, at a pH of 8.0 was required. The 
citrate/Tris was brought to a rolling boil and the slides placed into this solution, with 
the lid tightly sealed, for the optimum time according to the antibody being tested 
(see later for details of each antibody used).  Once retrieved; the slides were 
transferred back into distilled water for the immunohistochemical procedure. 
3.3.6 Immunohistochemistry (IHC) 
The tissue samples were bathed in Tris Buffered Saline (TBS) for 5 minutes and 
transferred into 0.3% Hydrogen Peroxide/TBS solution for 10 minutes.  The tissue 
was then washed in TBS twice. Tissue was encircled using a hydrophobic marker to 
allow more than one section with different antibodies to be stained per slide and to 
keep all reagents on/around the tissue. 
For some IHC procedures another technique to bathe the tissue was adopted.  This 
was the “coverslip” method.  A glass coverslip was placed on top of the 
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primary/secondary antibody to create a thin film over the tissue and ensure that 
the whole section was completely covered to avoid the edges drying-out.   
Some tissue samples (depending on the species that the antibody is raised in) 
needed blocking with horse serum to prevent none specific binding to cell 
receptors.  If this was required at this stage – the tissue samples were transferred 
into a humidified chamber, 2 drops of horse serum applied, mixed and left for 20 
minutes.  
The tissue was subsequently incubated with the desired primary antibody (see table 
4).  The primary antibody was diluted to the recommended concentration and 
incubated for the optimum time.  After blocking with the horse serum (if applicable) 
this was removed and the slides were transferred back into the humidified 
chamber. All antibodies were diluted using BSA diluent (0.5% BSA/TBS) and applied 
to each tissue sample.  
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Table 3-5 - Antibody data 
Antibody Concentration Host Species Antigen 
Retrieval 
Time 
Horse 
serum 
Incubation 
Time 
Incubation 
Temperature 
Supplier Supplier Code Clone 
Beta Catenin 1:200 Rabbit MAb 2 minutes, 
Citrate 
Y Overnight  4⁰C Cell Signalling Technology 
Herts, UK 
#95825 6B3 
BCAM 1:100 Rabbit MAb 2 minutes, 
Citrate 
Y Overnight 4⁰C Abcam Cambridge, UK Ab111181 EPR4164 
KI67 1:200 Mouse MAb 4 minutes, 
Citrate 
N Overnight 4⁰C Novocastra, Newcastle, 
UK 
NCL-Ki67-MM1 MM1 
SOX-9 1:400 Goat Polyclonal 4 minutes, 
Citrate 
Y Overnight 4⁰C R&D Systems 
Abingdon,UK 
AF 3075 Met1-Lys151 
SSEA-1 1:800 Mouse MAb 3 minutes, 
Tris 
N Overnight 4⁰C Biolegend, San Diego, CA 
92121 
125601/2 MC-480 
Sialylated SSEA-1 1:400 Mouse MAb 3 minutes, 
Citrate 
N Overnight 4⁰C Aviva Systems Biology, 
San Diego, CA 92121 
OAMA01510 258-12767 
Androgen Receptor 1:75 Mouse MAb 3 minutes, 
Citrate 
N Overnight 4⁰C Dako, Glostrup, Denmark M3562 AR441 
Oestrogen Receptor 
Alpha 
1:50 Rabbit Polyclonal 2 minutes, 
Citrate 
Y 2 hours Room 
Temperature 
Abcam, Cambridge, UK Ab137738  
Oestrogen Receptor 
Beta 
1:50 MouseMAb 2 minutes, 
Citrate 
N Overnight 4⁰C Serotec, Kidlington, UK MCA1974S PPG5/10 
Progesterone 
Receptor 
1:1000 Mouse MAb 2 minutes, 
Citrate 
N 30 minutes Room 
Temperature 
Dako, Glostrup, Denmark M3569 PgR 636 
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3.3.7 Controls for Antibodies 
To check the quality of the antibody staining and the protocol carried out - it was 
important to stain a tissue that is positive for this antibody so that appropriate 
staining intensity is determined as a benchmark for the samples being tested.  This 
is termed a positive control. 
An internal control was placed in each run when performing multiple runs at 
different times to make sure there was consistency between each experiment.  This 
was usually a sample that was stained in the first IHC run and was thus repeated in 
all subsequent runs with the same primary antibody.  A negative control was one 
that - instead of the primary antibody being added to the tissue; it was replaced by 
the IgG of the animal in which the antibody was raised in.  This produces a negative 
stain with no DAB detected and confirms the specificity of the antibody being 
tested. 
Table 3-6 - Controls in experiment 
Antibody Positive Control Internal Control Negative Control 
Beta Catenin Liver SPCN 129-2 Rabbit IgG 
BCAM Tonsil SPCN 126-2 Rabbit IgG 
KI67 Tonsil SPCN 126-2 Mouse IgG 
SOX-9 Prostate SPCN 129-2 Goat IgG 
SSEA-1 Kidney SPCN 41-1 Mouse IgG 
Sialylated SSEA-1 Mouse Gut SPCN 126-2 Mouse IgM 
Androgen 
Receptor 
Prostate SPCN 118 Mouse IgG 
Oestrogen 
Receptor Alpha 
Endometrium – 
same as internal 
EndoCa 72 Rabbit IgG 
Oestrogen 
Receptor Beta 
Endometrium – 
same as internal  
EndoCa 72 Mouse IgG 
Progesterone 
Receptor 
Endometrium – 
same as internal 
SPCN 118 Tube Mouse IgG  
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Table 3-7 - Picture at x400 Magnification of Controls for each Antibody 
Antibody External Positive 
Control 
Internal Control Negative Control 
Beta 
Catenin 
   
BCAM 
   
KI67 
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SOX-9 
   
SSEA-1 
   
Sialylated 
SSEA-1 
   
Androgen 
Receptor 
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Oestrogen 
Receptor 
Alpha 
SAME AS INTERNAL 
  
Oestrogen 
Receptor 
Beta 
SAME AS INTERNAL 
  
Progester-
one 
Receptor 
SAME AS INTERNAL 
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A formula for antibody calculations: 
Final Volume = (Number of sections + 10%) x Amount applied to each section 
 
 
 
 
 
After incubation the tissue samples were washed twice In TBS for five minutes each.  
The samples were dried and placed back into the humidified chamber and the 
Horseradish Peroxidase (HRP) labelled secondary antibody (chosen according to 
animal the antibody was raised in) was placed onto the tissue sample and incubated 
for 30 minutes.  Two washes for five minutes of TBS were required after incubation. 
The slides were then dried and placed into the humidified chamber and 
Diaminobenzidine (DAB) + substrate solution of dilution 30 µl DAB: 1000 µl diluent 
was placed onto the tissue sample for 10 minutes. Afterwards, the DAB solution 
was tapped off and the slide was immersed in water. 
The next step was to make sure that the unstained/negative nuclei were stained 
with haematoxylin for visualisation under a light microscope.  The samples were 
placed into haematoxylin solution for 1 minute 30 seconds. They were then washed 
under cold water.  The samples were then dipped into a solution of 1% acid alcohol.  
This is because the haematoxylin used, is a “regressive” stain therefore the sample 
is over-stained and then reduced in intensity by 1% acid alcohol solution.  This 
solution also reduces background blue staining to produce clear, light-blue nuclei 
that can be observed under light microscopy. The tissue was washed under cold 
water for five minutes for optimum staining intensity.   
 
 
Final 
Volume 
Antibody 
Volume 
Dilution 
Factor 
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3.3.8 Dehydration 
Before the slides were mounted they underwent the dehydration procedure.  They 
were transferred through 70% ethanol, 90% ethanol, two dishes of 100% ethanol 
and two dishes of xylene (see below for details). 
Table 3-8 - Dehydration procedure 
Dehydration solution Immersion Time 
70% Ethanol 1 minute 
90% Ethanol 1 minute 
100% Ethanol 1 3 minutes 
100% Ethanol 2 3 minutes 
Xylene 1 5 minutes 
Xylene 2 10 minutes 
 
The final step was to prepare the slides for observation under the microscope.  
Cover slips were placed over the tissue using consul mount glue and left to dry. 
3.4 Reverse Transcriptase - Polymerase Chain Reaction 
3.4.1 Ribonucleic Acid (RNA) Extraction 
This is the purification of RNA from biological samples.  It is important to purify 
intact RNA from biological samples for the success of downstream applications.91 
For worthwhile results from RT-PCR the best purification methods must be used.  
RNA is prepared using multi-component kits.  The kit used for the samples under 
study was: Pure Link RNA mini kit (Ambion, Life Technologies, Paisley, UK). 
Samples were collected and stored in “RNA Later” solution, in the freezer at -20⁰C 
(short-term) and -80⁰C (long-term).  During this procedure it was important to 
prevent contamination by wearing gloves sprayed with ethanol and cleaning all 
equipment before use with “RNA ZAP”.   
Once the fume hood and all equipment inside it was cleaned, frozen sections were 
removed from the freezer to thaw.  Microfuge tubes were prepared corresponding 
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to the number of samples being extracted.  Using appropriate barrier protection, 
1000 µl of TRIzol was pipetted into a bijoux.  The tissue sample was placed into a 
bijoux container with TRIzol. This solution broke down the cellular components of 
the tissue.  Care was taken to label each sample to avoid experimental error. 
3.4.1.1 Homogenising  
A bijoux container was prepared with alcohol and TRIzol for the cleaning of the 
probe of the homogeniser between each sample to avoid RNA contamination 
between samples. The tissue was then broken down into a cell suspension.  Once 
the probe had been cleaned, the procedure was repeated for each tissue sample 
until all tissue was homogenised.  
3.4.1.2 Phase Separation 
Each cell suspension was then transferred into a microtubule for the next phase of 
the procedure.  The tissue/TRIzol solution was allowed to sit for 5 minutes to allow 
complete dissociation of nucleoprotein complexes.  200 µl of chloroform was added 
to each sample and mixed thoroughly.  The tissue solution was subsequently placed 
into a centrifuge and spun for 15 minutes at 4⁰C.  After spinning, the clear liquid 
(this contains the RNA) was pipetted off each sample, being careful not to get any of 
the pink coloured protein-mixture into the solution – as this would contaminate.  
Usually, approximately 500 microlitres of clear liquid could be pipetted off at a time.  
The liquid was then mixed with the equivalent amount of 70% ethanol.  
3.4.1.3 Binding, washing and elution 
500 µl of each sample was pipetted into a spin cartridge for filtering the RNA out of 
the solution.  The sample was centrifuged for 30 seconds at room temperature to 
enable this to happen. The remaining un-spun sample was added to the cartridge 
and centrifuged to ensure all of the RNA had been filtered and was bound to the 
membrane inside the spin cartridge.  The next step was to wash the sample.  700 µl 
of Wash Buffer 1 (from the kit) was added to the cartridge and centrifuged for 30 
seconds.  To complete the wash; 500 µl of Wash Buffer 2 (from the kit) was added 
to the spin cartridge and centrifuged for 30 seconds, twice.  The spin cartridge then 
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needed to be centrifuged for 1 minute to dry off the membrane.  The cartridge was 
placed into a recovery tube (from the kit) and 30 µl of RNase-free water was 
pipetted onto its membrane.   To ensure the water detached the RNA from the 
membrane, the tubes were left for 1-2 minutes. For final filtering of the RNA/H20, 
the recovery tubes were centrifuged for 2 minutes at room temperature.  The 
cartridge was removed and the RNA-filled solution remained in the tube ready to be 
stored at -70⁰C. Care was taken to ensure all equipment was cleaned, particularly 
the probe of the homogeniser for future use.  
3.4.2 Deoxyribonuclease (DNase) Treatment  
Treatment with the enzyme DNase destroys any genomic Deoxyribonucleic acid 
(DNA) contamination in the RNA sample.  Reverse transcriptase-PCR (RT-PCR) uses 
the technique of converting RNA back into DNA.  After this, target genes are 
amplified. This could potentially include any genomic DNA present in a sample.  If 
the sample is contaminated with genomic DNA, one could not decide whether the 
RT-PCR results are due to the complementary-DNA generated or the genomic DNA 
in the sample.  To prevent this – we add DNase to the RNA samples (an enzyme 
which breaks down DNA).92  The solutions used were: 10x DNase1 reaction buffer - 
B 03035, DNase1 enzyme - B 03036 (New England BioLabs Inc, Hitchin, Herts, UK) 
and RQ1 DNase STOP solution - M 199A (Promega Corp, Madison, WI 53711-5399 
USA). 
Before beginning; “RNA ZAP” was used to clean the lab bench and all equipment 
used during the procedure.  With samples of total RNA thawing in an ice-bath, 
microfuge tubes were prepared corresponding to the number of samples that 
needed Dnase treatment.  8 µl of each total RNA sample was pipetted into the 
microfuge tubes. 1 µl of Dnase 1 was pipetted into the RNA solution.  1 µl of 10x 
buffer was then to the mixture.  The samples with the Dnase/buffer/RNA mixture 
were inserted to a 37°C incubator for 30 minutes.  1 µl of “DNase STOP” solution 
was added to each sample.  The samples were inserted back into the incubator and 
heated at 65°C for 10 minutes.  They were then stored at -70°C before 
complementary-DNA synthesis. 
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Total RNA was quantified using a NanoDrop ND-1000 spectrophotometer (Thermo 
Fisher).  Absorbance ratios were also recorded; the 260/280nm ratio demonstrates 
the RNA purity.  The concentration of each sample was 1000ng/µl. 
Table 3-9 – RNA Spectrophotometry Values for matched fallopian tube and endometrium in Postmenopausal 
and Secretory Phase Samples. 
Sample (EP: Postmenopausal, 
SPCN: Secretory Phase) 
RNA ng/µl RNA A260/280 
EP 26 Tube 316.10 2.02 
EP 26 Eutopic Endometrium 934.22 2.08 
EP 27 Tube 403.87 2.07 
EP 27 Eutopic Endometrium 572.58 1.99 
EP 30 Tube 344.79 2.00 
EP 30 Eutopic Endometrium 431.44 1.98 
SPCN 143 Tube 318.08 1.91 
SPCN 143 Eutopic Endometrium 997.84 2.02 
SPCN 152 Tube 165.20 2.05 
SPCN 152 Eutopic Endometrium 1021.90 2.06 
SPCN 159 Tube 359.44 2.01 
SPCN 159 Eutopic Endometrium 838.84 2.05 
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Table 3-10 - RNA Spectrophotometry Values for matched fallopian tube and endometrial explants in the 
Secretory Phase +DHT (Treated with DHT) or –DHT (untreated.) 
Sample RNA ng/µl RNA A260/280 
SPCN 163 Endometrium +DHT 63.24 1.78 
SPCN 163 Endometrium -DHT 19.28 1.92 
SPCN 163 Tube +DHT 51.64 1.88 
SPCN 163 Tube  -DHT 48.54 1.78 
SPCN 172 Endometrium +DHT 1063.61 2.12 
SPCN 172 Endometrium -DHT 1316.40 2.11 
SPCN 172 Tube +DHT 551.39 2.06 
SPCN 172 Tube -DHT 594.36 2.03 
SPCN 175 Endometrium +DHT 679.78 2.06 
SPCN 175 Endometrium -DHT 602.78 2.06 
SPCN 175 Tube +DHT 789.17 2.02 
SPCN 175 Tube -DHT  781.84 1.89 
 
3.4.3 Complementary – DNA (cDNA) Synthesis 
cDNA is a double stranded version of messenger RNA (mRNA).  A technique for 
making cDNA is to use the enzyme reverse transcriptase.  A template of mRNA is 
added to the enzyme so that it makes a single strand of cDNA. With this single 
stranded cDNA; double stranded DNA can be synthesised.93 By generating cDNA and 
adding a primer sequence, the positive sequences can subsequently be amplified 
using polymerase chain reaction (PCR). 94  The kit used for this procedure was (AMV) 
First Strand cDNA Synthesis Kit E65505 (New England BioLabs Inc, Hitchin, Herts, 
UK).  All equipment was sterilised under UV light before beginning the procedure.   
For each sample: 2 µl of dT23UN with a variable amount of nuclease-free H2O and a 
variable amount of sample were combined together.  The total mixture volume was 
8 µl.  After RNA spectrophotometry of each sample (using a NanoDrop machine); 
the approximate concentration of RNA was quantified in each sample.  The RNA 
concentration was expressed in nanograms/76icroliter (ng/µl).  We needed to 
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convert this into a microgram (1000 nanograms).  Not every sample’s RNA 
concentration was the same; therefore 1000 ng/µl of each sample was needed to 
have the same concentration of RNA for each sample.  
For example:  If the concentration of RNA was found to be 500 ng/µl in order to 
make this 1000 ng, we multiplied this by 2.  Therefore in this instance, we needed 2 
microliters of sample to be added to the mixture to make 1000 ng. 
Once the quantity of sample was determined, nuclease-free H2O was added to the 
mixture to make up a total volume of 8 µl.  Referring to the example above; if 2 µl of 
dT23UN and 2µl of RNA were needed, then 4 µl of NF-H2O was added to make an 8 
µl mix.  
The sample-mix was denatured at 70⁰C for five minutes.  After this, 12 µl of 
“multimix” was added to each sample.  The “multimix” consisted of a solution made 
up of 10 µl of “AMV reaction mix” and 2 µl of “AMV enzyme mix.”  Samples were 
subsequently incubated at 42⁰C for 1 hour for the enzyme mixture to bind to the 
RNA in the sample and begin cDNA synthesis. 
After one hour incubation; the samples were heated to 80°C for five minutes to 
arrest the synthesis reaction.  30 µl of NF-H2O was then pipetted into to each 
sample to make a total volume of 50 µl for each sample.  Samples were stored at -
80°C for future PCR.   
3.4.4 Polymerase Chain Reaction and Electrophoresis 
Polymerase chain reaction is based on the ability of a substance called DNA 
polymerase to produce and amplify DNA sequences complimentary to the template 
strand.  A pair of primers are added (one on each strand) and bind specifically to the 
3’ ends of the target sequence after heating the DNA to separate the strands. The 
primers then promote DNA polymerase enzyme called Taq to use the free 
nucleotides to bind to these sequences and synthesise a complimentary DNA 
sequence. The polymerase can only bind to molecules with a primer attached 
making this a very specific way of identifying a DNA sequence. The process above is 
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called a cycle and is repeated many times on the copied DNA strands to amplify the 
sequence; eventually forming billions of target sequence molecules.95 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-2 - How PCR works8   
For preparation of the primer with cDNA it was essential to carry out this procedure 
in a sterile ultraviolet hood to prevent contamination.  All equipment used in this 
experiment was UV sterilised for 10 minutes.   
A combination of HotStart Taq 2x master mix (New England Biolabs Inc, Hitchin, 
Herts, UK), the primer mix and nuclease-free water was prepared.  A total volume 
of 9 µl “mastermix” per sample was used in this experiment.  5 µl of which was Taq 
Hotstart, the amount of primer mix depending whether it was AR, SOX9 or BCAM 
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gene expression being tested (either 0.5 µl or 1 µl) and nuclease-free water was 
added to make the solution up to 9 µl. All primer concentrations were 100µM.  The 
amount of “mastermix” was prepared according to the quantity of samples used for 
example; for a sample size of 15, the “mastermix” needed was 15 x the quantity of 
each substance in the mix.  1 µl of the cDNA sample was pipetted into a microtubule 
with the 9 µl of “mastermix.”  For the PCR reaction, the internal control of the cDNA 
experiment that did not contain reverse transcriptase (NoRT) was added to the 
sample set, a negative control for the PCR experiment was also needed. This was 
achieved by adding 1 µl of nuclease-free water instead of cDNA.  A positive control 
was also needed for the validation of the target gene in the PCR which was 
dependent on the primer used.  Sample mixtures were placed in a PCR machine and 
the appropriate program selected - as temperatures and times varied at each stage 
depending on the primer sequence.  In some instances, primers investigating 
particular target sequences needed more PCR cycles than others. The samples were 
held in a 4°C environment after the PCR reactions had taken place (See below for 
details for each primer).  
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Table 3-11 - Primer Details, Controls and Programs 
Primer 
Name 
Sequence (5’-3’) Company Amount per 
sample for 
PCR 
Positive 
Control 
Program for PCR 
YWHAZ  Forward CGTTACTTGGCTGAGGTTGCC 
Reverse 
GTATGCTTGTTGTGACTGATCGAC 
SIGMA 1 µl N/A Stage 1:  
95°C - 30 seconds. 
Stage 2: (30 cycles) 
95°C – 20 seconds. 
56°C – 20 seconds. 
68°C – 30 seconds. 
Stage 3:  
68°C – 5 minutes. 
4°C Hold. 
GAPDH Forward 
ACCACAGTCCATGCCATCAC 
Reverse 
TCCACCACCCTGTTGCTG 
SIGMA 0.5 µl N/A Stage 1:  
95°C - 30 seconds. 
Stage 2: (25 cycles) 
95°C – 20 seconds. 
61°C – 20 seconds. 
68°C – 30 seconds. 
Stage 3:  
68°C – 5 minutes. 
4°C Hold. 
SOX9 Forward 
GTACCCGCACTTGCACAAC 
Reverse 
TCTCGCTCTCGTTCAGAAGTC 
SIGMA 0.5 µl LNCAP Stage 1:  
95°C - 30 seconds. 
Stage 2: (35 cycles) 
95°C – 20 seconds. 
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56°C – 20 seconds. 
68°C – 30 seconds. 
Stage 3:  
68°C – 5 minutes. 
4°C Hold. 
Androgen 
Receptor 
(AR) 
Forward 
AGGATGCTC TACTTCCGCCC 
Reverse 
CTGGCTGTACATCCGGGAC 
SIGMA 0.5 µl LNCAP Stage 1:  
95°C – 2 minutes. 
Stage 2: (30 cycles) 
95°C – 20 seconds. 
58°C – 20 seconds. 
68°C – 30 seconds. 
Stage 3:  
68°C – 5 minutes. 
4°C Hold. 
BCAM Forward 
CCTCGTCGTTGCTGTCTTCT 
Reverse 
TTGCAGATAGCAGGCCACT 
SIGMA 0.5 µl HEK293 Stage 1:  
95°C – 30 seconds. 
Stage 2: (30 cycles) 
95°C – 20 seconds. 
56°C – 20 seconds. 
68°C – 30 seconds. 
Stage 3:  
68°C – 5 minutes. 
4°C Hold. 
 82 
 
After the PCR procedure was finished, the samples were loaded into an agarose gel 
and a current passed through the samples to show the expression of the target 
sequence in each sample.  To make the gel, a casting tray was prepared in an 
electrophoresis chamber.  To make a 2% agarose gel (standard for all primers 
except GAPDH) - 2g of agarose powder was added to 100 millilitres of TBE buffer.  
GAPDH required a 1.5% agarose gel - 1.5g agarose powder in 100mls of TBE buffer. 
The solution was microwaved for a minimum of 4 minutes gently swirling the 
mixture half-way through.  The powder was completely dissolved and a clear 
solution remained.  The gel was then cooled to a warm temperature without it 
setting. 
10 microliters of “Sybr safe” liquid was pipetted into the gel solution. “Sybr safe” 
binds to the base pairs in the DNA so that when UV light is applied, the DNA is 
exposed and an image can be taken. The solution was mixed gently by swirling so 
that the “Sybr safe” incorporated itself into the solution.   
The gel was poured into an electrophoresis casting tray, making sure no large air 
bubbles remained in the mixture. Electrophoresis combs were inserted into the tray 
to create wells needed for the addition of the samples.  The liquid, gel mixture was 
left to stand for at least 20 minutes so that it set into a solid gel.  Making sure the 
gel was orientated so that the wells were horizontally spread across the casting tray 
once the gel has set; the combs were pulled out gently, to leave the wells ready for 
sample-insertion.  2 microliters of loading dye was added to each sample so that it 
appeared on the gel and because it contained the heavy substance, glycerol.  This 
made sure that the sample fell accurately into the well without spreading across the 
gel and contaminating adjacent samples.  10 microliters of each sample were 
pipetted into the wells and a 50 base pair DNA ladder marked the beginning of each 
set. The electrophoresis machine was set to 110 volts for 45 minutes.  Care was 
taken to ensure the current was rising from the top of the chamber and moving 
towards the samples in a way that they would move away from the wells and down 
the gel. 
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After 45 minutes the gel was ready for photographing.  This was performed in a UV 
Chamber.  The gel was unloaded onto a UV plate and UV light was passed through it 
to create an image of the gene expression in the samples onto the computer.  After 
adjusting the brightness of the sample a picture was saved onto the computer or 
printed indicating the varying expression between each of the samples.    
3.5 Tissue Explant Culture 
The principle of explant culture is to isolate cells from a tissue or small pieces of the 
tissue itself; that have been collected from a donor (in this case human fallopian 
tube and eutopic endometrium).  In growth media, small pieces of tissue adhere to 
a growth surface and migrate outwards – this is known as outgrowth.  The cells 
selected have the ability to migrate.96    
This lab procedure took place in a class II microbiological safety cabinet – this was to 
take care to prevent contamination with live tissue specimens and maintain a sterile 
environment for preparing the tissue samples for culture.  The hood was sterilised 
before and after use with 70% ethanol.   
In this study matched eutopic endometrial samples and fimbrial fallopian tube 
samples were collected and incubated for 24 hours with Dihydrotestosterone (DHT 
– SIGMA).  A small amount of DMEM/F12 media was poured into a petri-dish 
assigned to holding tube tissue and another for eutopic endometrial tissue.  The 
tissue was placed into the corresponding petri-dish so as to wash the cells before 
incubation.  A 1mM DHT solution was prepared by mixing with methanol.  A 5% 
mixture of 10% charcoal-stripped foetal bovine serum with DMEM/F12 media was 
then prepared for culture of the cells.  DHT was added to the serum/media 
combination at a concentration of 1ul DHT in 1000 µl of serum/media.  A vehicle 
was included for comparison with the DHT by addition of 1 µl of methanol instead 
of DHT.  A 24-well dish was labelled clearly for incubation of: fallopian tubes with 
DHT, fallopian tubes without DHT, eutopic endometrium with DHT and 
endometrium without DHT. 1000 µl of DHT mixture was pipetted into wells labelled 
“DHT” and 1000 µl of vehicle was added into each well labelled “vehicle.”  Tissue 
samples were cut into 3-4 mm sections and equal quantities of tissue sections were 
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added into each well making sure that the fallopian tube tissue was separate from 
the endometrial tissue. Contamination was prevented by submerging the scalpel 
and sterile forceps into 70% ethanol after tissue was dissected and placed into each 
mixture.  Ensuring that the lid was on the well plate; the samples were placed into a 
36.9⁰C CO2 incubator for 24 hours.  After 24 hours each cultured tissue sample was 
either immersed in RNA later and frozen for future PCR or placed in NBF and 
refrigerated for paraffin embedding and IHC (all explained above).  
3.6 Sample Analysis 
3.6.1 Immunohistochemistry 
Once samples had dried in the fume hood after mounting, they were analysed and 
scored according to the DAB staining intensity of the tissue.  The method of scoring 
changed according to the antibody that was used in the procedure: 
Table 3-12 - Scoring Techniques according to antibody. 
Antibody Scoring Method 
Beta Catenin Nuclear:  Percentage Positive 
Cytoplasmic:  Quickscore 
Junctional: Quickscore 
BCAM Quickscore 
KI67 Percentage Positive 
SOX9 Threshold analysis on image J 
SSEA-1 Quickscore 
Sialylated SSEA-1 Quickscore 
Androgen Receptor Modified Quickscore 
Oestrogen Receptor Alpha  Modified Quickscore 
Oestrogen Receptor Beta Modified Quickscore 
Progesterone Receptor Modified Quickscore 
 
 Tissue was analysed using the Nikon Eclipse 50 microscope and images were 
analysed, captured and saved using computer software called NIS elements 4.00.  
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The camera used with this software and connected to the microscope was called 
Nikon Digital Sight camera.  
3.6.1.1 Quickscore 
Quickscore analysis is a way of scoring sections that differ in intensity throughout 
the tissue.  This method takes into account the percentage of tissue that is stained 
and also the changing intensity throughout the sample. 
To begin, the slide was placed under the microscope and the quality of the stain 
was observed.  Some nuclei were stained with blue haematoxylin – these were 
negative.  Some cells were stained with brown DAB – these were positive.  When 
looking at a cytoplasmic staining the DAB concentrated inside the cell with no 
defined edge.  If junctional staining was present the DAB outlined the cell.  It either 
outlined the whole cell, the lateral parts of the cell junction or the basal layer of the 
cell.  A nuclear stain had brown DAB staining in the round nuclei inside the cell and 
it was confined to this organelle.  Some antibodies like Beta Catenin had staining in 
all three parts of a cell.  In this case, each part stained had to be scored separately 
as function of this antibody changes if it’s junctional compared to if its nuclear. 
Samples were divided into compartments; basal glands, basal stroma (if applicable), 
superficial glands, superficial stroma (if applicable) and luminal epithelium for 
endometrial tissue.  For tube the epithelial compartment and stromal compartment 
were analysed. 
The intensity of the staining was observed in each compartment.  The scores were 
divided into: 
0 = none, 1 = weak staining, 2 = moderate staining, 3 = strong staining. 
The overall percentage of staining was evaluated throughout the compartment:   
If 25% is stained – a score of 1 is given. 
If 50% is stained – a score of 2 is given. 
If 75% is stained – a score of 3 is given. 
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If 100% is stained – a score of 4 is given. 
The highest a compartment could score is 12.  This meant that 100% of the 
compartment is strongly stained.  The calculation is: 
3 (strong staining observed) X 4 (100% stained) = 12 
If this was not the case, the percentage scores could be spread across each 
intensity-score and each score given was multiplied and the total was added 
together: 
Table 3-13 - Example of Quickscore 
Sample 0 (None) 1 (Weak) 2 
(Moderate) 
3 (Strong) Total /12 
Basal 
Glands 
2 1 1  3 
Superficial 
Glands 
 1 2 1 8 
 
The scores were recorded in excel then processed to form a graph and statistically 
analysed using GraphPad Prism software (see below). 
3.6.1.2 Threshold Analysis 
For SOX-9 scoring it was necessary to use this method of analysis.  It involved 
capturing images on image J software, taking away the stromal compartment to 
leave the glands or epithelium, splitting the image into DAB and haematoxylin stains 
separately and recording the percentage threshold of each stain.  This used the 
principle that haematoxylin is a background stain and should be the baseline for 
calculating the amount of DAB that had stained the sample.  Using this principle, the 
DAB staining did not exceed the haematoxylin staining. 
10 images were captured of each layer to represent the compartment or the whole 
tissue was captured in the case of some isthmic tubes.  These images were saved as 
Tiff files and opened in imageJ.  Selecting the free-hand selection tool – an outline 
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was drawn carefully around the edge of the gland and the surrounding stroma was 
cleared, leaving just the glandular epithelia.  
Once the glands were cut out, “colour deconvolution” was selected.  This separated 
the DAB from the haematoxylin staining and created separate pictures in order to 
calculate the threshold of the colour. The threshold tool was selected, the 
haematoxylin image was highlighted and area of staining calculated by imageJ.  By 
selecting the measure tool the area that was highlighted, was measured.  The same 
process was repeated on the DAB stained picture.   
Figure 3-3 - Threshold analysis of epithelia using imageJ.  Guide to analysis in order from 1-4. 
88 
 
 
The following calculation was then made to obtain the overall percentage threshold 
of this image: 
Area stained = Percentage area of DAB stain 
  Percentage area of haematoxylin stain 
This analysis and measurement was made for all 10 pictures taken for each 
compartment.  An average of each of the measurements was made to represent an 
overall score of the tissue compartment: 
Picture scores for 1+2+3+4+5+6+7+8+9+10/10 = overall score for compartment 
3.6.1.3 Percentage Positive Staining 
This method of analysing a stained section is an estimate of the area of stained cells 
expressed as an overall percentage.  For some antibodies the DAB staining did not 
vary in intensity throughout the tissue sample – it was either positive or negative.  
In this case the most appropriate method of quantifying the staining of the antibody 
was to estimate the percentage of positive cells.  Each compartment was analysed 
and a close approximation of the positively stained cells were calculated.  The 
percentages were recorded in Excel and graphically represented on GraphPad. 
3.6.1.4 Modified Quickscore 
Steroid receptor antibody staining changed in intensity throughout and so the most 
appropriate way of analysing these is to use a quickscore method.  The percentage 
area stained was usually divided into 25% increments however a modified 
quickscore method narrowed the percentage bands.  This modification refined the 
scoring of each sample. The principle being; if >40% of a section was stained at a 
certain intensity then it was assumed that the majority of the compartment had 
that particular staining intensity.  If a lower percentage of the section was stained 
the scoring was spread over the bands to show the variation within the tissue 
sample. This essentially narrowed the percentage staining bands. They were divided 
as follows (the intensity scoring was the same as section 3.6.1.1): 
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0 -19% = 1 
20 - 39% = 2 
40% = 3 
>40% = 4 
The highest score a compartment could get was 12 therefore the percentages were 
divided and spread over the intensities but could never exceed a quickscore of 12.  
3.6.2 Polymerase Chain Reaction 
3.6.2.1 Densitometry 
After the images were taken of the electrophoresis gel, densitometry was 
performed to determine the relative transcript levels of AR, SOX9 and BCAM.  This 
could be achieved using the imageJ software.  The image was rotated to ensure that 
the wells were straight so that a band of expression could be plotted.  Using the 
rectangular selection tool a tight frame was created around the bands (each band 
corresponding to the relative transcript level in the sample).  This software enabled 
the user to create a graph in the form of a histogram representing the relative 
mRNA expression with each peak corresponding to each sample.  The peaks were 
then connected using the straight line selection tool.   The wand tool was then 
selected to click on each graph, identifying the area under the peak.  A table was 
created to numerically quantify the area selected and this represented the amount 
of signal in each sample.  
The methods above were performed in triplicate.  The ratio of each gene transcript 
was normalized to YWHAZ and GAPDH independently.  YWHAZ and GAPDH were 
the housekeeping genes used in this study.  These arbitrary values were used to 
compare the relative RNA levels between the different samples. 
3.6.3 Statistical Analysis of Data 
3.6.3.1 Organisation of Data in Excel 
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The scores of the IHC samples were split into compartments.  All 17 premenopausal 
matched samples were dated and re-organised into their cycle stages.  Further 
analysis was always cycle-stage specific to analyse any cycle-dependent variation in 
the eutopic endometrium and the fallopian tube.  The postmenopausal samples 
were also grouped together.    
3.6.3.2 GraphPad Prism 
GraphPad Prism is a piece of software for Windows and Mac computers that 
enables a scientist to produce 2D scientific graphs, curves (nonlinear regression,) 
statistics and organise data. It is normally used by biologists, social and physical 
scientists.97  
Once data was collected in an excel spreadsheet – that being scoring or 
densitometry data; It was copied into GraphPad and a graph produced.  GraphPad 
enables the user to select the graph necessary for representing the data 
appropriately.  The graph selected for analysis of the trends between each group, in 
each compartment was a bar chart. GraphPad automatically created a spreadsheet 
in which to place data. The data was organised as below: 
 
Figure 3-4 - Example of GraphPad Spreadsheet data for BCAM in menstrual phase. BG – Basal glandular 
epiethalia, SG  - Superficial Glandular Epithelia, LE – Luminal Epithelia, Fimbrial fallopian tube and Isthmic 
Fallopian Tube. 
Once the data was pasted into the spreadsheet a bar chart graph was automatically 
plotted of this data.  It was then labelled and formatted further so that it looks like 
below:  
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Figure 3-5 - Example of GraphPad Spreadsheet data for BCAM in menstrual phase. BG – Basal glandular 
epiethalia, SG  - Superficial Glandular Epithelia, LE – Luminal Epithelia, Fimbrial fallopian tube and Isthmic 
Fallopian Tube. 
On the X axis, the data was split into cycle stages.  On the Y axis, the score for each 
sample in that phase was plotted.  
Bar charts were created for each compartment across the menstrual cycle stages.  
Layouts were created within GraphPad prism to analyse the trends across all of the 
compartments and compare fallopian tubal mucosa with endometrial mucosa.  
These can be found in chapters 4, 5 and 6.      
For the PCR relative mRNA expression graphs a whisker graph with minimum to 
maximum values to show spread of expression values within each sample group 
was used. Columns for tissue and phase were plotted for example; fallopian tube in 
the secretory phase or postmenopausal fallopian tube. The normalised 
ratio/relative expression values were plotted along the Y axis.  A representative 
graph is below:  
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Figure 3-6 - Example of a whisker graph for BCAM PCR 
3.6.3.3 Statistical Analysis 
Descriptive statistics were calculated as each graph was produced.  For the sample 
groups analysed, median with range was plotted on the graphs and commented on 
throughout the results section.  Non-parametric T-Tests (Mann-Whitney and 
Wilcoxon tests) were performed where appropriate on the IHC and PCR data. 
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Chapter 4 Investigating Phenotypic Similarities between 
Fallopian Tube and Endometrium 
 
4.1 Introduction 
The fallopian tube and endometrium have the same embryological origin1, arising 
from the Mullerian ducts.18 Recent studies investigating the phenotypical 
differences in endometrial epithelial cells have revealed for the first time a set of 
markers that distinguish the epithelial cells from the stratum basalis of the 
endometrium.  The markers identified were nuclear SOX9, cell surface marker SSEA-
1 and nuclear beta catenin.2  Since the basalis is the germinal zone of the 
endometrium, the progenitor cells with regenerative abilities are expected to reside 
in this region.  It is thought that the abundance of progenitor cells residing in the 
basalis region give the endometrium its huge capacity to regenerate every month.3  
Agreeing with this notion, Valentijn et al demonstrated that basalis epithelial cells 
sorted on the expression of surface marker SSEA1, contain the cells with the ability 
to generate endometrial gland-like phenotype in 3D culture in vivo.2  Recently, it has 
also been thought that the distal fallopian tubal mucosa may also contain a stem 
population,4 an increase in cells expressing markers that were shown to be stem cell 
markers in other tissues, were identified here.1 This suggests that in the fallopian 
tube, the distal mucosa may be the equivalent to progenitor cell-rich endometrial 
basalis.  Definite stem or progenitor cells for either of these epithelial regions, are 
yet to be identified.  The characterisation of the epithelial layer of different parts of 
the fallopian tube in the context of the basalis markers that have recently been 
described in the endometrium, is yet to be done.  
Therefore, this chapter describes the work characterising the epithelial layer of the 
fallopian tube in the context of a panel of markers that were expressed by basalis 
epithelial cells with the germinal capacity in the endometrium - SOX9, SSEA-1 and 
beta catenin. Expression pattern of two new potential markers of basalis epithelium 
(sialylated SSEA-1 & BCAM) were also assessed. 
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BCAM is a marker that is localised to the basal layer of epithelial cells and is a 
receptor for laminin.65  Laminins have many functions including; adhesion, motility, 
growth, differentiation and apoptosis.  Basolateral BCAM staining on the epithelial 
cell surface indicates that there is an interaction with laminin which is thought to be 
important to maintain epithelial basolateral polarity. 98 
SOX9 is a transcription factor and has been located in basal epithelia of the 
prostate, the intestinal crypts and the outer root sheath of hair follicles.  Progenitor 
cells are all thought to reside in these particular regions.75 
SSEA-1 is an embryonic stem-cell surface marker and has recently been immuno-
localised to the glandular epithelial cells of the stratum basalis, confirming that this 
region is phenotypically distinct from the stratum functionalis.2 
Beta catenin is a downstream regulator of the canonical Wnt pathway and its 
accumulation in the nucleus leads to the activation of Wnt-responsive target 
genes.28 Studies have shown that the Wnts activate intracellular cascades that 
regulate cellular proliferation, differentiation, migration, and polarity.80  Nuclear 
beta catenin has been identified in a sub-population of epithelial cells in the basalis 
layer of the endometrium, whilst the nuclei of the stratum functionalis epithelia 
rarely expressed this marker.64 
The cell surface carbohydrate molecule, sialylated SSEA-1 (Sialyl SSEA1) is a marker 
that is involved in adhesion and cell to cell recognition.  It has been identified as the 
key marker by which the oocyte attracts sperm in order to facilitate fertilisation.99   
It is also abundantly present on the surface of epithelial cells in the endometrium 
and increases around the secretory phase of the menstrual cycle (the implantation 
period), along with MUC1.  It is thus thought to play a role in facilitating the 
implantation of an embryo.82 
A study comparing the markers that characterise the endometrium and in 
particular, the basalis layer has been conducted in order to gain an insight into 
whether the fallopian tubal epithelia is phenotypically similar to the endometrial 
glandular epithelia in this region. It was also necessary to investigate whether 
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postmenopausal epithelia of the endometrium and fallopian tube changed 
expression of these markers in this period.        
4.1.1 Patient Demographics and Methods 
This study was conducted over a 12 month period from August 2013-August 2014.  
For this procedure N=17 premenopausal samples were split into groups according 
to the menstrual cycle phase (see: Table 4-1- Number of samples in each group for 
immunohistochemistry) were stained from matched full thickness eutopic 
endometrium and fallopian tube taken from the isthmic and fimbrial ends of the 
tube. 
N=5 matched full thickness eutopic endometrium and fallopian tube 
postmenopausal sections were also collected. 
Table 4-1- Number of samples in each group for immunohistochemistry 
Study Group Number Eutopic 
Endometrium 
Number Isthmic 
Tube 
Number Fimbrial 
Tube 
Menstrual phase 4 3 3 
Proliferative phase 6 6 3 
Secretory phase 7 5 4 
Postmenopausal 5 2 5 
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Table 4-2 – Table of Demographics for Patients in Immunohistochemical Study  
Menstrual Cycle 
Phase 
Sample 
number 
 Age BMI Smoker Parity 
Menstrual 
Phase 
4 Mean (± 
SD) 
Median 
Range 
41 
(±4) 
40.5 
37-47 
29.3 
(±5.0) 
30.8 
21.2-
34.4 
1 (25%) 2 (±1) 
2 
1-3 
Proliferative 
Phase 
6 Mean (± 
SD) 
Median 
Range 
43 
(±5) 
43 
37-53 
29.3 
(±6.7) 
26.1 
23.1-
39.2 
0 (0%) 2 (±1) 
2 
0-3 
 
Secretory Phase 7 Mean (± 
SD) 
Median 
Range 
43 
(±4) 
44 
37-48 
27.7 
(±6.6) 
23.8 
21.7-
40.1 
3 (43%) 2 (±1) 
2 
1-4 
Postmenopausal 5 Mean (± 
SD) 
Median 
Range 
57 
(±7) 
55 
48-66 
25.6 
(±1.8) 
24.9 
23.6-
28.1 
2 (40%) 2 (±1) 
2 
1-3 
 
For polymerase chain reaction 3 matched secretory phase samples and 3 matched 
postmenopausal samples were examined; the tubal tissue was fimbrial.  Inclusion 
and exclusion criteria can be found in chapter 3. 
Table 4-3 - Table of Demographics for Patients in RT-PCR Study 
Menstrual Cycle 
Phase 
Sample 
number 
 Age BMI Smoker Parity 
Secretory Phase 3 Mean (± 
SD) 
Median 
Range 
41 (±7) 
 
45 
32-47 
26.9 
(±3.7) 
 
26.6 
22.6-
31.6 
0 (0%) 1 (±1) 
 
0 
0-2 
Postmenopausal 3 Mean (± 
SD) 
Median 
Range 
57 (±7) 
 
52 
52-66 
29.5 
(±7) 
 
24.9 
24-39.6 
1 (33%) 
 
 
3 (±0.5) 
 
3 
2-3 
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4.1.2 Reference Genes for Polymerase Chain Reaction 
Two reference genes were used in the reverse transcriptase-PCR reactions. YWHAZ 
was suggested to be one of the best housekeeping genes for normal/diseased 
endometrium for qPCR, whilst GAPDH was shown not to perform so well.  GAPDH 
has been shown to be a better housekeeping gene in the fallopian tube than 
YWHAZ for qPCR.  In this study matched endometrium and fallopian tube were 
investigated and therefore GAPDH and YWHAZ were chosen to produce an efficient 
normalised ratio of both tissues.  Relative expression of the target sequence under 
study was determined by using two reference genes, resulting in the production of 
two graphical representations of gene expression. As a result of having two 
reference genes instead of one, the validity of each of these reference genes could 
be examined.  Observing the expression of BCAM, SOX9 and AR in the samples with 
both YWHAZ and GAPDH as housekeeping genes – the graphical patterns for all 
genes were relatively similar.  With BCAM it could be seen that after being 
normalised to both GAPDH and YWHAZ, similar patterns of relative expression were 
produced – thus proving to be effective reference genes for both fallopian tube and 
endometrial tissue. 
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Figure 4-1 - Whisker plot graphs with median, minimum and maximum values for BCAM/ YWHAZ and GAPDH as 
reference genes.  Relative expression values for Postmenopausal fallopian tube (N=3), Postmenopausal eutopic 
endometrium (N=3), Secretory phase fallopian tube (N=3) and Secretory phase eutopic endometrium (N=3). 
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Differences between GAPDH and YWHAZ were observed in the SOX9 PCR results.  
The general trend was similar with lower endometrial secretory phase expression of 
SOX9 in comparison to the postmenopausal samples and secretory tube however; 
with YWHAZ as the reference gene it appeared that the median SOX9 mRNA 
expression in the secretory phase fallopian tube was higher than all other sample 
sets. Whilst this is strikingly clear on observation; the maximal and minimal 
expression scale on the box and whisker diagram overlapped with the other sample 
sets which meant that the relatively higher tubal expression was not statistically 
significant (P=>0.05).  The protein expression of SOX9 shows a stronger expression 
in the postmenopausal tube in comparison to the secretory tube.  With this in mind, 
the PCR - graph that most depicts the protein expression pattern, is the relative 
expression of SOX9 with GAPDH as the housekeeping gene.  This is because 
postmenopausal fallopian tube had relatively higher SOX9 expression than the 
fallopian tube in secretory phase.  As a consequence, the GAPDH data for 
normalisation of RT-PCR for AR, SOX9 and BCAM has been chosen to represent the 
mRNA expression in fallopian tube and endometrium in the results. 
 
  Figure 4-2 - Whisker plot graphs with median, minimum and maximum values for SOX9/ YWHAZ and GAPDH as 
reference genes.  Relative expression values for Postmenopausal fallopian tube (N=3), Postmenopausal eutopic 
endometrium (N=3), Secretory phase fallopian tube (N=3) and Secretory phase eutopic endometrium (N=3).  
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4.2 Basalis Markers 
4.2.1 Basal Cell Adhesion Molecule (BCAM) 
4.2.1.1 Immunohistochemistry 
It has been found previously that BCAM is present in the cell junctions; either 
basolaterally or covering the whole cell surface of epithelial cells using 
immunohistochemical staining techniques.  The study findings regarding this 
molecule are described below:  
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Figure 4-3 – Images for BCAM IHC staining at 400x magnification across the menstrual phase, proliferative 
phase, secretory phase and postmenopause.  In the stratum basalis, stratum functionalis, luminal epithelia, 
isthmic fallopian tubal epithelia and fimbrial fallopian tubal epithelia. 
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Figure 4-4 – Bar graphs showing median quickscores with range for the immunohistochemical staining of BCAM 
divided by tissue and compartments throughout the menstrual cycle phases and postmenopause. A) Bar graph 
of fallopian tube quickscores with: Isthmic fallopian tube in the menstrual phase (N=3), fimbrial fallopian tube in 
the menstrual phase (N=3), Isthmic fallopian tube in the proliferative phase (N=6), Fimbrial fallopian tube in the 
proliferative phase (N=3), Isthmic fallopian tube in the secretory phase (N=5), fimbrial fallopian tube in the 
secretory phase (N=4), postmenopausal isthmic fallopian tube (N=1), postmenopausal fimbrial fallopian tube 
(N=5). B) Bar graph of basal glandular epithelia quickscores with: basal glands in the menstrual phase (N=4), 
proliferative phase (N=6), secretory phase (N=7) and postmenopause (N=5). C) Bar graph of functional glands in 
the menstrual phase (N=4), proliferative phase (N=6) and secretory phase (N=7).  D) Bar graph of luminal 
epithelia in menstrual phase (N=3), proliferative phase (N=6), secretory phase (N=7) and postmenopause (N=4).  
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Starting with junctional/basal expression of BCAM in the premenopausal fimbrial 
end of the tube; interestingly the highest expression lies in the proliferative phase 
of the cycle and there is a drop in junctional staining during the secretory phase 
(median = 11 and 8.5, respectively).  Junctional staining is seen in the 
postmenopausal fimbrial epithelial cells with expression comparable to that in the 
secretory phase of the cycle (median = 9 and 8.5 respectively).  The isthmic section 
of the fallopian tube shows a different pattern of BCAM junctional staining across 
the menstrual cycle.  It appears that this molecule is present consistently across the 
cycle with little variation of expression therefore does not appear to be cycle 
dependent.  There is a sharp increase in junctional/basal BCAM expression however 
in the postmenopausal isthmic region. 
In the basalis layer of the endometrium, epithelial glands showed positivity for 
BCAM, this was however subject to change throughout the phases of the menstrual 
cycle.  Junctional BCAM expression in the basal glandular compartment was highest 
in the proliferative phase of the cycling endometrium (MQS=7) and lowest in the 
secretory phase (MQS=5), a rise in this molecule in the junctions of the endometrial 
epithelia is seen in the postmenopausal population (MQS=8). Functional glandular 
epithelia also express BCAM with the same pattern as the basalis but with much 
weaker expression in the secretory phase (MQS=2).  Luminal epithelia show very 
high junctional levels of BCAM in the proliferative phase (MQS=9) with the same 
overall pattern as the rest of the endometrium.  Postmenopausal lumen has 
moderate junctional expression reflective of the menstrual phase of cycling 
endometrium (MQS=6.5).  
It appeared that junctional staining of BCAM in the fimbrial end of the fallopian 
tube had the same pattern of expression throughout the menstrual cycle as the 
endometrium due to the fact that BCAM increased in the proliferative phase and 
was lowest in the secretory phase. Also notably, the isthmic region did not vary 
during the menstrual cycle showing that this region is potentially distinctive from 
the rest of the distal reproductive tract.  High expression of BCAM in the junction is 
present in both the fimbrial tube and basal glands in postmenopausal women.  
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Luminal junctional staining is weaker than the tubes and basalis endometrium 
(MQS=6.5). 
4.2.1.2 Distribution of Junctional Staining Between Tissue 
Compartments 
In the endometrial basalis compartment throughout the menstrual cycle the 
distribution of junctional staining varied greatly.  Most samples seem to have a 
mixture of epithelial cells with basal, basolateral and whole cell staining. A minority 
of tissue samples had only basolateral staining in the menstrual and proliferative 
phase.  More samples in secretory phase were found to have only basolateral 
staining (3/6).  In the functionalis it was clear that the vast majority of the sample 
population had whole cell junctional epithelial staining in abundance with only 
some basal stained epithelia.  Interestingly, the luminal epithelium had mostly 
basolateral staining, particularly the samples in the secretory phase of the 
menstrual cycle.   Although the vast majority of the fallopian tube (isthmic and 
fimbrial ends) showed basal and basolateral staining regardless of menstrual phase; 
it is to be noted that the fimbrial end of the fallopian showed a number of samples 
with whole cell BCAM staining in comparison to 100% of isthmic samples having 
basal staining of BCAM.  
In the postmenopausal basal endometrium all samples in the population showed 
glands with whole cell junctional staining.  The lumen had whole cell staining 
however; some basolateral staining remained.  In contrast to the premenopausal 
fallopian tube the postmenopausal tube contained more whole cell tubal junctional 
staining with some basolateral BCAM remaining. 
 
 
 
 
W 
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4.2.1.3 Reverse Transcriptase - Polymerase Chain Reaction (RT-PCR). 
Using RT-PCR techniques; BCAM primer was added to each of the samples to 
investigate the mRNA expression of this molecule.   
 
Figure 4-5 – Whisker graph with median and minimum to maximum values showing relative expression of BCAM 
in N=3 matched postmenopausal eutopic endometrium and fallopian tube samples and N=3 matched secretory 
phase eutopic endometrium and fallopian tube samples normalised to GAPDH,  the reference gene.      
BCAM mRNA was expressed most abundantly in the postmenopausal eutopic 
endometrium closely followed by postmenopausal distal tubal tissue.  Secretory 
phase eutopic endometrium was found to have the lowest mRNA expression overall 
and secretory phase tube had slightly higher relative expression, but lower than the 
postmenopausal samples.   
After observing the graphical results for both RT-PCR and IHC – it is clear that both 
expression patterns support each other.  Postmenopausal protein and mRNA 
expression of BCAM in eutopic endometrium was higher than that of the secretory 
phase protein and mRNA. 
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4.2.2 (Sex Determining Region Y)-Box 9 (SOX9) 
4.2.2.1 Immunohistochemistry 
Threshold analysis of expression of SOX9 looked at the percentage of positive 
nuclear DAB staining over negative haematoxylin staining.  
 
Figure 4-6 - Images for SOX9 IHC staining at 400x magnification across the menstrual phase, proliferative phase, 
secretory phase and postmenopause.  In the stratum basalis, stratum functionalis, luminal epithelia, isthmic 
fallopian tubal epithelia and fimbrial fallopian tubal epithelia 
106 
 
 
Figure 4-7 – Bar graphs showing median threshold percentage with range for the immunohistochemical staining 
of SOX9 divided by tissue and compartments throughout the menstrual cycle phases and postmenopause. A) Bar 
graph of fallopian tube threshold percentage with: Isthmic fallopian tube in the menstrual phase (N=3), fimbrial 
fallopian tube in the menstrual phase (N=3), Isthmic fallopian tube in the proliferative phase (N=6), Fimbrial 
fallopian tube in the proliferative phase (N=3), Isthmic fallopian tube in the secretory phase (N=5), fimbrial 
fallopian tube in the secretory phase (N=4), postmenopausal isthmic fallopian tube (N=2), postmenopausal 
fimbrial fallopian tube (N=5). B) Bar graph of basal glandular epithelia threshold percentage with: basal glands 
in the menstrual phase (N=4), proliferative phase (N=6), secretory phase (N=7) and postmenopause (N=5). C) Bar 
graph of functional glands in the menstrual phase (N=4), proliferative phase (N=5) and secretory phase (N=6).  
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Beginning in the fallopian tube, the fimbrial end had varying patterns of expression 
throughout the menstrual cycle.  The highest median threshold percentage (MTP) 
was found to be during the menstrual phase (58 %).  The proliferative phase saw a 
decrease in nuclear SOX9 (MTP 35%) and a subsequent small increase in expression 
in the secretory phase (MTP 44 %).  An increase in SOX9 is seen to occur in the 
postmenopausal distal tubal epithelium (MTP 76 %). Interestingly it seems as 
though the expression of SOX9 increases in a step-wise manner in the isthmic end 
of the fallopian tube from the beginning to the end of the menstrual cycle with the 
most abundantly positive staining occurring in samples collected during the 
female’s secretory phase (MTP 63%).  A small increase in SOX9 expression is 
apparent after the menopause (MTP 66 %).  
The endometrial basal glands have positive SOX9 staining throughout the menstrual 
cycle however during the secretory phase – there is a decrease in MTP in 
comparison to the other two phases (MTP 38 %).  No difference in nuclear SOX9 
was observed between the menstrual and proliferative phases.  Postmenopausal 
endometrium had very strong positive SOX9 expression in the basalis (MTP 86 %).  
The functionalis’ superficial glands had a very similar pattern of expression 
throughout the menstrual cycle to the basalis.  A small 5% increase in MTP was seen 
to occur during the proliferative phase in functional glands, however. A dramatic 
diminution of SOX9 was observed during the secretory phase (MTP 29 %). 
On comparison of all compartments the isthmic end of the tube seemed to have its 
own unique variation of expression of SOX9 throughout the menstrual cycle.  Both 
tubal regions however did see an increase in expression of SOX9 protein expression 
in the secretory phase; an observation that is the opposite of what was revealed in 
the endometrium.  As stated above - the superficial and basal endometrial 
compartments mirror each other, with the functionalis compartment’s SOX9 
expression appearing to be at a lower level if displayed graphically.  Even though 
the infundibular end of the tube was seen to increase its SOX9 protein expression 
after proliferative phase the MTP was similar to that of the endometrial layers.  The 
most unanimous finding between the endometrium and fallopian tubal regions was 
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that - postmenopausal SOX9 protein expression increased to high MTP levels; 
exceeding that of cycling endometrium and fallopian tube. 
4.2.2.2 RT-PCR mRNA expression of SOX9 
 
Figure 4-8 - Whisker graph with median and minimum to maximum values showing relative expression of SOX9  
in N=3 matched postmenopausal eutopic endometrium and fallopian tube samples and N=3 matched secretory 
phase eutopic endometrium and fallopian tube samples normalised to GAPDH, the reference gene.      
The densitometry data collected for the PCR mRNA expression of SOX9 displays 
evidence that postmenopausal expression of SOX9 in the eutopic endometrial and 
fimbrial tubal samples are the same.  Secretory phase distal fallopian tube had 
stronger mRNA levels of SOX9.  The secretory endometrium showed expression 
comparative to that of the postmenopausal tissue.   
Although subtle, the expression of SOX9 relative to GAPDH is higher in the 
postmenopausal eutopic endometrium and fimbrial fallopian tube than the 
secretory phase tissue.  This reflects the IHC results and supports the conclusion 
drawn from the IHC data that SOX9 is higher in endometrium and fallopian tube 
when in the postmenopausal state. 
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4.2.3 Stage Specific Embryonic Antigen-1 (SSEA-1) 
4.2.3.1 Immunohistochemistry 
As described in previous chapters, SSEA-1 is a cluster of differentiation molecule.  It 
is present on the surface of cells and its expression can be measured using the 
quickscore method taking into account the overall percentage of positive staining 
and the distribution of intensity of this staining throughout the tissue compartment. 
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Figure 4-9 - Images for SSEA-1 IHC staining at 400x magnification across the menstrual phase, proliferative 
phase, secretory phase and postmenopause.  In the stratum basalis, stratum functionalis, luminal epithelia, 
isthmic fallopian tubal epithelia and fimbrial fallopian tubal epithelia. 
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Figure 4-10 - Bar graphs showing median quickscores with range for the immunohistochemical staining of SSEA-
1 divided by tissue and compartments throughout the menstrual cycle phases and postmenopause. A) Bar graph 
of fallopian tube quickscores with: Isthmic fallopian tube in the menstrual phase (N=3), fimbrial fallopian tube in 
the menstrual phase (N=3), Isthmic fallopian tube in the proliferative phase (N=6), Fimbrial fallopian tube in the 
proliferative phase (N=3), Isthmic fallopian tube in the secretory phase (N=5), fimbrial fallopian tube in the 
secretory phase (N=4), postmenopausal isthmic fallopian tube (N=2), postmenopausal fimbrial fallopian tube 
(N=5). B) Bar graph of basal glandular epithelia quickscores with: basal glands in the menstrual phase (N=4), 
proliferative phase (N=6), secretory phase (N=7) and postmenopause (N=5). C) Bar graph of functional glands in 
the menstrual phase (N=4), proliferative phase (N=5) and secretory phase (N=7).  D) Bar graph of luminal 
epithelia in menstrual phase (N=3), proliferative phase (N=5), secretory phase (N=7) and postmenopause (N=4).  
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Beginning at the fimbrial end of the fallopian tube, SSEA-1 is present but with low 
expression.  Cyclical variation was seen to occur in this region with low expression in 
the menstrual phase and an increase during the proliferative phase.  No SSEA-1 was 
seen to be expressed during the secretory phase.  In comparison to the cycling 
endometrium, the SSEA-1 expression in the postmenopausal population increased.  
The isthmic region of the fallopian tube was observed to have exactly the same 
pattern as described above but at a higher overall expression level than the fimbrial 
tube Median Quickscores (MQ) of 4,5,1,4 and 1,2,0,3 respectively. 
The endometrium was seen to vary according to tissue compartment greatly.  High 
expression of SSEA-1 existed within the basal epithelia although there was cyclical 
variation.  The menstrual and proliferative phases have high expression of this 
molecule and a decrease is then seen in the secretory phase (MQ = 5). 
Postmenopausal SSEA-1 in basal epithelia is very high (MQ = 10).  The Functionalis 
and Luminal layers showed a different pattern of expression with lower expression 
reflected in the quickscore analysis.  Although little variation between the 
menstrual phases existed there seemed to be a slightly higher expression of this 
molecule in the menstrual population and lower expressions of SSEA-1 in the 
proliferative and secretory phases.  The lumen had low expression of SSEA-1 in the 
postmenopausal period (MQ = 2.5) 
On comparison of the expression patterns in the different tissue compartments, the 
tubes had a similar expression pattern throughout the menstrual phases to the 
basalis compartment of the endometrium however, at a much lower level than the 
basal glands.  The quickscores observed in this tissue where in the same region as 
the functionalis layer of the endometrium - but with a pattern that reflected the 
changes seen in the basalis.  The superficial glandular epithelia and the luminal 
epithelia had a similar downward trend throughout the cycling endometrium and 
the luminal epithelia maintained this low expression after the menopause; unlike 
the basal glands which demonstrated a high SSEA-1 expression (MQ = 2.5 and 10, 
respectively). 
4.2.4 Beta Catenin 
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Beta catenin, a key part of the canonical Wnt pathway (as explained previously) can 
be found in the nuclei, cytoplasm and junctions of cells. 
 
Figure 4-11 - Images for Beta Catenin IHC staining at 400x magnification across the menstrual phase, 
proliferative phase, secretory phase and postmenopause.  In the stratum basalis, stratum functionalis, luminal 
epithelia, isthmic fallopian tubal epithelia and fimbrial fallopian tubal epithelia. 
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4.2.4.1 Immunohistochemistry (Nuclear) 
 
Figure 4-12 - Bar graphs showing median percentage positive with range for the immunohistochemical staining 
of Nuclear Beta Catenin divided by tissue and compartments throughout the menstrual cycle phases and 
postmenopause. A) Bar graph of fallopian tube percentage positive nuclei with: Isthmic fallopian tube in the 
menstrual phase (N=2), fimbrial fallopian tube in the menstrual phase (N=3), Isthmic fallopian tube in the 
proliferative phase (N=6), Fimbrial fallopian tube in the proliferative phase (N=3), Isthmic fallopian tube in the 
secretory phase (N=5), fimbrial fallopian tube in the secretory phase (N=4), postmenopausal isthmic fallopian 
tube (N=2), postmenopausal fimbrial fallopian tube (N=5). B) Bar graph of basal glandular epithelia percentage 
positive nuclei with: basal glands in the menstrual phase (N=4), proliferative phase (N=6), secretory phase (N=7) 
and postmenopause (N=5). C) Bar graph of functional glands in the menstrual phase (N=4), proliferative phase 
(N=6) and secretory phase (N=7).  D) Bar graph of luminal epithelia in menstrual phase (N=3), proliferative phase 
(N=6), secretory phase (N=7) and postmenopause (N=4).  
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The nuclear positive staining for beta catenin was very low throughout both the 
tubes and endometrium however; there was some positivity and some variation 
between cycle stages that can be commented on.  The distal fallopian tube had the 
lowest percentage positive nuclear beta catenin in the proliferative phase of the 
cycling population with a slightly higher expression in the secretory phase.  The 
postmenopausal population had a median positive beta catenin of 10% - this being 
higher than the premenopausal population.  More proximally at the isthmic end of 
the tube greater variability could be seen.  The lowest expression of beta catenin 
also occurred during the proliferative phase and the highest expression was seen in 
the menstrual phase population.  Secretory phase of the menstrual cycle saw a 
slight increase in expression of nuclear beta catenin but by no means as abundant 
as the menstrual phase population.  Like the fimbrial end, increased percentage 
positivity was seen in the postmenopausal isthmic tube (Median = 25 %).   
The endometrium has great compartmental variability.  Starting in the basalis 
endometrial glands from median percentage positive scores it seems as though 
nuclear beta catenin increases in a step-wise manner throughout the menstrual 
cycle; with the lowest expression in the menstrual phase and the highest expression 
in the secretory phase (median 26 %).  Postmenopausal basal epithelia also 
expressed nuclear beta catenin but at a low level (median 15%).  The superficial 
glandular epithelia had consistently low nuclear beta catenin throughout the 
menstrual cycle with little variability.  The luminal epithelia had negative nuclear 
beta catenin staining in the menstrual, proliferative and secretory phases of the 
cycle (median 0 %).  The postmenopausal lumen had more nuclear positivity 
(median 7%) than the cycling endometrium but lower than the basalis region 
(median 15 %).  
On comparison of the tissues and compartments there is some variability seen.  The 
tubes share a similar pattern of beta catenin expression throughout the menstrual 
cycle however; the basalis epithelial glands express nuclear beta catenin in a 
different pattern.  As has been described the glands increase their nuclear beta 
catenin in a step-wise manner throughout the cycle with the highest positivity being 
in the secretory phase.  The tubes show their highest expression in the menstrual 
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and secretory phases and the lowest nuclear beta catenin in the proliferative phase.  
The basalis glandular epithelia also had an overall higher expression of nuclear beta 
catenin than the tubes and other compartments of the endometrium.  The 
postmenopausal expression of nuclear beta catenin in the basalis was also slightly 
higher than the fimbrial tube (15 and 10 %, respectively).  The highest beta catenin 
expression in the postmenopausal population was seen in the isthmic tube (median 
25 %). The superficial epithelia had very low expression of nuclear beta catenin and 
in contrast to the tubes and basalis, showed little variability through the cycle.  
Luminal epithelia had absent nuclear beta catenin throughout the whole menstrual 
cycle with no variability. The negligible percentage positive nuclei in the lumen are 
similar to the superficial glandular epithelia. 
 
4.2.4.2 Immunohistochemistry (Cytoplasmic) 
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Figure 4-13 - Bar graphs showing median quickscores with range for the immunohistochemical staining of 
Cytoplasmic Beta Catenin divided by tissue and compartments throughout the menstrual cycle phases and 
postmenopause. A) Bar graph of fallopian tube quickscores with: Isthmic fallopian tube in the menstrual phase 
(N=2), fimbrial fallopian tube in the menstrual phase (N=3), Isthmic fallopian tube in the proliferative phase 
(N=5), Fimbrial fallopian tube in the proliferative phase (N=3), Isthmic fallopian tube in the secretory phase 
(N=5), fimbrial fallopian tube in the secretory phase (N=4), postmenopausal isthmic fallopian tube (N=2), 
postmenopausal fimbrial fallopian tube (N=5). B) Bar graph of basal glandular epithelia quickscores with: basal 
glands in the menstrual phase (N=4), proliferative phase (N=6), secretory phase (N=7) and postmenopause 
(N=5). C) Bar graph of functional glands in the menstrual phase (N=4), proliferative phase (N=6) and secretory 
phase (N=7).  D) Bar graph of luminal epithelia in menstrual phase (N=4), proliferative phase (N=6), secretory 
phase (N=7) and postmenopause (N=4).  
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The cytoplasmic presence of beta catenin was moderately expressed in fallopian 
tubes and eutopic endometrium.  Cyclical variation occurred in all tissues.  The 
fimbrial fallopian tube expressed cytoplasmic beta catenin most abundantly during 
the proliferative phase of the menstrual cycle (MQ = 6).  The weakest presence of 
beta catenin in the cytoplasm occurred during the menstrual phase (MQ = 2).  
Isthmic fallopian tube (proximal) had lowest expression of beta catenin during the 
secretory phase of the menstrual cycle (MQ = 2).  Both the menstrual and 
proliferative phases had moderate cytoplasmic beta catenin presence.  
Postmenopausal cytoplasmic beta catenin is moderate in both the proximal and 
distal ends (MQ = 5.5 and 7, respectively). 
In matched eutopic endometrium; the basal epithelial cells also had moderate 
expression of cytoplasmic beta catenin.  Cyclical variation was subtle but a slight 
increase during the proliferative phase was observed (MQ = 6).  The functional 
glandular epithelia were noticeably lower than the other compartments with 
median quickscores of 3 or lower.  Little cyclical variation occurred however; 
proliferating glands had a slight increase in expression of beta catenin (MQ = 3).  
The luminal epithelial cytoplasmic presence of beta catenin was low with no cyclical 
variation (MQ = 1).  Postmenopausal cytoplasmic beta catenin was high in basal 
glandular epithelia (MQ = 8).  Moderate luminal expression of beta catenin was 
observed (MQ = 4). 
On comparison between the two tissues and compartments both basal glandular 
epithelia and tubal epithelia showed moderate expression of cytoplasmic beta 
catenin throughout.  The fimbrial fallopian tube and basal glandular epithelia had 
the same expression of beta catenin during the proliferative phase.  The isthmic 
tube had lowest expression during the secretory phase whereas fimbrial tube had 
weaker expression during the menstrual phase.  Low expression of beta catenin was 
observed in the functional epithelial glands and luminal epithelia with little cyclical 
variation.  Overall cyclical variation of beta catenin throughout the menstrual cycle 
was less obvious than seen in the tubal epithelia.  Postmenopausal expression was 
higher in all tissues and compartments.  Highest expression of cytoplasmic beta 
catenin was observed in the basal glands, closely followed by the fimbrial epithelia 
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(MQ = 8 and 7, respectively).  Both proximal tubal epithelia and lumen had 
moderate expression of this molecule in the postmenopausal sample population. 
4.3 Luminal Surface marker 
4.3.1 Sialylated SSEA-1 (Sialyl SSEA-1) 
4.3.1.1 Immunohistochemistry 
 
Figure 4-14 - Images for Sialylated SSEA-1 IHC staining at 400x magnification across the menstrual phase, 
proliferative phase, secretory phase and postmenopause.  In the stratum basalis, stratum functionalis, luminal 
epithelia, isthmic fallopian tubal epithelia and fimbrial fallopian tubal epithelia. 
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Figure 4-15 - Bar graphs showing median quickscores with range for the immunohistochemical staining of 
Sialylated SSEA-1 divided by tissue and compartments throughout the menstrual cycle phases and 
postmenopause. A) Bar graph of fallopian tube quickscores with: Isthmic fallopian tube in the menstrual phase 
(N=3), fimbrial fallopian tube in the menstrual phase (N=3), Isthmic fallopian tube in the proliferative phase 
(N=6), Fimbrial fallopian tube in the proliferative phase (N=2), Isthmic fallopian tube in the secretory phase 
(N=5), fimbrial fallopian tube in the secretory phase (N=4), postmenopausal isthmic fallopian tube (N=2), 
postmenopausal fimbrial fallopian tube (N=5). B) Bar graph of basal glandular epithelia quickscores with: basal 
glands in the menstrual phase (N=4), proliferative phase (N=6), secretory phase (N=7) and postmenopause 
(N=5). C) Bar graph of functional glands in the menstrual phase (N=4), proliferative phase (N=5) and secretory 
phase (N=7).  D) Bar graph of luminal epithelia in menstrual phase (N=3), proliferative phase (N=4), secretory 
phase (N=7) and postmenopause (N=4).  
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The sialylated form of SSEA-1 is abundantly expressed in the human fallopian tubes.  
Starting with the fimbrial epithelia, strong expression of Sialyl SSEA-1 existed on the 
surface of the cells.  The expression of this molecule goes down in the proliferative 
phase with the highest levels being in the menstrual phase and the lowest in the 
proliferative phase (MQ = 9 and 4.5, respectively).  This surface marker is expressed 
very strongly at the isthmic end of the fallopian tube.  It seems to follow the same 
expression pattern as the fimbrial tube but at a higher expression level.  Lower 
expression is during the proliferative phase (MQ = 8) and higher expression is seen 
in the menstrual and secretory phases (MQ = 10).  Postmenopausal expression of 
Sialyl SSEA-1 is very high with the MQ of the fimbrial epithelia being 9 and the MQ 
at the isthmic end being 10.5 therefore increasing more proximally.  The overall 
expression at the isthmic end of the tube was generally higher in the 
premenopausal population. 
The basalis endometrial glands have a moderate expression of Sialyl SSEA-1 with the 
highest expression being in the proliferative phase and lowest expression in the 
secretory phase of the menstrual cycle (MQ = 7.5 and 5, respectively). The 
postmenopausal levels of Sialyl SSEA-1 reflect that of the proliferative phase of the 
cycling endometrium i.e. there is relatively strong expression in this population 
group (MQ = 8).  The expression of Sialyl SSEA-1 is more weakly expressed in the 
superficial glandular epithelia.  The lowest expression is during the proliferative 
phase and slightly higher expression can be seen in the menstrual and secretory 
phases but the quickscores remain low throughout (MQ = 3 and 4, respectively). 
Interestingly the luminal epithelia strongly express this molecule.  The expression 
pattern varies greatly with the strongest surface staining being in the menstrual 
phase and then decreasing until the secretory phase where the expression is lowest 
(MQ = 11 and 6, respectively). The postmenopausal lumen had moderate 
expression of this molecule with an MQ of 7; a median quickscore that is close to 
the basalis endometrium therefore suggesting a lack of phenotypic variability 
between the two layers during this time.  
The comparison of the tissues shows that - whilst expression is apparent in the 
basalis compartment of the endometrium, the strongest Sialyl SSEA-1 was present 
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in the luminal epithelia.  The high quickscore values given across the menstrual 
phases and postmenopausal tissue of the luminal epithelia are very similar to that 
of the isthmic and fimbrial tube.  Although the isthmic tubal epithelia had a strong 
presence of Sialyl SSEA-1 – the pattern of expression seemed to negatively correlate 
throughout the cycle with the fimbrial and luminal epithelia.  The fimbrial tube had 
the same pattern of variable expression throughout the menstrual cycle as the 
lumen.  The difference in expression between the phases however; was more subtle 
in the fimbrial tube than the lumen. The weakest expression of Sialyl SSEA-1 was on 
the surface of the superficial glandular epithelia.  Basal glandular epithelia has the 
same strong expression of Sialyl SSEA-1 in the proliferative phase as the luminal and 
fimbrial epithelia (MQ = 8).  In the postmenopausal population the fallopian tube 
seems to have stronger expression of Sialyl SSEA-1 than the endometrium overall. 
4.2 Summary of Results and Discussion Points 
4.2.1 Comparison between the endometrial basalis epithelium and 
fallopian tubal epithelium 
The results have been explained in detail above however, there are some salient 
points that will be summarised.  
An observation from the results was that the distal tubal epithelia and endometrial 
basalis epithelia have the same cyclical pattern of BCAM expression.  Notably, more 
whole cell surface staining was observed in these regions suggesting less 
engagement with laminin.   
Table 4-4 – Table demonstrating the quickscore levels of BCAM represented by the symbol + in distal fallopian 
tube and basal glandular epithelia.  The key below explains the corresponding expression levels according to the 
results shown in graphs in figure 4-4. 
KEY 
Quickscore Value/Percentage Positive Representative Symbol for each value 
(+) 
>0 ≤3 OR >0% ≤25% + 
>3 ≤6 OR >25% ≤50% ++ 
>6 ≤9 OR >50% ≤75% +++ 
>9 ≤12 OR >75% ≤100% ++++ 
123 
 
BCAM Fimbrial Fallopian 
Tubal Epithelia 
Endometrial Basalis 
Epithelia 
Menstrual Phase +++ +++ 
Proliferative Phase ++++ +++ 
Secretory Phase +++ ++ 
Postmenopausal +++ +++ 
 
It is apparent from the results that SSEA-1, SOX9 and cytoplasmic/ nuclear beta 
catenin were expressed throughout the menstrual cycle in the endometrial basalis 
epithelium.  Highest expression was seen in the postmenopausal samples.  It can 
also be seen that the same is true for both the isthmic and fimbrial portions of the 
fallopian tubal epithelium for the expression of SOX9 and cytoplasmic beta catenin.  
Generally however, SSEA-1 expression was lower than the endometrial basalis.  
Table 4-5 – Tables demonstrating the quickscore and percentage positive levels of SSEA-1, cytoplasmic beta 
catenin and SOX9 represented by the symbol + in fallopian tube and basal glandular epithelia.  The key above 
explains the corresponding expression levels according to the results shown in graphs in figures 4-7, 4-10 and 4-
13. 
SSEA-1 
 Isthmic Fallopian 
Tubal Epithelia 
Fimbrial Fallopian 
Tubal Epithelia 
Endometrial 
Basalis Epithelia 
Menstrual Phase ++ + +++ 
Proliferative Phase ++ + +++ 
Secretory Phase + - ++ 
Postmenopausal ++ + +++ 
 
Cytoplasmic Beta Catenin 
 Isthmic Fallopian 
Tubal Epithelia 
Fimbrial Fallopian 
Tubal Epithelia 
Endometrial 
Basalis Epithelia 
Menstrual Phase ++ + ++ 
Proliferative Phase ++ ++ ++ 
Secretory Phase + ++ ++ 
Postmenopausal ++ +++ +++ 
 
SOX9 
 Isthmic Fallopian 
Tubal Epithelia 
Fimbrial Fallopian 
Tubal Epithelia 
Endometrial 
Basalis Epithelia 
Menstrual Phase ++ +++ +++ 
Proliferative Phase ++ ++ +++ 
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Secretory Phase +++ ++ ++ 
Postmenopausal +++ +++ ++++ 
 
The results above suggest that the postmenopausal endometrium retains a basalis 
phenotype and fallopian tubal epithelia show an increase in some basalis markers, 
postmenopause. 
Sialylated SSEA-1 was high in the fallopian tubal epithelia, particularly in the isthmic 
portion of the fallopian tube.  This is a discussion point for chapter 7.  It may suggest 
that there is a unique functional role for the carbohydrate ligand on the antigen in 
the epithelial cells of the proximal fallopian tube, possibly playing a part in the 
creation of a sperm reservoir. 
Table 4-6 – Table demonstrating the quickscore levels of Sialylated SSEA-1 represented by the symbol + in isthmic 
and fimbrial fallopian tubal epithelia.  The key above explains the corresponding expression levels according to 
the results shown in figure 4-15. 
Sialylated SSEA-1 Isthmic Fallopian 
Tubal Epithelia 
Fimbrial Fallopian 
Epithelia 
Menstrual Phase ++++ +++ 
Proliferative Phase +++ ++ 
Secretory Phase ++++ +++ 
Postmenopausal ++++ +++ 
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Chapter 5 Investigating Sex Steroid Hormone Receptor 
Expression and Proliferation in Human Fallopian Tube and 
Endometrium 
 
 
5.1 Introduction 
Endometrium is the main target organ for ovarian steroid hormones. These 
hormones induce their effects on the endometrium via similar receptors. The 
steroid hormone receptors are: Oestrogen receptor (ER), progesterone receptor 
(PR) and androgen receptor (AR). Endometrial expression of the steroid hormone 
receptors has been investigated in some detail.  Expression of the steroid receptors 
vary throughout the menstrual cycle in response to the fluctuating steroid 
hormones in the circulation.   
There are 2 main isoforms of oestrogen receptors, namely ER alpha and ER beta – 
the effect of E2 via ER alpha particularly affects proliferation of the endometrium. 
The ESR1 gene encodes for ER alpha and the ESR2 gene encodes for ER beta and 
they are located on different chromosomes.45  ER alpha is more highly expressed in 
glandular and stromal cells of the endometrium than ER beta.  ER beta is thought to 
play a direct inhibitory role in the glandular epithelia of the endometrium.46  Both 
receptors were found to decrease during the secretory phase of the menstrual 
cycle.  In all cells of the endometrium, ER expression reaches its maximum 
expression in the late proliferative phase of the menstrual cycle suggesting the 
maximum E2 effect at that particular time in the cycle, which also correlates with 
high proliferative activity.    Brandenburger et al.  Found that E2 working via ER 
alpha up-regulates PR expression.47  Moderate expression of ER is present in glands 
and stroma in the postmenopausal endometrium.49    
PR has two isoforms originating from the same gene – PR-A and PR-B.  There are 
both direct and indirect routes of action of progesterone on the endometrial 
epithelium.  Progesterone may act directly on the glandular epithelia via epithelial 
PR and indirectly through the action on stromal PR thereby inducing a variety of 
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growth factors that act on the epithelial cells of the endometrium.  Expression of PR 
in the epithelium tends to increase during the proliferative phase and decrease in 
the mid-secretory phase, when progesterone is highest.  Progesterone down-
regulates its own receptor. Stromal PR expression remains consistently high 
throughout the menstrual cycle.40  After menopause, it has been reported that 
moderate glandular expression of PR is present but weak expression is evident in 
the stromal compartment.49   The particular antibody clone used in this study 
recognised both PR-A and PR-B isoforms.      
Studies have shown that androgen receptor is predominantly located in the stroma 
of the endometrium and the receptor responds to the cyclical variation of the 
circulating hormone showing an increase AR expression in the proliferative and 
secretory phases of the menstrual cycle.31  This receptor has been reported to 
persist in the stroma of the endometrium, after menopause.32 
Although the general consensus is that the steroid receptor expression in the 
endometrium is fully characterised, the existing evidence is very limited for the 
details of steroid receptor expression in functionally very different stratum basalis 
and functionalis.  There are also no conclusive studies on comparisons of healthy 
pre and post-menopausal endometrium. For these reasons, from the existing data, 
it is difficult to conclude the normal pattern of steroid receptor expression in 
healthy human endometrium. Therefore, this study also examined the different 
zones of the full thickness endometrium across the cycle in pre-menopausal women 
and in a group of healthy postmenopausal women.  
Some evidence exists on steroid receptor presence in human fallopian tube, which 
showed that the tubal epithelial expression of ER alpha and beta were present and 
more prominent in the secretory phase of the menstrual cycle.42  Another study 
claimed that epithelial expression of ER alpha was down-regulated after treatment 
with progesterone.43  The latter study conflicts with the evidence above that stated 
that ER alpha increased during the secretory phase, when progesterone was 
highest.   PR A and B has been reported to be expressed in both the epithelia and 
stroma of human fallopian tubal mucosa.  There have been reports that PR is 
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reduced during the secretory phase, in the fallopian tube. Progesterone treatment 
down-regulates PR in the tube. This is consistent with endometrial response of this 
receptor during the menstrual cycle.42, 43  Very little evidence surrounds the 
presence of AR in the fallopian tubes except that it is abundantly expressed in the 
nuclei of the epithelia.34      
Detailed examination of steroid hormone expression in both distal and proximal 
parts of the tube, across the menstrual cycle of premenopausal women and in 
postmenopausal women is yet to be compared with the matched normal 
endometrial steroid receptor expression. This chapter describes the examination of 
matched full thickness eutopic endometrium and proximal (isthmic) and distal 
(fimbrial) parts of the fallopian tube in pre and postmenopausal women for the 
expression of steroid receptors. Furthermore, correlations were made with the 
steroid receptor expression with the co-expression of the proliferative marker KI67 
to understand if the endometrial cell proliferation is particularly associated with 
alteration in the steroid receptor expression.    
5.1.1 Summary of Methods and Demographics 
For this investigation 17 premenopausal matched eutopic endometrial and fallopian 
tube samples (Isthmic and fimbrial region) were collected and stained for KI67, AR, 
ER Alpha, ER Beta and PR using immunohistochemistry techniques, grouped 
throughout the menstrual phases (See Table 5-1 - Number of samples in each group 
for immunohistochemistry). N=5 matched full thickness eutopic endometrium and 
fallopian tube postmenopausal sections were also collected. 
Table 5-1 - Number of samples in each group for immunohistochemistry 
Study Group Number Eutopic 
Endometrium 
Number Isthmic 
Tube 
Number Fimbrial 
Tube 
Menstrual phase 4 3 3 
Proliferative phase 6 6 3 
Secretory phase 7 5 4 
Postmenopausal 5 2 5 
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Table 5-2 - Table of Demographics for Patients in Immunohistochemical Study 
Menstrual Cycle 
Phase 
Sample 
number 
 Age BMI Smoker Parity 
Menstrual 
Phase 
4 Mean (± 
SD) 
Median 
Range 
41 
(±4) 
40.5 
37-47 
29.3 
(±5.0) 
30.8 
21.2-
34.4 
1 (25%) 2 (±1) 
2 
1-3 
Proliferative 
Phase 
6 Mean (± 
SD) 
Median 
Range 
43 
(±5) 
43 
37-53 
29.3 
(±6.7) 
26.1 
23.1-
39.2 
0 (0%) 2 (±1) 
2 
0-3 
 
Secretory Phase 7 Mean (± 
SD) 
Median 
Range 
43 
(±4) 
44 
37-48 
27.7 
(±6.6) 
23.8 
21.7-
40.1 
3 (43%) 2 (±1) 
2 
1-4 
Postmenopausal 5 Mean (± 
SD) 
Median 
Range 
57 
(±7) 
55 
48-66 
25.6 
(±1.8) 
24.9 
23.6-
28.1 
2 (40%) 2 (±1) 
2 
1-3 
 
Messenger-RNA (mRNA) expression of Androgen Receptor was also investigated 
using reverse transcriptase –polymerase chain reaction (RT-PCR) on 3 secretory 
phase and 3 postmenopausal matched eutopic and fimbrial fallopian tube tissue 
samples.  Immuno-staining for steroid receptors of the tissue samples were scored 
using a modified quickscore method (see chapter 3 for detailed description) and 
percentage positive staining was used to analyse the KI67 Staining. Densitometry 
was performed on the PCR samples to evaluate relative mRNA expression of each 
sample using YWHAZ and GAPDH as the reference genes for endometrial and 
fallopian tube samples. 
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Table 5-3 - Table of Demographics for Patients in RT-PCR Study 
Menstrual Cycle 
Phase 
Sample 
number 
 Age BMI Smoker Parity 
Secretory Phase 3 Mean (± 
SD) 
Median 
Range 
41 (±7) 
 
45 
32-47 
26.9 
(±3.7) 
 
26.6 
22.6-
31.6 
0 (0%) 1 (±1) 
 
0 
0-2 
Postmenopausal 3 Mean (± 
SD) 
Median 
Range 
57 (±7) 
 
52 
52-66 
29.5 
(±7) 
 
24.9 
24-39.6 
1 (33%) 
 
 
3 (±0.5) 
 
3 
2-3 
 
5.2 Marker of Proliferation: KI67 
KI67 was present in the nuclei of epithelial cells and stroma in the endometrium; 
which has been shown to be a good indicator of the proliferative activity of a cell.86 
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Figure 5-1 - Images for KI67 IHC staining at 400x magnification across the menstrual phase, proliferative phase, 
secretory phase and postmenopause.  In the stratum basalis, stratum functionalis, luminal epithelia, isthmic 
fallopian tubal epithelia and fimbrial fallopian tubal epithelia. 
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Figure 5-2 - Bar graphs showing median percentage positive nuclei with range for the immunohistochemical 
staining of KI67 divided by tissue and compartments throughout the menstrual cycle phases and 
postmenopause. A) Bar graph of basal glandular epithelia percentage positive nuclei with: basal glands in the 
menstrual phase (N=4), proliferative phase (N=5), secretory phase (N=7) and postmenopause (N=5.) B) Bar graph 
of functional glands in the menstrual phase (N=4), proliferative phase (N=4) and secretory phase (N=7.) C) Bar 
graph of luminal epithelia in menstrual phase (N=3), proliferative phase (N=4), secretory phase (N=7) and 
postmenopause (N=4.)  D) Bar graph of fallopian tube percentage positive nuclei with: Isthmic fallopian tube in 
the menstrual phase (N=3), fimbrial fallopian tube in the menstrual phase (N=3), Isthmic fallopian tube in the 
proliferative phase (N=6), Fimbrial fallopian tube in the proliferative phase (N=3), Isthmic fallopian tube in the 
secretory phase (N=3), fimbrial fallopian tube in the secretory phase (N=4), postmenopausal isthmic fallopian 
tube (N=2), postmenopausal fimbrial fallopian tube (N=5.) 
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5.2.1 Immunohistochemistry 
Epithelial cells in the basalis layer of the endometrium showed variability in ki67 
expression throughout the menstrual cycle.  As expected, highest expression was 
seen in the proliferative phase of the menstrual cycle with 20% Median Percentage 
Positive (MPP) staining.  Lowest percentage positivity in the cycling endometrium 
was seen in the population in secretory phase of the menstrual cycle (MPP 10%).  
The postmenopausal epithelia (remaining basalis) showed very low positivity (MPP 
2 %).  It was of note that the stromal and epithelial compartments of the basalis 
layer of the endometrium had a different expression pattern of KI67.  Highest 
percentage positivity of stromal KI67 expression was seen in the menstrual phase of 
the cycle (MPP 12.5 %) whilst lower expression (MPP 5 %) was seen during the rest 
of the cycle phases studied.  Very low KI67 expression was seen in the 
postmenopausal endometrium (MPP 2 %).  The functional epithelial cells had the 
same pattern of KI67 expression as the basal epithelial cells.  The highest epithelial 
expression of KI67 was in the proliferative phase had a MPP of 42.5 %.  In the 
secretory phase, the lowest KI67 expression was observed in epithelial cells - with 
an MPP of 10 %.  Functional stromal KI67 staining had the same pattern of 
expression as epithelial cells with less variability between the cycle phases.  The 
luminal epithelium had higher secretory phase KI67 expression than in the rest of 
the phases (MPP 25 %).  Interestingly, in the luminal epithelium, the lowest KI67 
positivity was seen in the proliferative phase (MPP 17.5 %).   
The epithelial cells of the fimbrial/infundibular end of the fallopian tube showed a 
clear difference in Ki67 staining throughout the menstrual cycle.  In the menstrual 
phase, low KI67 expression was apparent with MPP staining at 5%.  There was then 
an increase in expression of KI67 in the proliferative phase (MPP 20%).  This was 
followed by a dramatic decrease in expression in the secretory phase of the 
menstrual cycle (MPP 4%).  This Low expression of KI67 seen in secretory phase was 
almost similar to that seen in the postmenopausal fallopian tube (MPP 5%).  The 
isthmic fallopian tube had very low KI67 expression throughout the menstrual cycle 
with little variability except for an increase in expression during the menstrual 
133 
 
phase of the menstrual cycle (MPP 10%).  Postmenopausal isthmic tube had 
negligible positive KI67 expression (MPP 1 %).  
Over all it can be seen that the functionalis compartment of the endometrium has 
higher expression of KI67 than the stratum basalis compartment and fallopian 
tubes.  The most dramatic difference in expression could be seen in the fimbrial end 
of the fallopian tube in the proliferative phase of the menstrual cycle with a median 
percentage increase of 15 % between the menstrual and proliferative phase.  The 
same pattern of expression throughout the menstrual cycle was seen between the 
basal glands, the functional glands and stroma and the fimbrial fallopian tube where 
the highest expression was in the proliferative phase population and lowest 
expression was in the secretory phase.  The isthmic tubal epithelia and basal 
stromal nuclei had the same pattern of expression with higher expression in the 
menstrual phase.  Very low percentages of positive KI67 nuclei were seen in the 
postmenopausal population.  It seemed that some samples had no presence of this 
molecule at all, whereas other samples had some KI67 expression therefore 
revealing a median low positive expression within the postmenopausal tissue 
samples.     
5.3 Results: Sex Steroid Receptors 
 
5.3.1 Androgen Receptor  
 
5.3.1.1 Immunohistochemistry for Fallopian Tube and Endometrial Mucosa 
Using a modified quickscore to evaluate the staining for AR in the fallopian tube and 
endometrial epithelia and stroma; large differences in staining were seen between 
the tissues and the compartments. 
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Figure 5-3 - Images for Androgen Receptor IHC staining at 400x magnification across the menstrual phase, 
proliferative phase, secretory phase and postmenopause.  In the stratum basalis, stratum functionalis, luminal 
epithelia, isthmic fallopian tubal epithelia and fimbrial fallopian tubal epithelia 
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Figure 5-4 - Bar graphs showing median modified quickscores with range for the immunohistochemical staining 
of Androgen Receptor divided by tissue and compartments throughout the menstrual cycle phases and 
postmenopause. A) Bar graph of basal glandular epithelia quickscores with: basal glands in the menstrual phase 
(N=4), proliferative phase (N=6), secretory phase (N=6) and postmenopause (N=5.) B) Bar graph of functional 
glands in the menstrual phase (N=4), proliferative phase (N=5) and secretory phase (N=6.)  C) Bar graph of 
luminal epithelia in menstrual phase (N=3), proliferative phase (N=5), secretory phase (N=6) and postmenopause 
(N=4). Postmenopausal modified quickscore significantly different (P<0.05) to the secretory, proliferative and 
menstrual phase luminal epithelia after analysis with the Mann-Whitney U, non-parametric test. D) Bar graph of 
fallopian tube quickscores with: Isthmic fallopian tube in the menstrual phase (N=3), fimbrial fallopian tube in 
the menstrual phase (N=3), Isthmic fallopian tube in the proliferative phase (N=5), Fimbrial fallopian tube in the 
proliferative phase (N=2), Isthmic fallopian tube in the secretory phase (N=3), fimbrial fallopian tube in the 
secretory phase (N=4), postmenopausal isthmic fallopian tube (N=1), postmenopausal fimbrial fallopian tube 
(N=5.) 
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In the basalis region of the matched endometrial samples, the basal glandular 
epithelial cells had low/negligible AR expression.  The menstrual phase had very low 
positive staining with a Median Quickscore (MQ) of 0.5 and the proliferative and 
secretory phase samples were found to be negative for AR.  In the postmenopausal 
endometrium, basal epithelial cells showed low positivity (MQ = 2).  The stroma 
showed a different picture.  This compartment had strong positive staining for AR 
with median quickscores of 8.5/12 and above.  There was little variation between 
cycle phases however; the highest presence of AR was in the secretory phase of the 
menstrual cycle and slightly lower in the proliferative phase and menstrual phase 
(MQ = 9 and 8.5, respectively).  High stromal expression of AR was present in the 
postmenopausal population (MQ = 10).  The superficial glandular epithelia in the 
functionalis had the same expression of AR as the basalis glands, a very low positive 
expression in the menstrual phase population and no AR presence in the 
proliferative and secretory samples.  Superficial stromal expression of AR was 
moderate; with median quickscore values of 5 and above.  Slight phasic variability 
was shown to occur with a minor increase in AR staining in the endometrium in the 
menstrual phase (MQ = 5.5).  The luminal epithelium, like the glands, had very low 
AR presence. All median quickscore values were 1 or below.  The menstrual phase 
had the higher level of expression and the proliferative phase was negative for AR.  
In contrast, postmenopausal luminal epithelia showed a statistically significant 
increase in expression of AR. (P<0.05). 
The immediate finding within the distal fallopian tubal population was that there 
was strong AR presence.  MQ of 7/12 and above were scored for this region of the 
fallopian tube - indicating strong staining with high percentage of positive nuclei for 
AR.  Cyclical variation was present with the highest expression of AR being in the 
menstrual and secretory phase of the menstrual cycle (MQ = 9).  Even higher 
expression was noted in the postmenopausal sample population (MQ = 11).  The 
proximal end of the cycling fallopian tube had a slightly lower median quickscore 
levels than the fimbrial end (7 and above).  Like the distal end, the lowest 
expression of AR fell within the population in the proliferative phase of the cycle 
and the highest expression of AR was found to be in the secretory phase of the 
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menstrual cycle.  In the postmenopausal state, this region had very strong, 
abundant AR staining (MQ = 12).  Stromal staining was very weakly observed in all 
of the samples with little variation so was omitted from scoring.  The epithelial 
staining was the most prominent. 
Comparing the endometrial tissue with fallopian tubes it was clearly evident that 
tubal epithelial cells had high AR expression comparable to; the stromal 
compartment of the endometrium.  With the phenotypic differences between these 
cells however; they cannot be functionally comparable to each other.  The glandular 
epithelial cells in all compartments of the endometrium had a contrasting low 
expression of AR.  The pattern of expression of AR throughout the premenopausal 
cycling population was high in the fallopian tubal epithelia.  This was also the case 
for the basal stromal compartment however; less cyclical variation was seen.  The 
functional stroma also had relatively lower AR expression in the proliferative phase 
like the basal stromal compartment.  In the postmenopausal state the tubal 
epithelia appeared to have relatively higher AR expression than in the cycling 
endometrium in all tissues and compartments.  Highest AR presence seemed to be 
in postmenopausal isthmic tube closely followed by fimbrial tube and basal stroma 
(MQ = 12, 11 and 10, respectively).  Lowest postmenopausal expression of AR was 
seen in glandular epithelium of the endometrium.  
5.3.1.2 Reverse Transcriptase – PCR for Androgen Receptor 
mRNA detection of androgen receptor (AR) was present in both endometrium and 
fallopian tubes.  Relative expression of AR differed between tissues and between 
pre and post-menopausal women. 
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Figure 5-5 - Whisker graph with median and minimum to maximum values showing relative expression of 
Androgen Receptor in N=3 matched postmenopausal eutopic endometrium and fallopian tube samples and N=3 
matched secretory phase eutopic endometrium and fallopian tube samples normalised to GAPDH,  the reference 
gene.      
The highest relative expression of AR was detected in postmenopausal fallopian 
tubes, whilst the lowest mRNA expression of AR was found to be located in the 
secretory phase eutopic endometrium.  On comparing tissues tubal expression of 
AR was consistently higher in both cycling females and postmenopausal females 
than eutopic endometrium.  Postmenopausal expression of AR in both the fallopian 
tube and eutopic endometrium was relatively higher than the premenopausal, 
secretory phase population. 
After comparing protein expression of AR to mRNA expression - the data sets are 
consistent with each other. Postmenopausal expression of AR is relatively higher in 
comparison to the secretory phase population in both endometrium and fallopian 
tubes, like the PCR outcome.  Fallopian tubal protein expression of AR is also 
consistently higher than endometrial expression in both pre and postmenopausal 
sample sets. 
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5.3.2 Progesterone Receptor 
In the presence of Progesterone Receptor (PR), positive DAB staining is detected in 
epithelial and stromal cell nuclei.  
Figure 5-6 - Images for Progesterone Receptor IHC staining at 400x magnification across the menstrual phase, 
proliferative phase, secretory phase and postmenopause.  In the stratum basalis, stratum functionalis, luminal 
epithelia, isthmic fallopian tubal epithelia and fimbrial fallopian tubal epithelia 
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Figure 5-7 - Bar graphs showing median modified quickscores with range for the immunohistochemical staining 
of Progesterone Receptor divided by tissue and compartments throughout the menstrual cycle phases and 
postmenopause. A) Bar graph of basal glandular epithelia quickscores with: basal glands in the menstrual phase 
(N=4), proliferative phase (N=6), secretory phase (N=7) and postmenopause (N=4). B) Bar graph of functional 
glands in the menstrual phase (N=4), proliferative phase (N=5) and secretory phase (N=7).  C) Bar graph of 
luminal epithelia in menstrual phase (N=2), proliferative phase (N=6), secretory phase (N=7) and postmenopause 
(N=4). D) Bar graph of fallopian tube quickscores with: Isthmic fallopian tube in the menstrual phase (N=3), 
fimbrial fallopian tube in the menstrual phase (N=3), Isthmic fallopian tube in the proliferative phase (N=6), 
Fimbrial fallopian tube in the proliferative phase (N=3), Isthmic fallopian tube in the secretory phase (N=5), 
fimbrial fallopian tube in the secretory phase (N=4), postmenopausal isthmic fallopian tube (N=2), 
postmenopausal fimbrial fallopian tube (N=5). 
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Endometrial expression of progesterone receptor in the basal epithelial cells varied 
throughout the menstrual cycle.  At the beginning of the cycle progesterone 
receptor was very strongly expressed in the epithelial nuclei (MQ = 12/12).  As the 
female enters the secretory phase of the cycle, a reduction in expression of this 
receptor appeared to occur (MQ = 8/12).  The basalis stromal nuclei also expressed 
progesterone receptor abundantly (MQ = 12/12). A slight reduction in expression of 
PR was also seen to occur in the secretory phase population (MQ = 10). 
Postmenopausal expression of PR was strong in both the epithelial and stromal 
compartment (MQ = 12/12).  In the functionalis, the highest PR expression in both 
epithelia and stroma was seen to occur in the proliferative phase of the menstrual 
cycle (MQ = 12/12).   Lowest presence of this receptor was evident in the secretory 
phase of the menstrual cycle in the epithelial and stromal cell nuclei (MQ = 7 and 
8/12, respectively). Luminal expression of PR had the same pattern of expression as 
the functionalis layer of the endometrium, with relatively strong PR staining in the 
postmenopausal population, equivalent to fimbrial epithelial PR expression.  
Progesterone receptor was strongly expressed in fallopian tubes.  The fimbrial 
epithelial cells were consistently strongly expressing this receptor throughout the 
menstrual cycle.  No cyclical variation was seen.  The postmenopausal fimbrial 
epithelial cells however show a diminished expression of this receptor falling to a 
median quickscore (MQ) of 9/12 from 12/12 that was seen in the premenopausal 
population. Tubal stroma also expressed this receptor; at the fimbrial end the 
receptor was highly expressed in both the pre and postmenopausal population (MQ 
of 9/12 and above).  The highest expression of PR seemed to be during the 
secretory phase of the menstrual cycle (MQ 12/12).  Stromal expression of PR fell 
slightly in the postmenopausal fimbrial tube (10/12).  The isthmic epithelia of the 
fallopian tube also had constant strong expression of PR with no variation between 
phases in the premenopausal population (MQ = 12/12).  Postmenopausal 
expression of this receptor decreased dramatically (MQ = 4/12).  Isthmic stroma 
showed very strong expression of PR in both the pre and postmenopausal 
population. 
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On comparing the tissues and regions; the tube appeared to maintain a high level of 
PR expression throughout the menstrual cycle with no variation between phases of 
the cycle and region of the tube.  The difference found between the proximal and 
distal tube, occurred within the postmenopausal population.  The isthmic epithelia 
had a lower expression of this receptor than the fimbrial epithelia (MQ = 4 and 9, 
respectively). The isthmic stroma had comparatively lower expression of PR in the 
menstrual and proliferative phases of the cycling population and a lower expression 
of PR in the postmenopausal population than the distal end.  The tube differed from 
the endometrium because it did not vary its expression of PR throughout the 
menstrual cycle. Unlike the fallopian tube, the basal glandular epithelia and stroma 
both showed a reduction in PR during the secretory phase.  The postmenopausal 
basalis had high levels of this receptor whilst tubal epithelial expression diminished.  
Stroma at the fimbrial end of the tube maintained high levels of PR in the 
postmenopausal population, in the same way that the postmenopausal endometrial 
basal epithelia and stroma does. The functionalis showed distinctively high PR 
expression in the epithelia during the proliferative phase of the cycle, with relatively 
lower levels of PR in the menstrual and secretory phases.  The basalis did not show 
variation between the menstrual and proliferative phases in this sample set 
however also found a reduction in expression of PR during the secretory phase of 
the menstrual cycle.  Functional stroma had exactly the same pattern of PR 
expression as basal stroma. 
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5.3.3 Oestrogen Receptor Alpha 
Figure 5-8 - Images for oestrogen receptor alpha IHC staining at 400x magnification across the menstrual phase, 
proliferative phase, secretory phase and postmenopause.  In the stratum basalis, stratum functionalis, luminal 
epithelia, isthmic fallopian tubal epithelia and fimbrial fallopian tubal epithelia. 
 
144 
 
 
Figure 5-9 - Bar graphs showing median modified quickscores with range for the immunohistochemical staining 
of Oestrogen Receptor Alpha divided by tissue and compartments throughout the menstrual cycle phases and 
postmenopause. A) Bar graph of basal glandular epithelia quickscores with: basal glands in the menstrual phase 
(N=4), proliferative phase (N=5), secretory phase (N=7) and postmenopause (N=5). B) Bar graph of functional 
glands in the menstrual phase (N=3), proliferative phase (N=4) and secretory phase (N=7).  C) Bar graph of 
luminal epithelia in menstrual phase (N=2), proliferative phase (N=2), secretory phase (N=7) and postmenopause 
(N=4).  D) Bar graph of fallopian tube quickscores with: Isthmic fallopian tube in the menstrual phase (N=3), 
fimbrial fallopian tube in the menstrual phase (N=2), Isthmic fallopian tube in the proliferative phase (N=6), 
Fimbrial fallopian tube in the proliferative phase (N=1), Isthmic fallopian tube in the secretory phase (N=5), 
fimbrial fallopian tube in the secretory phase (N=3), postmenopausal isthmic fallopian tube (N=2), 
postmenopausal fimbrial fallopian tube (N=5). 
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The endometrium showed positivity for ER alpha in both the epithelial cells and 
stromal cells.  Beginning in the epithelial nuclei of the basalis region of the 
endometrium; the highest expression of ER alpha appeared to be during the 
proliferative phase of the menstrual cycle and lowest presence of ER alpha in the 
epithelia was during the secretory phase of the menstrual cycle (MQ = 9 and 2, 
respectively). Stromal expression of this receptor was lower in the premenopausal 
population however follows the same pattern as the epithelia, though to a lesser 
degree.  Postmenopausal epithelia of the endometrium had low- moderate 
expression of this receptor (MQ = 4,) whilst stromal expression was very weak.  The 
functionalis layer of the endometrium has both stromal and epithelial expression of 
ER alpha.  Highest expression lies within both the menstrual and proliferative 
phases of the menstrual cycle, leaving the lowest expression of epithelial ER alpha 
within the secretory phase population (MQ = 8, 8 and 4 respectively).  Stromal ER 
alpha found the highest concentration of ER alpha to be in the proliferative phase 
(MQ = 6). The luminal ER alpha expression was highest during the secretory phase 
of the menstrual cycle (MQ = 7), differing from the glandular epithelia.  High luminal 
epithelial expression was apparent in the postmenopausal endometrium (MQ = 
7.5). 
Fimbrial epithelia had high ER alpha expression in the proliferative phase.  This also 
reflects the expression seen in the basal and superficial glands of the endometrium.  
ER alpha remained high in the secretory phase in the fimbrial fallopian tubal 
epithelia which is not seen in the endometrium, where a reduction of ER alpha is 
seen during the secretory phase in both compartments.   
Nuclear expression of ER alpha in the fimbrial tubal epithelia was high.  Slight 
cyclical variation could be seen in this region.  The highest presence of this receptor 
appeared to occur in the proliferative phase and remained high during the secretory 
phase (MQ = 12/12).  Therefore the lowest expression of ER alpha was seen during 
the menstrual phase of the cycling, premenopausal fallopian tube. Expression of ER 
alpha was moderate-high in the postmenopausal population but lower than the 
premenopausal population (10/12).  Wide variation between cycle stages was 
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observed in the fimbrial tubal stroma. High ER alpha expression occurred during the 
proliferative phase of the menstrual cycle with lower ER alpha in the menstrual and 
secretory phases (MQ = 8, 2.5 and 0, respectively).  Postmenopausal stromal 
expression of this receptor was very low (MQ = 1).  More proximally, at the isthmic 
end of the fallopian tube high epithelial expression of ER alpha was evident.  Cyclical 
change in the epithelia occurred, but in a different way to the more distal end of the 
tube. Highest epithelial expression occurred during the secretory phase of the 
menstrual cycle and diminished expression occurred in the proliferative phase (MQ 
= 12 and 7.5, respectively).  Postmenopausal expression of ER alpha in the epithelia 
is low-moderate (MQ = 4.5).  The isthmic stroma also had wide cyclical variation of 
ER alpha but this region showed the lowest expression of this receptor to occur 
during the proliferative phase and highest expression during the menstrual phase.  
As with the distal tubal stroma, postmenopausal presence of ER alpha was weak 
(MQ = 0.5). 
Larger variation in fimbrial tubal stromal expression of ER alpha was seen in 
comparison to the consistently low median levels in the basalis endometrial stroma. 
Like the fimbrial end of the tube, the functional stroma had higher expression of ER 
alpha in the proliferative phase of the cycle therefore following the same pattern of 
expression. The isthmic epithelial portion of the fallopian tube had a different 
pattern of expression than all other regions or tissues’ being that ER alpha 
expression was higher during the secretory phase of the menstrual cycle.  On the 
contrary to the endometrium and distal fallopian tube; the isthmic stromal nuclei 
also seemed to show a low expression of ER alpha in the proliferative phase of the 
cycle.  Highest postmenopausal epithelial expression of ER alpha was within the 
fimbrial epithelia (MQ = 10). Remaining epithelial compartments had low-moderate 
expression of the receptor.  In contrast, stromal expression of ER alpha was very 
weak throughout all tissues.  
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5.3.4 Oestrogen Receptor Beta 
Figure 5-10 - Images for oestrogen receptor beta IHC staining at 400x magnification across the menstrual phase, 
proliferative phase, secretory phase and postmenopause.  In the stratum basalis, stratum functionalis, luminal 
epithelia, isthmic fallopian tubal epithelia and fimbrial fallopian tubal epithelia. 
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Figure 5-11 - Bar graphs showing median modified quickscores with range for the immunohistochemical staining 
of Oestrogen Receptor Beta divided by tissue and compartments throughout the menstrual cycle phases and 
postmenopause. A) Bar graph of basal glandular epithelia quickscores with: basal glands in the menstrual phase 
(N=4), proliferative phase (N=6), secretory phase (N=7) and postmenopause (N=5). B) Bar graph of functional 
glands in the menstrual phase (N=3), proliferative phase (N=5) and secretory phase (N=7).  C) Bar graph of 
luminal epithelia in menstrual phase (N=3), proliferative phase (N=3), secretory phase (N=7) and postmenopause 
(N=4). D) Bar graph of fallopian tube quickscores with: Isthmic fallopian tube in the menstrual phase (N=3), 
fimbrial fallopian tube in the menstrual phase (N=3), Isthmic fallopian tube in the proliferative phase (N=6), 
Fimbrial fallopian tube in the proliferative phase (N=2), Isthmic fallopian tube in the secretory phase (N=3), 
fimbrial fallopian tube in the secretory phase (N=4), postmenopausal isthmic fallopian tube (N=1), 
postmenopausal fimbrial fallopian tube (N=5). 
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The basalis glandular epithelia expressed ER-B.  Weaker expression occurred in the 
menstrual phase with an increase in ER-B during the proliferative phase and 
remained high into the secretory phase of the cycle (MQ = 4, 8 and 8).  Weaker ER-B 
expression was observed in the postmenopausal basal epithelia (MQ = 4).   Stromal 
cells of the basalis also expressed ER-B.  An increase in this receptor was seen to 
occur in the proliferative phase (MQ = 9.5). A subsequent reduction in presence of 
ER-B arose in the secretory phase of the cycling population (MQ = 4).  
Postmenopausal expression of ER-B remained low in stromal nuclei.  Consistently 
moderate-high expression of ER-B existed in the functionalis compartment of the 
endometrium, in both stroma and epithelial cell nuclei.  No cyclical variation 
occurred with average median quickscores of 8 throughout.  Luminal epithelial 
presence of ER-B had an increase in ER-B expression during the proliferative phase 
increasing to a moderate quickscore of 6, this moderate expression was maintained 
during the secretory phase.  Postmenopausal expression of ER-B in the lumen was 
moderate (MQ =6.5). 
Oestrogen receptor beta (ER-B) is present in the nuclei of epithelial and stromal 
cells.  Starting at the distal end of the fallopian tube, epithelial expression was 
highest in the secretory phase of the menstrual cycle however in both the 
menstrual and proliferative phases, ER-B expression was strongly expressed (MQ = 
12, 10 and 10/12 respectively).  The isthmic fallopian tube had a different pattern of 
expression.  ER-B decreased in a step-wise manner throughout the menstrual cycle 
with the highest expression in the menstrual phase (MQ = 10). Weakest expression 
of ER-B was noted in the secretory phase, with a median quickscore of 4. Epithelial 
expression of ER-B in the postmenopausal population was strong at the fimbrial and 
isthmic end of the fallopian tube (MQ = 12).  Wide variation between stages of the 
menstrual cycle was seen in the fimbrial stroma of the fallopian tube.  Highest 
stromal expression of ER-B was seen in the proliferative phase and lowest in the 
secretory phase (MQ = 12 and 3.5).  Isthmic stroma had lower overall expression 
and less variation but the same pattern of expression as the distal end of the tube.  
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Postmenopausal expression of ER-B was moderate in the fimbrial fallopian tube 
(MQ = 6). Isthmic tubal stroma had moderate – high expression (MQ = 8). 
 After comparing the tissues, the epithelia of the distal fallopian tube had highest 
expression of ER-B in the secretory phase of the menstrual cycle, this is also the 
case in basal glandular epithelial cells however the overall strength of ER-B 
expression was higher in the distal fallopian tubes than the endometrium as a 
whole.  The isthmic end of the fallopian tube was seen to have a different pattern of 
expression with less ER-B during the secretory phase – the expression was more 
reflective of the luminal compartment of the endometrium (MQ = 4 and 3, 
respectively).  In the postmenopausal population higher receptor expression was 
observed in the fallopian tube than the endometrium.  Lowest ER-B expression 
occurred in the postmenopausal basal glandular epithelia.  The tubal stroma and 
the stroma of the basalis endometrium had the same pattern of ER-B expression 
with abundant ER-B during the proliferative phase and reduced receptor expression 
in the secretory phase population.  Functional stromal presence remained 
constantly moderate-high therefore showing no cyclical variation.  
Postmenopausally, the isthmic tubal stroma had a higher presence of ER-B in 
comparison to the endometrial stromal compartment.  
                      
 
 
 
 
         
 
 
151 
 
5.4 Comparing proliferation with sex steroid receptor expression. 
5.4.1 KI67 and Androgen Receptor 
 
Figure 5-12 - Bar graphs showing median percentage positive and median quickscore values with range for the 
immunohistochemical staining of KI67 and AR in isthmic and fimbrial fallopian tube throughout the menstrual 
cycle phases and postmenopause. For details of individual graphs see figures 5-2 and 5-4, respectively. 
Observing the pattern of expression of KI67 and androgen receptor in the distal 
fallopian tubes it was noticeable that KI67 expression was generally low except 
during the proliferative phase, where there was a sharp increase in percentage of 
positive cells.  This was not the case with AR; the receptor was abundant in all 
phases of the menstrual cycle.  The decrease in AR expression during the 
proliferative phase opposes the increase of KI67 activity in the fimbrial fallopian 
tube during this phase. Not only was this the case, high expression of AR was 
apparent in the postmenopausal population whereas very low/negligible positivity 
of KI67 is evident.  The same applies to the proximal tube; high AR expression is 
throughout the pre and postmenopausal population whereas low KI67 is shown in 
this region.   
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Figure 5-13 - Bar graphs showing median percentage positive and median quickscores with range for the 
immunohistochemical staining of KI67 and AR in endometrial compartments throughout the menstrual cycle 
phases and postmenopause. For details of individual graphs see figures 5-2 and 5-4, respectively. 
In the endometrium, the basalis glandular epithelium had low or negligible 
expression of AR in the cycling population.  Ki67 was variable in this population with 
an increase in positivity around the proliferative phase of the menstrual cycle.  An 
increase in AR was seen to occur in the postmenopausal basal glands whereas this 
population sample had the opposite effect on KI67 expression being that it was low.  
Androgen receptor was high in the basal stroma, particularly in the postmenopausal 
endometrium and interestingly KI67 positivity was lowest in this population.  In the 
functionalis layer of the endometrium when KI67 was highest, during the 
proliferative phase, AR was low.  The stroma had both moderate expression of KI67 
and AR however, a slight decrease in AR was observed during the proliferative 
phase and a slight increase in KI67 was seen during this phase.  Low luminal 
epithelial expression of KI67 was observed in postmenopausal lumen whereas high 
AR expression was seen in this population. 
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5.4.2 KI67 and Progesterone Receptor 
Figure 5-14 - Bar graphs showing median percentage positive and median quickscores with range for the 
immunohistochemical staining of KI67 and PR in isthmic and fimbrial fallopian tube throughout the menstrual 
cycle phases and postmenopause. For details of individual graphs see figures 5-2 and 5-7, respectively. 
 
Progesterone receptor was highly expressed in the fallopian tubes; a decrease in 
expression of this receptor was observed in the postmenopausal samples and this 
also occurred with KI67.  This was the case for both proximal and distal ends of the 
tube. 
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Figure 5-15 - Bar graphs showing median percentage positive and median quickscores with range for the 
immunohistochemical staining of KI67 and PR in endometrial compartments throughout the menstrual cycle 
phases and postmenopause. For details of individual graphs see figures 5-2 and 5-7, respectively. 
Correlation of KI67 and PR in the basalis endometrium showed a decrease in 
expression of both molecules during the secretory phase in both the glandular 
epithelial cells and stromal cells of this layer.  In the functional endometrium, the 
same cyclical pattern of expression exists between KI67 and PR.  There is an 
increase in expression during the proliferative phase and a decrease in expression 
during the secretory phase of the cycling functional glands.  Functional stromal 
expression of KI67 has subtle variation with a decrease in expression during the 
secretory phase which correlates with PR expression during this phase.  The KI67 
expression was low in the luminal epithelia whereas the PR expression dynamically 
changed throughout the menstrual cycle – comparable to the glandular epithelia.     
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5.4.3 KI67 and Oestrogen Receptor Alpha  
 
Figure 5-16 - Bar graphs showing median percentage positive and median quickscores with range for the 
immunohistochemical staining of KI67 and ER Alpha in isthmic and fimbrial fallopian tube throughout the 
menstrual cycle phases and postmenopause. For details of individual graphs see figures 5-2 and 5-9, respectively. 
 
Starting in the distal tube, the expression of ER ALPHA was high throughout.  The 
cyclical pattern of expression had some correlation with KI67 positivity.  Expression 
of ER ALPHA increased during the proliferative phase in the same way that KI67 did.  
Postmenopausal decrease in KI67 correlated with a decrease seen in ER ALPHA 
expression in this region.  The same pattern also occurred in the postmenopausal 
isthmic tube.  In the fallopian tubes however, KI67 was relatively low throughout 
whereas ER ALPHA expression was high.  KI67 was not expressed in tubal stroma 
which was different to ER ALPHA therefore could not be correlated.  
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Figure 5-17 - Bar graphs showing median percentage positive and median quickscores with range for the 
immunohistochemical staining of KI67 and ER Alpha in endometrial compartments throughout the menstrual 
cycle phases and postmenopause. For details of individual graphs see figures 5-2 and 5-9, respectively. 
The basal glands of the endometrium had the same pattern of expression after 
staining for KI67 and ER ALPHA.  There was an increase during the proliferative 
phase and a decrease seen during the secretory phase.  In the stroma of the basalis 
the low KI67 expression in both the secretory and postmenopausal population was 
also expressed with ER ALPHA staining.  KI67 and ER ALPHA correlated in the 
functionalis layer of the endometrium in both the glandular epithelia and stromal 
cells with a decrease in expression during the secretory phase of the menstrual 
cycle.  The luminal proliferative index was low and the ER ALPHA expression was 
moderate with a minor increase towards the secretory phase of the menstrual 
cycle.  The postmenopausal expression was also moderate. 
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5.4.4 KI67 and Oestrogen Receptor Beta  
 
 
Figure 5-18 - Bar graphs showing median percentage positive and median quickscores with range for the 
immunohistochemical staining of KI67 and ER-Beta in isthmic and fimbrial fallopian tube throughout the 
menstrual cycle phases and postmenopause. For details of individual graphs see figures 5-2 and 5-11, 
respectively. 
 
KI67 expression did not correlate with ER-B in the tubal epithelia except for the 
decrease in ER-B seen during the secretory phase in the isthmic tube. Again stromal 
expression of ER-B varied during the cycle however KI67 expression was not evident 
in the tubal stroma.  
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Figure 5-19 - Bar graphs showing median percentage positive and median quickscores with range for the 
immunohistochemical staining of KI67 and ER-Beta in endometrial compartments throughout the menstrual 
cycle phases and postmenopause. For details of individual graphs see figures 5-2 and 5-11, respectively. 
In the basalis endometrial epithelial cells the increased positivity of KI67 during the 
proliferative phase and reduced positivity in postmenopausal samples also occurred 
when the tissue was stained for ER-B.  The basal stroma had low expression of ER-B 
in the secretory cycling population and postmenopausal population therefore 
correlating with KI67 expression.  Moderate expression was seen with both KI67 
and ER-B expression in functional glandular epithelia however the cyclical variation 
with KI67 was not apparent in this population after staining with ER-B.  The same 
expression of KI67 and ER-B occurred in the functional stroma however, with 
moderate staining that remained constant throughout the menstrual cycle.  The 
luminal epithelial proliferative index had little cyclical variability and remained low 
in all population groups.  The ER beta expression was moderate with little cyclical 
variability.  ER beta could be influencing the normal function of the luminal 
epithelia, maintaining the cells in a low proliferative state. 
5.5 Summary of Results and Discussion Points 
5.5.1 Comparing the proliferative index and sex steroid hormone expression 
patterns of endometrial epithelia with fallopian tubal epithelia 
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Sex steroid hormones and their receptors play a major role in the proliferation and 
regeneration of the endometrium every month.  We are still unsure as to whether 
the steroid hormones have the same effect on the fallopian tubal mucosa.  The 
results in this thesis help to gain an insight into the possible proliferative abilities 
of the tubal and endometrial mucosa.  Expression patterns of the sex steroid 
hormones and their association with proliferation has also been analysed in both 
tissues. 
According to the marker of proliferation KI67, the most proliferative compartment 
is the functionalis layer where cell proliferation varies widely according to the 
menstrual cycle phase.  Generally, proliferation is low in the premenopausal tubal 
epithelium and basalis epithelium of the endometrium.  Postmenopausal 
expression of KI67 was very low in both fallopian tube and endometrial mucosa. 
Table 5-4 – Table demonstrating the percentage positive levels of KI67 represented by the symbol + in fallopian 
tube, basalis endometrial epithelia and functionalis endometrial epithelia.  The key below explains the 
corresponding expression levels according to the results shown in figure 5-2. 
KEY 
Quickscore Value/Percentage Positive Representative Symbol for each value 
(+) 
>0 ≤3 OR >0% ≤25% + 
>3 ≤6 OR >25% ≤50% ++ 
>6 ≤9 OR >50% ≤75% +++ 
>9 ≤12 OR >75% ≤100% ++++ 
 
KI67 - Epithelial 
 Isthmic 
Fallopian 
Tubal 
Epithelia 
Fimbrial 
Fallopian 
Tubal 
Epithelia 
Endometrial 
Basalis 
Epithelia 
Endometrial 
Functionalis 
Epithelia 
Menstrual Phase + + + + 
Proliferative 
Phase 
+ + + ++ 
Secretory Phase + + + + 
Postmenopausal + + + NA 
 
The data in this chapter suggests that steroid receptor expression has a unique 
pattern in fallopian tubal epithelial cells.  The most striking feature was the AR 
expression in the epithelia of the fallopian tube.  Epithelial AR was highly 
expressed in fallopian tubes in the premenopausal population.  AR was either 
absent or low in the epithelial cells of the endometrium, however.  AR is mainly 
limited to the stroma of the premenopausal endometrium.  In the 
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postmenopausal population, tubal epithelial AR expression remained high and 
some positivity was observed in the epithelial cells of the endometrium.  
Table 5-5 – Table demonstrating the modified quickscore levels of AR represented by the symbol + in fallopian 
tube, basalis endometrial epithelia and basalis endometrial stroma.  The key above explains the corresponding 
expression levels according to the results shown in figure 5-4. 
AR 
 Isthmic 
Fallopian 
Tubal 
Epithelia 
Fimbrial 
Fallopian 
Tubal 
Epithelia 
Endometrial 
Basalis 
Epithelia 
Endometrial 
Basalis 
Stroma 
Menstrual Phase +++ +++ + +++ 
Proliferative 
Phase 
+++ +++ - +++ 
Secretory Phase +++ +++ - +++ 
Postmenopausal ++++ ++++ + ++++ 
 
From the results and the pattern of AR expression in both mucosae, it could be 
suggested that stromal and epithelial androgen action may be different. AR may 
also influence epithelial cell proliferation. 
Another salient feature from the results in this particular chapter is that after 
observing the expression patterns of ER alpha and beta, the proximal and distal 
portions of the fallopian tube had varying patterns of expression suggesting that 
the two regions respond in a different way to oestrogen. 
Table 5-6 – Table demonstrating the modified quickscore levels of ER α and ER β represented by the symbol + 
in isthmic and fimbrial regions of the fallopian tube.  The key above explains the corresponding expression 
levels according to the results shown in figures 5-9 and 5-11, respectively. 
ER α Isthmic Fallopian 
Tubal Stroma 
Fimbrial Fallopian 
Stroma 
Menstrual Phase +++ + 
Proliferative Phase + +++ 
Secretory Phase + - 
Postmenopausal + + 
 
ER β Isthmic Fallopian 
Tubal Epithelia 
Fimbrial Fallopian 
Epithelia 
Menstrual Phase ++++ ++++ 
Proliferative Phase +++ ++++ 
Secretory Phase ++ ++++ 
Postmenopausal ++++ ++++ 
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The data suggests that proximal and distal fallopian tubal epithelia have unique 
patterns of expression for the steroid receptors, it may be suggested that there is 
a possible barrier created by the isthmus thereby separating the endometrial and 
fallopian tubal mucosa whilst in the premenopausal state. 
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Chapter 6 Effect of Androgens on Matched Fallopian Tubal 
and Endometrial Mucosa 
 
 
6.1 Introduction 
The effect of androgen has been investigated on endometrial tissue however; the 
authors stated that they used androstenedione (A4), a pro-hormone (Bukulmez et 
al).  In this study - dihydrotestosterone (DHT), an active androgen that binds to the 
androgen receptor, was used to treat the cells in vitro.  Other articles have 
published the use of DHT as a treatment in explant culture, including the creation of 
an in vitro model for human prostate.100  The effect of androgen on endometrial 
tissue has not been studied in great detail even though it has been speculated that 
this steroid hormone is important for the normal function of the cycling 
endometrium. 101   Androgen receptor expression was shown to be differentially 
expressed in the tubal mucosa compared to the endometrium (Chapter 5). 
Therefore we hypothesised that the effect of androgen in the two tissues will be 
different.   
Epithelial and stromal cells as well as endothelial cells and leucocytes are included 
in complex solid tissue architecture in both the endometrium and tubal mucosa. 
Correct cellular orientation within this complex architectural organisation and the 
cell-cell interaction is particularly important for the normal function including the 
hormonal responsiveness. For example, this fact is highlighted by the observation 
that the inhibitory effect on endometrial epithelial cell proliferation by 
progesterone is via an indirect effect on stromal cells that increase hand2 and 
supress stromal cell production of FGFs that act on epithelial cells.102  Therefore, 
examining hormonal responsiveness of endometrial cells in vitro requires the 
presence of at least stromal and epithelial cells. Furthermore, the growth in the 
usual 2D environment also may alter the functional ability and gene expression 
profile of cells in comparison to the 3D growth, which is more relevant to the 
existence in vivo. There are previous publications where small tissue samples (1-
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2mm) were grown in short-term (24-72) culture to assess the effect of a variety of 
hormones and drugs where authors have reported preservation of tissue 
architecture and similar data to that observed in vivo.103 Therefore, explant culture 
method - that keeps the normal tissue architecture in 3D and also retains the 
normal cellular components of the endometrium enabling them to exist and 
interact; was chosen as the preferred technique to study the effect of androgens on 
the tubal and endometrial mucosa.  This was the first study to investigate the effect 
of androgens on matched fallopian tube and endometrial mucosa, in explant 
culture.  Previous studies have looked at the effects of androgens on various tissues 
in vitro.   
It is thought that androgens up-regulate their own receptor.  AR was up-regulated 
by DHT treatment in human skeletal muscle in vitro. 104   Testosterone treatment on 
leydig cells of rats also found an increase in AR expression. 105 This needs to be 
investigated in endometrial and fallopian tube tissue in vitro. 
The treatment of fallopian tubes with androgens has not been studied to date.  
Fallopian tube tissue has been treated with progesterone in vitro.  The study found 
that ER alpha and PR mRNAs were down-regulated after treatment.43  This indicates 
that progesterone causes transcriptional changes by down-regulating its receptors.  
This treatment was in isolation and it is important to investigate the function of all 
of the steroid hormone receptors together in order to re-construct an environment 
that is reflective of the in vivo state.    
In this chapter, matched fallopian tube and endometrial tissue has been treated 
with DHT, in explant culture to study the immediate, direct effects that active 
androgens have on these tissues.  The effect that androgen has on proliferation was 
investigated by immuno-staining for Ki67.  The effect of androgen on its own 
receptor, AR has been explored through the use of IHC and RT-PCR techniques and 
the effect of DHT on the marker SOX9 was also studied.   
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6.1.1 Samples and Demographics 
Methods of analysis investigating the effect of androgens on matched tubal and 
endometrial tissue included; treating explant samples with dihydrotestosterone 
(DHT)/ Methanol (Vehicle) for 24 hours and either: embedding the tissue for 
immunohistochemistry (IHC) or RNA extracting the samples for reverse 
transcriptase-PCR (RT-PCR) analysis.  Methods can be referred to in chapter 3.   
Samples included in this analysis were; 4 matched eutopic endometrial samples 
with fimbrial fallopian tube tissue explants.  This sample set underwent IHC staining 
for Androgen Receptor (AR), SOX9 and KI67.  3 matched eutopic endometrial and 
fimbrial fallopian tube explant samples, in the proliferative phase of the menstrual 
cycle were RNA extracted for RT-PCR.  SOX9 and AR gene expression was analysed. 
  Table 6-1 – Patient Demographics for immunohistochemistry and reverse transcriptase-polymerase chain 
reaction explant study 
IHC/RT-
PCR 
Sample 
number 
 Age BMI Smoker Parity 
IHC 4 Mean (± 
SD) 
Median 
Range 
43.5 (±7) 
 
47 
31-49 
30.9 (±8) 
 
28.1 
23.3-
43.9 
1 2 (±1) 
 
1.5 
1-3 
RT-PCR 3 Mean (± 
SD) 
Median 
Range 
42 (±2) 
 
42 
39-45 
32.9 (±6) 
 
36.9 
24.6-
37.2 
0 3 (±1) 
 
2 
2-4 
 
 
 
169 
 
 
 
6.2 IHC Staining of Explants Treated with DHT 
6.2.1 KI67 
Figure 6-1 – Line graph representing the percentage positive KI67 values for N=4 matched eutopic endometrium 
and fallopian tube (fimbrial) samples grown in explant culture for 24 hours with DHT or vehicle (methanol). A) 
Fallopian tubal epithelial staining for KI67 in the untreated mucosa (-DHT) vs the treated mucosa (+DHT). B)  
Endometrial epithelial staining for KI67 in untreated mucosa (-DHT) vs treated mucosa (+DHT).  C)  Endometrial 
stromal staining for KI67 in untreated mucosa (-DHT) vs treated mucosa (+DHT). 
Explants showed some positivity for KI67.  Beginning with the fallopian tube 
explants; low positive staining was evident.  For samples that were not treated with 
DHT, positivity of <10% was observed.  The treated tissue with DHT shows a 2/4 
increase in KI67 positivity (3-5% and 5-10% increase).  One sample remained the 
same and another decreased very slightly (3-1 %). This therefore showed an overall 
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trend towards increasing expression of KI67 after DHT treatment.  Endometrial 
epithelial positivity varied greatly between samples.  In general after DHT 
treatment, KI67 increased in percentage positivity. Endometrial stroma also 
increased KI67 expression after DHT treatment in 2/4 tissue samples.  One treated 
sample’s KI67 expression decreased and another stayed the same.  The samples 
that had a decrease in KI67 expression after DHT treatment were different for each 
compartment therefore no consistent decrease was seen throughout the same 
sample.  Generally however, an increase in KI67 expression can be seen in the 
treated group of explants in comparison to the untreated sample set.  The sample 
size however; makes this impossible to conclude and would need further 
investigation with larger sample sizes.   
6.2.2 SOX-9 
Figure 6-2 - Line graph representing the percentage positive SOX9 values for N=4 matched eutopic endometrium 
and fallopian tube (fimbrial) samples grown in explant culture for 24 hours with DHT or vehicle (methanol). A) 
Fallopian tubal epithelial staining for SOX9 in the untreated mucosa (-DHT) vs the treated mucosa (+DHT). B)  
Endometrial epithelial staining for SOX9 in untreated mucosa (-DHT) vs treated mucosa (+DHT).   
After threshold analysis of each explant stained for SOX9, the fallopian tubal 
epithelia show positivity for SOX9 in both treated and untreated explant tissue 
samples.  2/4 samples showed a decrease in SOX9 expression after treatment with 
DHT, one sample stayed virtually the same and the other increased SOX9 
concentration.  The endometrial epithelia showed half of the samples increasing 
SOX9 expression after DHT treatment, and half decreasing SOX9 expression after 
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DHT treatment.  A prominent trend in both tissue sets was a comparatively lower 
SOX9 expression in the DHT treated tissue to the untreated samples. Expression 
levels of SOX9 were similar for both fallopian tubal epithelia and endometrial 
epithelia. Again, the sample size was small however.   
6.2.3 Androgen Receptor (AR)   
Figure 6-3 - Line graph representing the modified quickscore AR values for N=4 matched eutopic endometrium 
and fallopian tube (fimbrial) samples grown in explant culture for 24 hours with DHT or vehicle (methanol). A) 
Fallopian tubal epithelial staining for AR in the untreated mucosa (-DHT) vs the treated mucosa (+DHT). B) 
Fallopian tubal stromal staining for AR in the untreated mucosa (-DHT) vs the treated mucosa (+DHT).  C)  
Endometrial epithelial staining for AR in untreated mucosa (-DHT) vs treated mucosa (+DHT).  D)  Endometrial 
stromal staining for AR in untreated mucosa (-DHT) vs treated mucosa (+DHT). 
After fallopian tubes were treated with DHT the androgen receptor expression in 
the epithelia increased in all samples in the set in comparison to the vehicles.  
Endometrial epithelia did not change greatly overall.  One sample increased its 
receptor expression, one stayed the same and one decreased its expression. 
172 
 
Therefore a trend could not be seen.  Endometrial stroma increased its receptor 
expression after DHT treatment in comparison to the untreated tissue overall; with 
3/4 of the samples showing higher expression after DHT treatment. In general, it 
seemed as though DHT treatment in tubal epithelia and endometrial stroma caused 
a potential increase in AR expression. Therefore it could be suggested that fimbrial 
tubal epithelial response is comparable to endometrial stroma. Looking at 
expression of AR in both fallopian tube and endometrial tissues; it seems as though 
the strength of expression is higher in the tubes overall.  
6.3 RT-PCR 
Samples were normalised to GAPDH.  This was the reference gene chosen to 
represent the m RNA expression of the markers in this thesis.  See chapter 4 for 
explanation. 
6.3.1 Androgen Receptor 
 
 
 
 
 
 
 
 
Figure 6-4 - Whisker plot graphs with median, minimum and maximum values for AR/GAPDH In N=3, secretory 
phase matched fallopian tube explants +DHT, fallopian tube explants –DHT, eutopic endometrial explants +DHT 
and eutopic endometrial explants –DHT.  
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Reverse transcriptase-PCR (RT-PCR) on fallopian tube and endometrial explants 
showed positive expression of AR relative to YWHAZ and GAPDH.  First, the 
expression pattern was the same with both reference genes, confirming their 
validity as housekeeping genes for endometrial and fallopian tubal mucosa.  
Fimbrial fallopian tube that had been treated with DHT expressed AR at a 
comparatively higher level than the untreated group.  Treated eutopic 
endometrium also expressed AR more highly than the vehicle. Also to note; the 
fallopian tube showed a stronger expression of AR overall than eutopic 
endometrium. Sample numbers were small however, with n=3.  A larger sample size 
would be needed to confirm these results. 
6.3.2 SOX9     
 
Figure 6-5 - Whisker plot graphs with median, minimum and maximum values for SOX9/GAPDH In N=3, secretory 
phase, matched fallopian tube explants +DHT, fallopian tube explants –DHT, eutopic endometrial explants +DHT 
and eutopic endometrial explants –DHT.  
RT-PCR of SOX9 showed positive mRNA expression in both endometrial and 
fallopian tube tissue.  Again, the same expression pattern could be seen with both 
YWHAZ and GAPDH.  In fimbrial fallopian tube, SOX9 was expressed more strongly 
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in the untreated group thus being comparatively less strong after treatment with 
DHT.  The same difference in SOX9 expression was evident in the eutopic 
endometrial samples.  The treated endometrium had less strong SOX9 expression in 
comparison to the untreated endometrium.  Eutopic endometrium had stronger 
SOX9 expression overall compared with the fimbrial fallopian tube.  Again the 
sample size was small and would need increasing for more robust results and 
statistical significance. 
6.4 Comparison of IHC and RT-PCR data 
6.4.1 AR 
A comparison between IHC and PCR data is necessary to see whether protein and 
mRNA expression reflect each other.  In summary, the protein expression of AR 
seems to increase after 24 hours of DHT treatment in both fallopian tubal epithelia 
and endometrial stroma.  The endometrial epithelia remained low and did not show 
a significant change after treatment.  The mRNA expression of AR was 
comparatively higher in the DHT treated group in comparison to the untreated 
group in both fallopian tube and endometrial mucosal samples.  These findings 
seem to be the same as each other; both showing an increase in AR expression after 
DHT treatment in endometrium and fallopian tube.  The protein and mRNA 
expression of AR also seemed to be higher in the fallopian tubal mucosa than the 
endometrium.  The RT-PCR results show expression of endometrial tissue including 
glands and stroma.  The fimbrial fallopian tube tissue is also a mixture of epithelia, 
stroma and some muscularis.  The individual layers cannot be distinguished in this 
experiment however; a consistent trend could be seen in both IHC and PCR data 
suggesting that DHT treatment could have an effect on AR expression. 
6.4.2 SOX9        
On comparison of SOX9 protein and mRNA expression the general trends were the 
same.  In summary; fallopian tubal epithelia expressed higher protein levels of SOX9 
in the untreated sample set.  The endometrium showed an overall reduced protein 
expression in the DHT treated samples due to the larger difference in threshold in 
the samples that had lower expression of SOX9 in the treated group compared with 
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the vehicle tissue.  The PCR data showed higher mRNA expression of SOX9 in the 
untreated tissue compared with the treated tissue in both endometrium and 
fallopian tube.  The PCR data suggests that after 24 hours of DHT treatment a 
decrease in SOX9 expression occurs in comparison to the same tissue that is 
untreated.  The IHC results also showed an overall decrease in SOX9 levels in the 
treated sample group however the data was less conclusive because some tubal 
and endometrial samples were showing an increase in SOX9 expression post-
treatment.  This meant that the overall decrease was very subtle and would need a 
larger sample size and further investigation to produce more conclusive results. 
6.5 Summary of Results and Discussion Points 
6.5.1 The effect of androgen on endometrial and fallopian tubal mucosal 
proliferation and gene expression using a tissue explant culture in vitro. 
The data obtained from this particular study suggested that DHT treatment for 24 
hours increased KI67 expression and up-regulated AR expression in fallopian tubal 
epithelia and endometrial stroma in particular.  RT-PCR mRNA expression of AR 
confirmed the IHC findings. 
Data obtained for the expression of SOX9 showed that DHT treated samples had 
lower mRNA expression of SOX9 in comparison to the untreated controls.  
From the data, it could be suggested that androgens increase the proliferative 
index of fallopian tubal and endometrial mucosa.  Androgens up-regulate their 
own receptor targeting the epithelia of the fallopian tube and stroma of the 
endometrium, specifically.  Finally, androgen reduces/ inhibits SOX9 expression in 
tubal and endometrial epithelia and this could possibly influence proliferation. 
SOX9 is thought to be a suppressor of the Wnt/beta catenin pathway.115 An active 
Wnt/beta catenin pathway may influence proliferation. Suppression of SOX9 may 
activate this pathway thus increasing proliferation. 
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Chapter 7 Discussion 
 
7.1 Investigating Phenotypic Similarities between Fallopian Tube 
and Eutopic Endometrium 
Tubal epithelium exists as a continuum with the endometrial epithelium and these 
tissues share the same embryonic origin. Both epithelia are of columnar phenotype. 
This is different to the cervical epithelium, which also adjoins the endometrium at 
the distal end of the reproductive tract in that it is a stratified squamous epithelium 
and has a well characterised boundary, in the transformation zone.106  As described 
in the introduction and hypotheses of this thesis, although both the endometrium 
and fallopian tubal mucosa have been characterised to some extent individually; 
little direct comparison has been made between both tissues with no exploration 
on a possible boundary between these epithelia, which has seemingly very different 
functions.  When considering the endometrium, although the two functional zones 
are well established both clinically and histologically, there is little data on the 
differences between exact cell types that are located in these zones. Recent 
evidence from our group in Liverpool has revealed some markers that characterise 
the basalis endometrial epithelial cells. This provides a start by which further 
markers can be identified with the possibility to explore functional relevance in the 
different endometrial zones.64, 2   
The work presented in this thesis examines the expression patterns of a variety of 
phenotypical markers that have been proposed to be, or shown to be differentially 
expressed in stratum basalis and functionalis.  The expression of the same markers 
has been examined in both proximal and distal fallopian tubal epithelium to identify 
a similarity between the two epithelia. Discussion below explains the data 
presented in this thesis in the context of the available evidence. 
7.1.1 Basal Cell Adhesion Molecule (BCAM) in Fallopian Tube and Endometrial 
Epithelia 
To my knowledge, this is the first description and comparison of the presence of 
BCAM in the endometrium and tubal epithelium, to date. The results section of this 
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thesis revealed that this molecule was abundantly present in the epithelial cell 
junctions of the fallopian tube and the endometrium.  Similar high expression was 
seen between the fimbrial fallopian tubal epithelia and basal glandular epithelia and 
moderate levels of expression were observed in the functional and luminal epithelia 
of the endometrium.  Proximal tube (isthmic area) showed moderate BCAM 
expression with little cyclical variability.  During the premenopausal menstrual 
cycle; a universal increase of BCAM expression occurred during the proliferative 
phase.  Lower expression was observed in the secretory phase.  The 
postmenopausal tissue (typically non-proliferative) also revealed higher expression 
scores for BCAM staining in the fallopian tube and in the glandular epithelium. 
Basolateral BCAM staining on the epithelial cell surface indicates that there is an 
interaction with laminin which is thought to be important to maintain the typical 
epithelial basolateral polarity associated with differentiated tall-columnar epithelial 
phenotype.98 The observed BCAM staining on the whole surface of the epithelial 
cells may suggest that these cells do not fully engage with laminin in the basement 
membrane, may be less polarised, more mobile and have a less differentiated 
phenotype.  As was described in the results, the tissues tended to have a mixture of 
basolateral and whole cell surface positive BCAM expression.  More whole cell 
surface expression of BCAM could be observed in the basal glandular epithelia, 
suggesting less engagement with laminin than the other compartments.  Basolateral 
junctional staining predominated in the secretory phase in the basal glands.  
Staining was strongly expressed in the basal glandular epithelia during the 
proliferative phase but this was predominantly whole cell surface staining.  This 
suggests that less engagement with laminin occurs during this phase.  
Postmenopausal endometrial BCAM showed a substantial amount of whole cell 
surface and some basolateral expression.   
During the postmenopausal period, both endometrial glands (which are atrophic, 
with a basalis phenotype)59 and tubal epithelia showed intense staining for BCAM 
indicating that; the epithelial cells in this region are similarly engaged with laminin 
in the postmenopausal period - which is typically in a hypo-oestrogenic state. 
Furthermore, this may also suggest that fallopian tube and endometrial epithelial 
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cellular engagement with laminin (in the basement membrane) exists as a 
continuum and are therefore, similar.  Messenger RNA expression for BCAM in the 
postmenopausal fallopian tube and matched endometrium was similarly higher in 
comparison to the same of the pre-menopausal secretory phase samples. This may 
support the hypothesis that, the epithelia of fallopian tube and endometrial basalis 
have a similar phenotype in the postmenopausal state. The limiting factor in PCR is 
that the mRNA expression reflects the whole endometrium and tubes and 
compartments cannot be split and may contain a different proportion of other cell 
types than the epithelial cells.   
BCAM is also known as Lutheran blood group glycoprotein.  Many refer to this 
molecule as Lutheran/Basal Cell Adhesion Molecule (LU/BCAM). This is because 
even though Lutheran is a known splice variant of BCAM in immunohistochemistry, 
antibodies cannot distinguish between LU and BCAM because both epitopes are in 
the extracellular domain.107  BCAM is a receptor for laminin.65 Laminins are an 
integral component of all basement membranes, 108  and have many cellular 
functions including roles in:  adhesion, motility, growth, differentiation and 
apoptosis.109  BCAM has been found to be present in some epithelial cells in human 
tissue.  Positive expression of this molecule has been found in hepatic epithelial 
cells, haematopoietic cells, chorionic villi of the placenta and the glomeruli, arterial 
cells and tubules of the kidney.110  BCAM has also been found on hair follicles and in 
areas of inflammatory epidermis.111  Presence of BCAM is found solely in 
erythrocytes of the blood.112  Further research would be required to confirm these 
findings in the endometrium and in tubes and to examine if similar functional roles 
of BCAM described in other organs are relevant to the function of BCAM in 
endometrial and tubal epithelium.      
7.1.2 (Sex Determining Region Y)-Box 9 (SOX9) 
The presence SOX9 in matched eutopic endometrial and fallopian tube samples in 
both pre and post-menopausal women was determined using 
immunohistochemistry (IHC) and reverse transcriptase- polymerase chain reaction 
(RT-PCR) laboratory procedures.  SOX9 is a high-mobility-group (HMG) domain 
transcription factor.113 Its nuclear location would therefore support that SOX9 was 
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functional in the cells of expression, which was observed in both eutopic 
endometrial and fallopian tubal epithelia. Threshold analysis using imageJ software 
was used to calculate the percentage of DAB/haematoxylin staining, to quantify the 
expression of this molecule.  SOX9 has been located in many human tissues 
including those in the female and male reproductive tract.2, 59  These include; sertoli 
cells of the testes in males and more recently, in the female endometrial 
epithelia.114, 64   
From the results in this thesis, it can be seen that strong positive staining of SOX9 is 
present in the basalis throughout the menstrual cycle with very strong positive 
staining in the postmenopausal state. In previous studies, the endometrial epithelia 
were found to express SOX9 abundantly in the basalis layer of the endometrium. 
SOX9 expression was also very high in the postmenopausal endometrium.64, 2  
Postmenopausal endometrium retains the basalis phenotype, which subsequently 
stores the progenitor cells in this region.2, 59  With this in mind, the high expression 
of SOX9 in the basalis and postmenopausal epithelia suggests that there may be a 
tissue specific role for SOX9 in this region.  It has also been suggested that SOX9 
influences the proliferation capacity of epithelial cells.  There is some evidence 
surrounding this.  An article by Akiyama et al suggested that cross-talk between 
SOX9 and β Catenin (Wnt pathway) influenced the proliferative abilities of 
chondrocytes.  They found that when SOX9 was overexpressed in mutant mice this 
resulted in inhibition of proliferation forcing differentiation of chondrocytes.  These 
changes were also evident in beta catenin inactivated mice, thus suggesting that 
interaction between these two molecules may control a chondrocyte’s ability to 
differentiate and proliferate.115  This was however an animal study, performed on 
mice and further research would be necessary to confirm if a similar phenomenon 
occurs in human tissues.  Other studies have supported these findings for example; 
haploinsufficieny of SOX9 in humans causes premature skeletal mineralisation.116  
Relating this evidence to the results; the high expression of postmenopausal 
epithelial SOX9 would be expected because the tissue is in a quiescent, non-
proliferating state, yet the Wnt/ β catenin pathway is not expected to be active in 
inactive epithelial cells.  The functional epithelial expression of SOX9 was generally 
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less strong than the basal compartment, which agrees with the possibility that the 
activated stem cell containing basalis epithelium which is expected to have an 
active, Wnt/β catenin pathway also has high SOX9 expression likely to regulate and 
harness the proliferation process. 
Relating this evidence to the fallopian tubes, both distal and proximal fallopian 
tubal epithelia showed high expression of SOX9. Particularly high expression was 
evident in the postmenopausal epithelia which was comparable to the basal 
glandular epithelia.  If strong presence of SOX9 indicates that epithelial cells are in a 
more quiescent, non-proliferating state; this would suggest that tubal epithelia are 
more quiescent or exhibiting a less differentiated phenotype in the postmenopausal 
period.  Similarly, more proliferative pre-menopausal tubal epithelia also showed 
high nuclear SOX9 expression and theoretically this would be beneficial because this 
would deter a blastocyst from implanting in the fallopian tube and therefore allow 
its transport towards the functional endometrium where implantation normally 
takes place.  This also provides evidence to suggest that tubal epithelial cells are 
phenotypically similar to basal glandular epithelial cells. 
The PCR data showing expression patterns of SOX9 relative to GAPDH supports all 
of the evidence above.     
Further research would be necessary to confirm the role of SOX9 in proliferation 
and differentiation in both endometrial and fallopian tubal cells.  Hypothetically, 
tubal pathology could also be associated with a loss of SOX9 expression.  This 
highlights the direction for research that could investigate this further. 
7.1.3 Stage Specific Embryonic Antigen-1 (SSEA-1). 
Immunohistochemistry was performed in matched eutopic endometrial and 
fallopian tubal samples to determine the presence of SSEA-1 (also known as Lewis X 
or CD15).  The staining pattern was observed and quickscore methods of analysis 
were used to record its presence. 
The antigenic epitope SSEA-1 or Lewis X carbohydrate has a role in the adhesion 
and migration of the preimplantation mouse embryo.117  It is a cell surface marker 
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and cell surface staining was observed on the endometrial and fallopian tubal 
epithelia after IHC.   
In this study, human fallopian tubes were compared with endometrium to examine 
whether any similarities were present between the fallopian tubal epithelia and 
glandular epithelia of the basalis/functionalis compartment of the endometrium.  
Basal glandular epithelia strongly expressed SSEA-1 in comparison to the functional 
epithelia. SSEA-1 has previously been found to accumulate in the basalis 
compartment of the endometrium - the region where progenitor cells reside.  
Studies in our lab discovered that SSEA-1 was strongly expressed in human 
glandular epithelia in the stratum basalis region of the endometrium. Endometrial 
cells were isolated on their expression of SSEA-1 and grown in 3D culture.  The 
SSEA-1 expressing cells were found to produce a higher number of endometrial 
gland-like spheroids in comparison to the cells from the same biopsy that did not 
express SSEA-1.2  The study also analysed epithelial SSEA-1 staining patterns and 
menstrual cycle variability in human endometrial samples.  From the results in this 
thesis it can be seen that SSEA-1 was particularly strong in the menstrual and 
proliferative phases which was similar to the staining reported in the previous 
publication that claimed that glandular epithelial expression was stronger in the 
proliferative phase.  Another similarity between this study and the article by 
Valentijn et al.  Was the observation in the postmenopausal endometrial glands; 
where SSEA-1 expression was very strong. It is known already that postmenopausal 
endometrium retains the basalis phenotype and this evidence further confirms that 
this marker is specific for cells that have a phenotypical similarity to the basal 
glandular epithelium of the endometrium.  Luminal epithelia had low SSEA-1 
expression in the postmenopausal population therefore differentiating the luminal 
epithelial cell from the basal glandular epithelial cells.   
With the similarities between these results and the previously reported results from 
our labs – this confirms the reproducibility of the data and thus increases the 
robustness of the findings. 
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SSEA-1 has not been described in the human tubal epithelium before and my results 
show the, premenopausal tubal epithelial expression of SSEA-1 to be low in 
comparison to the basal endometrial glandular epithelia.  This indicates that there 
may be phenotypic differences in endometrial and fallopian tubal epithelia in the 
premenopausal female.  Variability between cycle stages however, was the same in 
both the glandular epithelia and proximal and distal epithelia of the fallopian tube - 
with an increase in SSEA-1 expression during the proliferative phase and very low 
expression during the secretory phase of the menstrual cycle.  This shows that even 
though expression was lower, the expression pattern was similar – indicating similar 
cellular response between tissues.  Another interesting finding was that – a relative 
increase in expression of SSEA-1 was observed in postmenopausal fallopian tubal 
epithelial cells.  This was relative to the cycling epithelial expression of SSEA-1 in the 
tubes and was a finding also observed in the postmenopausal glandular 
endometrium.   Similarities in the pattern of the cellular expression of SSEA-1 
existed between both mucosal linings in both pre and postmenopausal women. It 
has briefly been mentioned that SSEA-1 is present in the epithelia of mouse 
oviducts but there was little conclusive evidence from this.  In this thesis, human 
tissue was tested for the presence of this marker to directly compare cells of the 
basalis endometrium and fallopian tubal tissue.118     
This marker was selected because its presence in specific tissue compartments has 
been postulated to indicate that primitive, progenitor cells may reside in those 
particular regions.  As has been previously stated; epithelial progenitor cells are 
likely to reside in the basalis compartment of human endometrium.119 This was 
considered because of the basalis compartment’s remarkable capacity to 
regenerate the functionalis layer of endometrium every month under steroid 
hormonal regulation. Evidence for this theory was first provided by Chan et al. who 
discovered clonogenic epithelial and stromal cells residing in the human 
endometrial tissue.120  Further research has expanded on this and has lead 
researchers to believe that a stem cell population resides primarily in the basalis 
compartment of human endometrium.  Recently, it has also been thought that the 
distal fallopian tubal mucosa may also contain a stem cell population,4 an increase 
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in cells expressing markers that were shown to be stem cell markers in other 
tissues, were identified here.1 This suggests that in the fallopian tube, the distal 
mucosa may be the equivalent to stem cell-rich endometrial basalis. The increase in 
expression of SSEA-1 in postmenopausal fallopian tubal epithelia provides evidence 
to suggest that the fallopian tubal mucosa becomes phenotypically more similar to 
the stem cell-rich endometrium, after menopause. 
7.1.4 Beta Catenin 
Beta catenin was localised to the cell nucleus, cytoplasm and junctions after IHC 
staining of endometrial and fallopian tubal tissue.  Here we focus on the nuclear 
and cytoplasmic staining as these cellular locations informs us about beta catenin’s 
involvement in the Wnt pathway.   
In this thesis, the results show that there is an increase in cytoplasmic beta catenin 
expression during the proliferative phase of the menstrual cycle in endometrial and 
tubal epithelia, especially in the basalis compartment of the endometrium and 
fimbrial tubal epithelia.  It has been found previously that endometrial positivity for 
beta catenin increases during the proliferative phase.121   Thereby suggesting that 
these particular cells have the capacity to proliferate and differentiate.  It has also 
been found that beta catenin is essential for normal endometrial epithelial function 
and glandular formation.  Overexpression has been found to cause hyperplasia in 
mice.122  From the results nuclear expression of beta catenin was low – a select 
population of nuclei were positive for this molecule in the basalis compartment of 
the endometrium.  This supports the results made previously in our labs, studying 
beta catenin expression in normal endometrium.64  Cytoplasmic positivity was 
stronger and more evident therefore quickscore levels were higher throughout.  
Again, like nuclear staining; cytoplasmic beta catenin was highest in the basalis 
region suggesting that this molecule resides here in the regenerative layer, like the 
intestinal crypts. The Wnt pathway is known to be involved in cellular 
differentiation, proliferation and migration.123  In the absence of Wnt protein 
molecules; beta catenin is degraded by its phosphorylation at its N terminus.  In the 
presence of Wnt this does not happen and beta catenin is allowed to accumulate in 
the cytoplasm and translocate to the nucleus where it can interact with HMG box 
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family and together, activate target genes.  It has been found that activation of beta 
catenin in chondrocytes results in an increase in cell proliferation and 
differentiation.124  The Wnt pathway is important in the organisation of the 
intestinal epithelium including maintaining cells in their undifferentiated state.  It 
has previously been found that loss of beta catenin results in a loss of intestinal 
epithelial cells in the intestinal crypts – the site where regeneration takes place.125  
The presence of beta catenin in fallopian tubal epithelia is yet to be compared to 
the endometrium.  Expression of nuclear beta catenin was low in this study but 
cytoplasmic accumulation of this molecule was moderate in the fallopian tubes.  
The distal fallopian tube saw an increase in cytoplasmic accumulation of beta 
catenin during the proliferative phase, similar to the expression pattern in the basal 
endometrial glands. Beta catenin was been shown to be expressed for the first time 
in fallopian tubal tissue in humans in 2013.  The article compared normal fallopian 
tubal epithelia with pathological tubes that had ectopic pregnancy.  The study found 
that beta catenin was located in the epithelial portion of the tube.  The study also 
found that women with salpingitis or ectopic pregnancy had significantly higher 
beta catenin expression than in the normal fallopian tube samples.  They did not 
evaluate the expression throughout the menstrual cycle nor did they compare it to 
endometrial glandular epithelia.126  Supporting evidence has claimed that an 
increase in beta catenin expression increases the proliferative abilities of an 
epithelial cell.115  Presence of this molecule in the fallopian tubes and its relatively 
large variation between cycle stages in comparison to the endometrial glandular 
epithelia provides evidence to show that tubal epithelial cells are responsive to the 
Wnt pathway and have some differentiation and proliferative abilities. 
A unanimous finding, in both tissues was that cytoplasmic beta catenin increased in 
the postmenopausal population.  Nuclear beta catenin remained low however; with 
a small subpopulation of positive cells.  Even though the postmenopausal epithelia 
are in a quiescent state; accumulation of cytoplasmic beta catenin could suggest 
that the epithelial cells in this population have the capacity to differentiate, thus 
making them more susceptible to hyperplastic or metaplastic changes. The low 
nuclear expression suggests that beta catenin may be prohibited from entering the 
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nucleus in this population. The progenitor cells in the postmenopausal 
endometrium could be the cells that are strongly positive for this molecule thus 
more vulnerable to change.  It may also be suggested that tubal epithelial cells have 
a similar phenotype to glandular epithelial cells in the postmenopausal population.   
7.1.5 Sialylated SSEA-1 (Sialyl-SSEA-1) 
IHC analysis with representative quickscore data showed the expression of this 
marker on the cell surface of epithelia in matched endometrial and fallopian tube 
samples.  
From the results it can clearly be seen that luminal epithelia of the endometrium 
were strongly positive for Sialyl-SSEA-1. The embryo attaches to the endometrial 
luminal epithelia at implantation therefore this would support previous evidence.  
The pattern of expression throughout the menstrual cycle however was not 
significantly different between phases therefore a larger sample size would be 
needed in order to confirm that Sialyl-SSEA-1 was abundant particularly during the 
implantation period.  The glandular epithelia showed some positivity but was 
generally weaker.  Postmenopausal endometrial expression of Sialyl-SSEA-1 was 
moderate in both the glandular epithelia and lumen suggesting that expression 
continues.  Similar expression was observed therefore showing phenotypical 
similarities between these cells in the postmenopausal state.  Hey et al.  Described 
the presence of Sialyl-SSEA-1 in human endometrium. The authors claimed that 
there was a link between this and the marker MUC1.  MUC1 has been found to be 
abundantly expressed during the implantation period and is thought to play a role 
in the promotion of adhesion for implantation. Here, the authors linked this marker 
with Sialyl-SSEA-1 - claiming that expression patterns throughout the menstrual 
cycle were similar, in particular the increase shown to occur during the secretory 
phase.82  Therefore it was speculated that Sialyl-SSEA-1 is associated with 
implantation of the embryo in endometrial tissue.   
Sialylated SSEA-1 or Sialylated Lewis X is a selectin ligand.  It is known to be an 
essential carbohydrate ligand for human sperm-egg binding.  This is because this 
oligosaccharide is most abundantly present as the terminal sequence on the N- and 
186 
 
O-glycans of the human zona pellucida (extracellular matrix of the oocyte).99  It has 
a role in the adhesion of various cancer cell types to endothelial cells127  
If Sialyl-SSEA-1 was the key component for adhesion during implantation; it would 
be expected that the tubal epithelial cells would be negative for this marker given 
that implantation would not normally occur in this site.  Interestingly the tubal 
epithelia, particularly at the isthmic end, strongly expressed this marker in this 
thesis.  There was a reduction of Sialyl-SSEA-1 during the proliferative and increased 
expression during the secretory phase.  It could be speculated that the presence of 
this marker has a different role in the premenopausal fallopian tube.  After 
ovulation, fertilisation occurs. There has been evidence to believe that in mammals; 
a sperm reservoir is formed in the isthmic fallopian tube after it has entered the 
uterus and ascended towards the fallopian tube in order to fertilise the oocyte.  The 
sperm is thought to stick to ciliated epithelial cells through the binding of 
carbohydrate residues on the surface of these cells. 128  This is thought to be present 
in order to restrict the amount of sperm entering the ampulla to promote a single 
sperm entering the oocyte and thus avoid polyspermy.129  With this in mind, a 
recent study in goats found that Sialyl-SSEA-1 was present on the oviductal 
epithelia.  It was particularly abundant in the isthmic and ampullary portion of the 
fallopian tube.  The authors suggested that this marker could have a role in the 
creation of a sperm reservoir.130  From the results in this thesis; it can be seen that 
in human tissue - the isthmic region of the fallopian tube abundantly expresses this 
marker. This data would expand on and support the suggestions made in previous 
studies in other mammals and would suggest that the proximal end of the fallopian 
tube is a reservoir for sperm in the premenopausal woman.  Further studies would 
need to confirm this and functional studies could be performed. Postmenopausal 
expression of Sialyl-SSEA-1 was abundant in the fallopian tube as well as the 
endometrium. The functional relevance of this is yet to be confirmed. 
7.2 Investigating Sex Steroid Hormone Receptor Expression and 
Proliferation in Human Fallopian Tube and Endometrium 
 
7.2.1 KI67 and Proliferation 
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KI67 is a protein that indicates the proliferative ability of a cell.  It marks the growth 
fraction of a cell population and is located in the nucleus.84  When a cell is positive 
for this protein after IHC staining - the DAB is clearly visible under a light microscope 
which enables accurate counting of positive cells and subsequent determination of 
the fraction of proliferating cells in the area of tissue being analysed.  
Overexpression of this marker has also been implicated in various cancers for 
example; breast cancer.  When cells are in the resting state KI67 is not present.84 
From the results it can be seen that the glandular epithelia in both the basalis and 
functionalis layers of the endometrium undergo cyclical variation with the highest 
KI67 expression in the proliferative phase and lowest during the secretory phase.  
Higher KI67 expression was detected in the superficial glandular epithelia indicating 
that this region has higher mitotic activity and cell proliferation. Stromal cells of the 
functionalis also had proliferative ability and less so in the basal stroma. Every 
month, under hormonal control, the endometrium undergoes cyclical changes 
where the mucosa has a period of regeneration and proliferation, secretion and 
shedding.  KI67 positivity has been detected in glandular epithelial cells of the 
endometrium.  A study by Ilie et al. showed that cyclical variation of this marker 
existed. Higher positivity was observed in the proliferative phase sample population 
in comparison to the secretory phase population (22.5 % and 2 %, respectively).  
This indicated that this marker could accurately demonstrate that during the period 
of increased mitosis and proliferation (the proliferative phase of the menstrual 
cycle) an increase in KI67 occurs.131  This was also stated by Konstantinos et al.  The 
authors also correlated KI67 scores with endometrial carcinoma severity.86  This 
could support the hypothesis that the basalis region is generally less proliferative 
and is the site of the undifferentiated, quiescent, progenitor cells.  Confirmation 
that KI67 is a good marker of proliferative activity was seen in the postmenopausal 
results which showed very little/negligible KI67 expression.  This is due to the fact 
the postmenopausal endometrium is in a more quiescent state.  
KI67 expression in the normal fallopian tube was generally low.  This would be 
expected because the endometrium regenerates and proliferates to promote the 
implantation of an embryo.  The normal fallopian tube however; does not function 
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as a site of implantation thus would be expected to have low proliferation.  There 
was still some cyclical variability at the distal end showing an increase in 
proliferative activity during the proliferative phase.  This could indicate that this 
region’s epithelia has proliferative tendencies under specific hormonal control. The 
proximal tubal epithelia did not show this cyclical variation, suggesting that it is 
phenotypically different to the distal end of the tube. KI67 has been identified in the 
oviducts of mammalian epithelia and its expression has been investigated as a 
marker of proliferation in fallopian tubes with dysplastic changes – to indicate 
whether there was an association with ovarian cancer.132 It has also been analysed 
in the oviducts of pigs to indicate whether steroid receptors affect proliferative 
activity, but not in humans.133  It is necessary to compare this marker with steroid 
receptor expression in the fallopian tubes to deliberate whether proliferation is 
affected by cyclical hormonal changes. Like the endometrial epithelia, 
postmenopausal KI67 expression was very low/negligible indicating that these cells 
also become more quiescent. 
7.2.2 Androgen Receptor (AR) 
Immunohistochemical staining with modified quickscore analysis methods and RT-
PCR techniques were used to study the nuclear expression of this receptor in both 
human endometrium and fallopian tube samples. 
It can be seen from the results that endometrial expression of AR is confined mainly 
to the stromal nuclei. This is in agreement with previous literature.  Stromal 
expression was stronger in the basal compartment compared to the functional 
compartment but both had abundant expression throughout the cycle.  Basal 
stromal expression of AR was highest during the secretory phase.  Glandular 
presence was low which has also been mentioned in previous studies.  This would 
suggest that any effects of androgens on the endometrial glandular epithelia would 
be through the activation of stromal AR – thus an indirect effect.  A statistically 
significant increase in luminal epithelial AR expression occurred in the 
postmenopausal population – showing that the receptor is up-regulated; possibly 
promoting an anti-proliferative state. Androgen levels in the serum undergo cyclical 
changes.  Studies have shown that total and free testosterone and androstenedione 
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have a mid-cycle peak and are relatively higher during the luteal phase.33 Androgen 
receptor activity has been explored in the endometrium.134 A study on AR knockout 
mice revealed that these animals had smaller uteri, abnormal uterine growth in 
response to gonadotrophins, large reductions in the number of pups in each litter 
and abnormal placentation.101 Various studies have reported that the androgen 
receptor is localised predominantly to the stromal cells of the endometrium (barely 
detectable in the glands), with an abundance of receptor expression during the 
proliferative, early and mid-secretory phases.31  After the menopause, AR persists in 
the stromal nuclei.32  
From the results, it can be seen that AR is strongly expressed in the epithelia of 
fallopian tubes.  The first striking difference between the endometrium and 
fallopian tube is that the expression here - is epithelial.  This would suggest that 
androgens have a direct effect on the epithelia of tubal mucosa as opposed to the 
indirect effect on endometrial epithelia.  The strong staining pattern is evident in 
both proximal and distal tubal epithelia with a unanimous decrease in androgen 
receptor expression during the proliferative phase and higher expression during the 
secretory phase.  This reflects the high serum androgen levels that are present 
during the early and mid-secretory phase of the menstrual cycle.33 Both the 
endometrial stroma and the tubal epithelia have high AR expression in the 
postmenopausal population.  RT-PCR results also confirmed this.  Only one previous 
study has mentioned the presence of androgen receptor in human tubal epithelia.  
This was an article written by Nodin et al. in which they identified the abundantly 
positive expression of this receptor in the epithelia of normal fallopian tubes.  They 
were however; comparing this mucosa to epithelial ovarian carcinoma and did not 
analyse this expression in conjunction with cyclical changes, nor did they compare 
the tubal expression with endometrium.34 Interestingly, this study found that 
epithelial ovarian carcinoma had dramatically reduced expression of AR in 
comparison to the normal healthy fallopian tubal tissue.  In this thesis it has been 
found that AR expression is strong in postmenopausal fallopian tubal epithelia.  
Most epithelial ovarian carcinoma cases occur after menopause.135 Therefore, we 
can confirm that that there is a difference in AR expression in normal, healthy 
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postmenopausal women.  The article failed to state whether the normal fallopian 
tube controls were in the postmenopausal or premenopausal state. Combining the 
evidence; it may be that changes/loss of AR expression may be implicated in the 
pathogenesis of epithelial ovarian carcinoma. As suggested in previous articles; AR 
could have an anti-proliferative function and promote the atrophic state that is 
apparent in the postmenopausal period.  The luminal epithelia up-regulates its 
receptor in the same way that the tube does.  This suggests that there is a 
continuum between the endometrium and the fallopian tube in this particular 
population.  
Correlations made between KI67 and AR revealed that tubal expression of KI67 
appeared to be the opposite of the AR expression for example; during the secretory 
phase KI67 decreased and AR increased.  Both endometrial stromal and fallopian 
tubal epithelial AR was strongly expressed in the postmenopausal population 
whereas KI67 expression was negligible. It has also been found that E2 up-regulates 
AR whereas progesterone has been found to down-regulate AR.136  An article by 
Slayden et al. found that anti-progestins up-regulated AR in human endometrium.  
Anti-progestins are known to inhibit endometrial growth therefore it was 
speculated that AR may influence this anti-proliferative effect and promote atrophy 
of the endometrium.137   These studies further point to the hypothesis that AR has 
anti-proliferative tendencies. 
7.2.3 Progesterone Receptor (PR) in Endometrial and Fallopian Tubal Mucosa 
Progesterone is known to down-regulate its own receptor. High concentrations of 
E2 induce PR synthesis.138 Given that the receptor is responsible for gene 
transcription - its presence is detected in the nucleus using immunohistochemistry 
techniques.  The particular clone used in this study recognised both PR-A and PR-B 
isoforms. 
In the present study, the results are in agreement with previous studies. A decline in 
PR occurred in both compartments of the endometrium during the secretory phase 
of the menstrual cycle. The expression was high during the proliferative phase of 
the cycle.  When E2 levels are particularly high.138 This occurred in both the stromal 
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and epithelial cells of the endometrium.  The stromal decline of PR in the basalis, 
during the secretory phase was less evident.  It has been speculated in previous 
studies that there is a need for PR during this phase in the stroma for continued 
growth and differentiation.139  Interestingly, PR expression was high in the 
postmenopausal population in both the stromal and epithelial compartments in the 
current study.  A previous study by Mylonas et al. revealed that PR-A expression 
was high in the postmenopausal population while PR-B expression was low. 140  Both 
PR-A and PR-B was detected with this antibody therefore separate isoforms could 
not be distinguished. 
The steroid hormone progesterone is essential for successful pregnancy to be 
maintained.  It is has essential roles in glandular differentiation and glycogenesis, 
proliferation of stroma and development of pre-decidual cells.138   Progesterone 
receptor has been identified in the human endometrium. It is known that PR varies 
throughout the menstrual cycle.141 From the results shown in this thesis it is also 
evident that PR varies in both the stromal and epithelial cells of the endometrium.  
Due to the high E2 levels during the proliferative phase of the menstrual cycle, PR 
increases in stromal and epithelial cells of the endometrium.140 During the mid - late 
secretory phase a decline in PR expression can be seen – this is due to the fact that 
during this phase, an increase in serum progesterone occurs.142   
In the current study, it seems that high progesterone expression was observed in 
epithelia and stroma of the fallopian tube throughout the menstrual cycle with 
little/no cyclical variation.  This conflicts with evidence from previous studies. 
Functional relevance of this receptor still remains unclear in this tissue.  
Postmenopausal localisation of PR has not been reported previously.  It seems as 
though epithelial PR is reduced but stromal PR remains high.  The stromal PR is 
therefore reflective of the stromal endometrial PR expression.  This suggests a 
phenotypic and possibly functional similarity between the stroma. The reduction of 
PR seen in the epithelial compartment of the fallopian tube suggests a unique 
phenotype of these cells in the postmenopausal population.  In a previous study, 
progesterone receptor was localised to the nucleus of all cell types in fallopian tubal 
mucosa.42 In the same study epithelial cells of the fallopian tubes decreased during 
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the secretory phase and mRNA levels also detected this pattern.  Another study, 
using PCR techniques saw a decline in the secretory phase in relative expression of 
PR.  Treatment of cells with progesterone caused down-regulation of PR-AB and B in 
vitro.  Horne et al.  However only had data collected from PCR techniques which 
would not take into account the individual compartments of the fallopian tube.43  
High exposure of fallopian tubal ciliated epithelial cells to progesterone caused a 
decrease in motility of the cilia leading to dysfunction and possible risk of ectopic 
pregnancy.143  This could explain the high progesterone receptor positivity detected 
in the premenopausal epithelial cells of the fallopian tube because the presence of 
the receptor indicates that there is a low interaction with progesterone in the 
normal fallopian tubal epithelia of the premenopausal female.  This could be the 
optimal environment for ciliary activity to occur and allow smooth transport of the 
oocyte down the fallopian tube.  It has been said that the delicate ratio between 
both PR isoforms is what makes the endometrium vulnerable to pathological 
change.140  This could also be the case in the fallopian tube.  Further functional 
studies are needed to confirm this. 
 Correlating the KI67 marker with PR in the endometrium.  It was observed that PR 
diminished during the secretory phase and KI67 also decreased.  Progesterone is 
high during the secretory phase and a reduction in proliferation is seen during this 
time, typically.  The high PR during the proliferative phase may indicate that the 
receptor influences proliferation in the premenopausal endometrium.  The 
discrepancy that is evident is that PR increases in the postmenopausal population.  
It could be that the particular isoform that dominates (PR-A) in this population may 
have anti-proliferative tendencies when expressed in isolation.  Progesterone 
receptor was highly expressed in the fallopian tubes whereas KI67 expression was 
low throughout, suggesting that this mucosa has unique steroid hormone response 
in comparison to the endometrial mucosa.  The postmenopausal tubal epithelia had 
both reduced PR expression and KI67 expression suggesting an anti-proliferative 
function of PR in this tissue sample.  Studies with immuno-staining for both PR-A 
and PR-B would be useful on postmenopausal endometrial and fallopian tubal 
tissue to see whether one isoform dominates. The luminal expression of PR 
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dynamically changed throughout the menstrual cycle whereas the proliferative 
index remained low.  This suggests that progesterone does not influence 
proliferation in this type of epithelia.  This steroid hormone may have a different 
function here. 
7.2.4 Oestrogen Receptor Alpha and Beta in the endometrial and fallopian tubal 
mucosa   
With the transcriptional effects of ER alpha and beta these receptors are present in 
the nuclei of cells.  IHC techniques can localise these receptors.  Oestrogen 
Receptors alpha and beta have been immunolocalised in the endometrium.  They 
have an essential role in the regulation of endometrial growth.47  
From the current study it is evident that both ER alpha and beta were present in 
human endometrium.  There also seems to be a lack of evidence surrounding the 
compartmental differences in ER expression throughout the endometrial zones.  ER 
alpha expression was higher during the proliferative phase of the menstrual cycle 
and reduced during the secretory phase in glandular epithelia.  This supported the 
evidence by Mylonas et al.  Whose results showed that both oestrogen receptors 
peaked during the proliferative phase of the menstrual cycle and declined in both 
the glandular and stromal tissue during the secretory phase.144 Functional stroma 
had the same pattern of expression as the epithelia.  Basal stroma had lower 
expression of ER alpha but a minor increase during the proliferative phase was 
observed.  In the past it has been suggested that oestrogenic effects occur mainly 
through ER alpha and ER beta modulates oestrogenic action.46    
ER beta expression in basal glandular epithelia appeared to increase during the 
proliferative and secretory phases of the menstrual cycle. The persistent expression 
of ER beta suggests that it may have a different function to ER alpha.  The functional 
glands had consistently high ER beta expression with no variation between phases, 
unlike the dynamic changes occurring with ER alpha. The basal stromal ER beta 
expression increased during the proliferative phase and decreased during the 
secretory phase.  The expression in the basalis was stronger for this receptor, 
suggesting that the receptor is dominant in this compartment. This indicates that it 
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may have a different role to the stratum functionalis.  These results conflicted with 
those of a study conducted by Taylor et al. which claimed that their IHC analysis 
demonstrated that ER beta expression was reduced in the proliferative phase and 
increased in the secretory phase in endometrial glandular epithelia.  Stromal ER 
beta did not correlate with other steroid receptors.145 It has been suggested that ER 
beta could have a different function to ER alpha; as it has been shown that it has 
opposite transcriptional effects after its binding to oestrogen and anti-
oestrogens.146   
The current results found that reduced expression of ER alpha and beta occurred in 
the postmenopausal population in the glandular and stromal compartments. This 
was supported by Mylonas et al. claiming that the postmenopausal endometrium 
has been shown to express ER alpha and beta at lower levels than the proliferative 
endometrium.140  Interestingly, the luminal epithelia had moderate expression of 
both ER alpha and beta in the postmenopausal population, suggesting that these 
receptors are active here.  The interaction between ER alpha and beta receptors 
could be influencing the luminal epithelial phenotype in the postmenopausal state.   
From the current study it was observed that ER alpha had variations in expression 
from the proximal to the distal end of the fallopian tube.  At the distal end of the 
tube, ER alpha was high in both epithelia and stroma during the proliferative phase 
consistent with previous studies on endometrial epithelia. This was also seen in 
endometrium indicating that the function of this receptor is the same in both 
tissues.  The proximal tube had the opposite trend; a higher secretory phase 
expression and lower proliferative phase expression was apparent, in keeping with 
evidence from Shao et al.42  The proximal and distal ends of the fallopian tube 
appear to have different cyclical activation patterns of ER alpha.  Further studies 
would need to confirm this.  
ER beta had differing expression between the proximal and distal ends of the 
fallopian tube.  Fimbrial epithelia had high secretory expression of the receptor, in 
keeping with previous evidence.42  The stroma however had low secretory ER beta 
expression suggesting that both cells have differing functions during this time.  The 
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proximal tubal stroma and epithelia had low expression of this receptor during the 
secretory phase.  The differing ER expression from the proximal to the distal ends of 
the fallopian tube suggests that these cells respond in a different way to each other 
and this may have functional significance.  In keeping with endometrial mucosa in 
the postmenopausal state; the ER alpha expression reduced consistent with the 
atrophic state that ensues throughout.  Interestingly, the ER beta expression 
increased.  This further points to the suggestions that ER beta has a unique 
function. It may even act to inhibit the activation of ER alpha in epithelia given the 
high postmenopausal expression of ER beta and lower ER alpha in the fallopian tube 
and endometrium.   
ER alpha and beta have previously been identified in human fallopian tubes. The 
study by Shao et al.  Identified both oestrogen receptors in the epithelia and stroma 
of the fallopian tube, however little or no ER beta was identified in the stroma.  
They claimed that a mid-secretory increase in both receptors occurred.  ER alpha 
also increased around the late ovulatory phase.  The study however; looked at 
expression of the steroid hormones in solely the ovulatory and secretory phase of 
the menstrual cycle.42 Horne et al.  Identified ER alpha and beta in the fallopian 
tubes and mRNA expression of these receptors were consistently high during the 
menstrual phase. ER beta decreased during the proliferative phase whereas ER 
alpha was highly expressed during this phase and moderate expression was 
observed during the secretory phase of the menstrual cycle for both receptors.43   
Both studies identified that ER was expressed during the secretory phase of the 
menstrual cycle however; the differing expression during the proliferative phase 
suggests that ER beta has a distinct function to ER alpha.  
This is the first study to make a correlation between KI67 and the oestrogen 
receptors in the fallopian tubes.  The comparison showed that the fimbrial tubal 
epithelial expression of ER correlated with KI67 showing that oestrogen receptor 
influenced proliferation in this cell.  Relative expression of Ki67 was low however. 
All tubal epithelia had reduced expression of ER alpha and KI67 postmenopause, 
further suggesting that this tissue is atrophic in this population. ER beta expression 
in the distal fallopian tubes did not correlate with KI67. This suggests that ER beta 
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does not have a proliferative function in this region.  Postmenopausal increase of ER 
beta suggest a non-proliferative or anti-proliferative function for this receptor. ER 
alpha in the endometrium also correlated with KI67 therefore further confirming 
that this receptor influences proliferation.  It has been stated in previous studies 
that ER alpha is associated with proliferation.145 The secretory ER beta expression 
was high and thus did not correlate with KI67 suggesting that this receptor may 
have a more secretory role. 
7.3 Effect of Androgens on Matched Tubal and Endometrial Mucosa 
Females produce and secrete a large amount of androgen, even more so than the 
female reproductive steroid, oestrogen.  Circulating androgens include: 
dehydroepiandrosterone sulphate (DHEAS), dehydroepiandrosterone (DHEA), 
androstenedione (A), testosterone (T) and dihydrotestosterone (DHT).  Even though 
the latter two have the smallest serum concentrations, they are the only two that 
bind to the androgen receptor.147  DHT can be used as a treatment in explant 
cultures to observe the effects of androgens on tissue.  Various tissues have been 
treated in vitro with androgens including the endometrium (to look into factors that 
mediate the induction of aromatase).148  In the current study it was found that the 
androgen receptor was highly expressed in fallopian tubal epithelia.  This differed 
from the mainly, stromal expression seen in the endometrium.   With this in mind, a 
study to compare the effects of androgens on the mucosa of fallopian tubes and 
endometrium enables us to gain an insight into the effects of this steroid on the 
mucosa of these tissues and elucidate any differences that could be observed to 
hypothesise further. This was the first study to look at androgen response in human 
fallopian tubes.  This was a small, preliminary, descriptive study and a larger sample 
size would confirm the findings from this thesis.  
7.3.1 Effect of Androgens on Androgen Receptor 
The current study found that AR protein expression in fallopian tubal epithelia was 
higher in the DHT treated group than the untreated group.  This suggested an up-
regulation of AR under the influence of DHT.  The endometrial stroma had higher 
expression of AR overall, after DHT incubation.  The response of androgens on the 
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androgen receptor in fallopian tubal epithelia demonstrates that the receptor is 
sensitive to the exposure of androgens – this suggests a functional relevance of 
androgens and its receptor within fallopian tubal epithelia. RT-PCR results also 
confirmed that the androgen receptor was at a higher relative expression in the 
samples that had been incubated with DHT.  This has further supported the theory 
that androgens up-regulate their receptor in endometrial and fallopian tubal 
mucosa.  Stronger AR protein and mRNA expression was evident in the fallopian 
tubal mucosa in comparison to the endometrium.  This was also supported by the 
high protein and mRNA expression in the original (non-explant) fallopian tube 
samples.  The functional relevance of this remains unclear.   
It has been found in previous studies that In vitro treatment of tissue with 
testosterone up-regulated the androgen receptor.105  It has also been shown that 
satellite cells from human skeletal muscle increased AR protein expression after 
DHT treatment in vitro.  The authors concluded here, that androgens increased 
muscle mass through mediating differentiation of mesenchymal precursor cells.104  
This further supports the evidence that AR is up-regulated by active androgens.  It is 
known that AR is confined mainly to the stromal compartment of the 
endometrium.31 Therefore androgens would respond mainly to the receptors in this 
compartment.  The up-regulation of this receptor after treatment with androgens 
confirms the previous discussion (see 7.2.2) that androgen receptor varied 
throughout the menstrual cycle in accordance with the cycling serum androgen 
levels in vivo.33 
A brief look at the effect of androgens on proliferation and the transcription factor 
SOX9; may further indicate the role of androgens in endometrial and fallopian tubal 
mucosa.    
7.3.2 Effect of Androgens on Proliferation Marker KI67 
In the normal state, the endometrial stroma and fallopian tubal epithelia had low 
KI67 expression when AR expression appeared to be strongly expressed.  Looking at 
the protein expression of KI67 after being treated with androgens it seemed as 
though there were some mixed results however; a general trend towards a higher 
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KI67 expression after treatment with DHT seemed to be the case in both 
endometrial and tubal mucosa.  With the small sample size it would be difficult to 
make any robust conclusions from this evidence however it may indicate that there 
is a delicate balance between the steroid hormone receptors and their proliferative 
abilities in vivo.  Any change in androgen levels could disturb this balance.  The 
increase in KI67 expression could indicate that under the influence of an excess of 
androgens in otherwise normal tissue, epithelial and stromal cells could be 
vulnerable to changes in capacity to differentiate and proliferate.  High AR 
expression and androgens are a key part in the development and progression of 
prostate cancer even though AR and androgens are required in the normal prostate.  
This demonstrates that any changes in the receptor and its environment could 
make a tissue susceptible to pathological change and increase its proliferative 
index.149 It is also important to note that in vivo, the other reproductive steroid 
hormones are also functioning alongside this hormone.  Therefore further explant 
treatment with progesterone, E2 and androgens on fallopian tubal and endometrial 
tissue would be a more accurate way of simulating the in vivo environment.  
Conclusions could then be drawn from observations made after removal/addition of 
each of the hormones in turn, therefore increasing our knowledge of the 
functionality of these hormones in fallopian tubal and endometrial mucosa.  
7.3.3 Effect of Androgens on SOX9 
The effect of androgens on SOX9 expression in normal fallopian tubal and 
endometrial tissue has not been considered before.  From the current study a 
downward trend was seen in mRNA expression of SOX9 in the samples incubated 
with DHT in comparison to the untreated group.  This suggests that androgens may 
decrease SOX9 expression.  The protein expression of SOX9 was less clear-cut 
however did also show an overall downward trend after DHT treatment in both 
fallopian tube and endometrial epithelia. The transcription factor SOX9 has been 
located in basal epithelia of the prostate, the intestinal crypts and the outer root 
sheath of hair follicles.  Stem and progenitor cells are all thought to reside in these 
particular regions.75  
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Studies have shown that SOX9 overexpression can down-regulate AR.  If androgens 
up-regulate AR and cause a decline in SOX9 – it may be that the decline in SOX9 is 
what facilitates the up-regulation of AR. SOX9 has also be implicated in particular 
pathological events for example prostate cancer.  Prostate cancer cells are known 
to be androgen dependent.  Androgens and androgen receptor are normally found 
in the luminal epithelia of the prostate.  This cell type is known to be more 
quiescent and less proliferative.  When prostate cells undergo malignant change, 
androgen receptor and androgen dependence increases however; their proliferative 
ability also increases.  This could suggest that other pathways and markers could be 
involved in the maintenance and growth of this cancerous cell-type.  This includes 
interactions between SOX9 and the Wnt/beta catenin pathway.150 As described 
previously.115  Cross-talk exists between SOX9 and the Wnt/beta catenin pathway.  
Here it was suggested – when SOX9 is overexpressed pathological change is the 
same as when beta catenin is inactivated.  The active Wnt/beta catenin pathway is 
involved in cellular proliferation and differentiation.  If androgens cause a reduction 
of SOX9 expression, the Wnt pathway may become more active.  As a result; target 
cells could increase their capacity to differentiate and proliferate.  This could mean 
that they are more susceptible to pathological change.  Again, the delicate balance 
between all of the reproductive steroid hormones is necessary and when one 
hormone dominates this can change the phenotypic and functional abilities of a cell.  
Cells that are particularly vulnerable to this change are progenitor cells with the 
capacity to differentiate.    
7.4 General Discussion 
This study was a descriptive analysis, characterising pre and postmenopausal 
fallopian tubal mucosa.  Normal fallopian tubes have not previously been analysed 
using markers that characterise the endometrium.  One of the aims of the study 
was to elucidate whether the fallopian tubes exhibited some phenotypic similarities 
with the basalis layer of the endometrium.  This endometrial compartment is of 
interest because it has the important role of regenerating the functionalis 
compartment of the endometrium every month.151  Its remarkable regenerative 
capability has led to studies to reveal that adult progenitor cells of various 
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phenotypes reside in the basalis compartment of the endometrium and 
postmenopausal, atrophic endometrium.152  As described in the introduction 
section of this thesis; novel evidence has emerged claiming that side population 
cells reside in the distal fallopian tubes that have the capacity to differentiate and 
migrate.  The question that came to mind therefore, was – does the fallopian tubal 
mucosa exhibit phenotypic similarities to the regenerative endometrial mucosa of 
the female reproductive tract that is also thought to contain adult progenitor cells: 
the basalis compartment of the endometrium? The markers that are known to 
phenotypically identify the basalis layer of the endometrium were tested and 
analysed on matched human fallopian tubal samples. 
After having discussed the individual markers it is necessary to consider the tubal 
and glandular epithelia as a whole.  It can clearly be seen that some similarities exist 
between the mucosae and some variations were also seen from the proximal to the 
distal end of the fallopian tubes themselves.   
Considering the results for BCAM, the receptor for laminin (EI Nemar et al), the 
fimbrial fallopian tubal epithelia had high expression of this molecule, which was 
also the case in the basal glandular epithelia.  The other compartments and 
proximal tube had moderate expression of this molecule.  This suggested that there 
was a similarity between the distal fallopian tubal and the basal glandular 
engagement with laminin in the epithelial cells.  This was further supported by the 
evidence that an increase in expression of BCAM occurred in the postmenopausal 
samples.  This suggested that phenotypical similarities exist between the tubal and 
endometrial epithelia.   
SOX9 is a transcription factor found to be abundantly expressed in the basalis 
region of the endometrium, it has also been located in tissues that contain a stem 
cell population and have regenerative capacity.64, 75  The results confirmed the 
strong presence of this molecule in the basalis region of the endometrium and 
interestingly, the fallopian tubes were also strongly positive for this marker.  This 
gives a good indication that the tubal epithelial cells share this phenotypical 
resemblance to the basalis layer of the endometrium.  This was reiterated by the 
201 
 
strong presence of SOX9 in the postmenopausal epithelia of the endometrium and 
fallopian tube. Strong SOX9 expression in postmenopausal, atrophic tissue (with the 
capability of regenerating under the correct hormonal stimuli)153 supports the 
theory that this marker resides in basal tissue regions that contain quiescent, 
progenitor cells.  The strong presence of this in fallopian tubal epithelia could 
suggest that cells residing in this region have stem-like properties.  Analysis of 
fallopian tubal epithelia for stem-cell markers would be required to confirm this.  
Beta catenin is a downstream molecule in the Wnt pathway.  There is evidence to 
suggest that cross-talk exists between this molecule and SOX9.115  The intestinal 
crypts, the prostate and the endometrium require this interaction in order to 
function as a regenerative tissue.  An interesting finding was that cytoplasmic beta 
catenin increased in the postmenopausal population (glands and tubal epithelia) 
but nuclear beta catenin remained low.  SOX9 expression was particularly high in 
this population suggesting that there may be an interaction between this molecule 
and beta catenin, interfering with the accumulation of beta catenin in the nucleus.  
With this in mind, the capacity for the epithelia to differentiate and regenerate may 
be reduced and a quiescent-type cell could remain. 
SSEA-1 a surface marker, varied throughout the menstrual cycle in the same way 
that the basalis endometrial epithelia did.  As previous studies have found, SSEA-1 
was particularly strong in the basalis compartment.2 Tubal epithelial expression was 
weaker in the cycling endometrium however; a relative increase in expression at 
both the proximal and distal ends occurred in the postmenopausal samples.  This 
was also the case with the basal glands.  Luminal epithelia remained low.  As with 
the markers above, it seems as though the cells become phenotypically more 
similar to the glandular epithelial cells after menopause.  Not only is this the case, 
SSEA-1 is thought to be present in tissue regions containing progenitor cells.  The 
positivity suggests that a population of cells exist in the tube that phenotypically 
resemble the basal glandular epithelia. 
As described in section 1.1.5, sialylated SSEA-1 is essential for sperm-egg binding.99  
The reason this marker was investigated was because it is thought to play many 
roles in the adhesion of cells in the body.  It is abundantly present on the lumen of 
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the endometrium because it is believed to play an important role in the adhesion 
process of the embryo during implantation.  An interesting finding was that tubal 
epithelia (especially at the proximal end) were highly positive for this molecule.  
Another theory drawn from these findings was that this marker indicated that there 
was adhesive properties of epithelia particularly in the proximal tube so that the 
epithelia could create a sperm reservoir for adequate control of sperm entering the 
ampulla. This has been discussed previously.128 
Proliferative tendencies in the epithelia of the fallopian tubes were low.  A slight 
increase during proliferative phase, in the distal tubal epithelia indicated that 
proliferation was cycle-dependent, to some extent.  The endometrium had the 
classical proliferative pattern of an increase during proliferative phase and decrease 
during secretory phase. Negligible KI67 in the postmenopausal samples confirmed 
the atrophic state that is adopted in the tissue during this period. 
Steroid receptors have been studied in some detail in endometrial tissue.  There has 
been evidence that the receptors also reside in fallopian tubal tissue however; some 
of this has been conflicting.  Most of the normal tissue has been compared with 
pathological events occurring in the tube for example; ectopic pregnancy.  This 
study has aimed to compare the fallopian tubal mucosa with normal endometrial 
mucosa in pre and postmenopausal women.  This is beneficial to see whether 
fallopian tubes respond to steroid hormones in the same way that the 
endometrium does throughout the menstrual cycle. 
Combining all of the evidence from section 7.2 - some interesting findings became 
apparent in the fallopian tubes.  Androgen receptor (AR) was strongly expressed 
throughout the fallopian tubal epithelia.  This differed from the stromal expression 
observed in the endometrium, showing that androgens directly affect the epithelia 
in fallopian tubes.  There was cyclical variation with a reduction in receptor 
expression during the proliferative phase and stronger expression during the 
secretory phase.  Postmenopausal expression was high.  This suggested that when 
receptor expression is high cells seem to be of a less proliferative type and have a 
more secretory role. The promotion of proliferation has been linked to the 
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expression of oestrogen receptor alpha (ER alpha).47  In the distal fallopian tube, 
higher expression during the proliferative phase and reduction of expression in 
postmenopausal samples would support the evidence above.  Interestingly, ER 
alpha and beta seemed to have opposing expressive tendencies throughout the 
menstrual cycle.  Postmenopausal expression of ER beta increased while ER alpha 
decreased.  The distal tubal epithelial expression of ER alpha increased during the 
proliferative phase.  The proximal tubal mucosa seemed to have the opposite 
receptivity to steroid hormones.  ER alpha was higher during the secretory phase 
and ER beta was low during this phase.  This region could experience more growth 
and differentiation during the secretory phase of the menstrual cycle. In fact, the 
higher secretory phase expression of ER alpha was shared with the luminal 
epithelia.  A functional similarity may occur in the premenopausal cycling female.  
Progesterone receptor was high throughout the menstrual cycle in the tubes 
suggesting that progesterone does not interact with these cells, particularly - which 
would be beneficial in this region as implantation does not occur here.  A decrease 
in receptor expression occurred in the postmenopausal proximal tubal epithelia 
indicating that the receptor is being down-regulated here. 
A small, preliminary study observing the effects of active androgen (DHT) on 
endometrial and fallopian tubal mucosa was conducted. Previous studies showed 
that active androgens up-regulate their receptor.105  This was also observed in this 
current study.  Although androgen receptor expression suggests a secretory role in 
a cell, high exposure to active androgens has indicated that proliferation increases.  
This would suggest that any small increase in exposure to this steroid hormone 
could change the function of a cell.  This is supported by the role of androgens in 
prostate cancer. Androgens play an important part in promoting cancerous change 
in this particular tissue (Heinlein CA et al). Exposure to Androgens seems to reduce 
expression of SOX9.  Overexpression of SOX9 has been linked to an inactive Wnt 
pathway therefore a reduction in expression of SOX9 could activate the Wnt 
pathway.  This could potentially increase the proliferative ability of the target cell.  
The evidence above would suggest that initial, direct exposure to active androgens 
could play a role in carcinogenesis.    
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7.5 Clinical Implications 
This study was a descriptive, characterisation study on a small sample population 
comparing normal fallopian tubal mucosa with endometrial mucosa.  The tissues 
were compared in a normal, healthy state because it is necessary to understand the 
basic phenotype of normal fallopian tubal cells before studying the tube in its 
pathological state. If baseline expression of particular markers or steroid receptors 
is known; then subsequent changes in any of these can be detected in pathological 
tissue and help to gain an insight into the pathogenesis of gynaecological disease. 
To theorise however; in the introduction it was mentioned that high grade serous 
ovarian carcinoma is now believed to begin in the fallopian tubes.  The evidence 
suggested that the fallopian tubal secretory epithelial cell is the cell of origin of this 
aggressive cancer.154  Data suggests that the fimbrial end of the tube is the site of 
origin and studies looking at particular cancer markers have supported this.155  
Recent studies using Fluorescence Activated Cell sorting (FACS) analysis have 
revealed that stem cells are more concentrated in the distal fallopian tube.4  A 
recent pulse-chase study on mice also revealed that quiescent stem-like cells were 
particularly concentrated in the distal fallopian tube and had potential migratory 
abilities.56  This stem cell population could have the capacity to differentiate under 
certain environmental changes.   
Evidence has suggested that an accumulation of abnormalities in gene expression 
occurs after menopause, in the previously benign tube which leads to the 
development of precursor lesions and carcinogenesis.155  As is already known, most 
endometrial carcinogenesis occurs in the postmenopausal period.  This suggests 
that cells residing in these regions are more vulnerable to malignant change.  From 
the results and discussions above it can be seen that the basalis markers increase in 
expression in the postmenopausal endometrial glands.  Not only was this the 
observation, but an increase in the expression of these markers also occurred in the 
postmenopausal distal fallopian tubal epithelia.  This would suggest that the cells of 
the distal fallopian tube become phenotypically more similar to the glandular 
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epithelia.  Positive expression of SSEA-1 and SOX9 is usually evident in tissue regions 
where progenitor cells reside.  This would support the evidence that the distal 
fallopian tube is a region where stem-like cells can be found.  With strong positive 
expression of the basalis markers in postmenopausal endometrial and fallopian 
tubal epithelia, the knowledge that the postmenopausal endometrium is at risk of 
malignant change and the evidence that both tissues contain cells with stem-like 
properties; there could be reason to believe that the postmenopausal distal 
fallopian tubal epithelia is a tissue region that is at risk of carcinogenesis.  
After the menopause, ovarian shut-down occurs and steroid hormone production in 
this organ ceases. This means that circulating levels of oestrogen and progesterone 
dramatically diminish.  Androgens however; are still produced by the adrenal gland 
and although circulating testosterone eventually diminishes, as the transition from 
the pre to postmenopausal state occurs, transient increases in circulating levels of 
this hormone occur.156  From the discussion above it has been suggested that 
exposure to active androgens (without other steroid hormonal exposure) causes an 
up-regulation of its receptor and an increase in the proliferation index of the cell.  It 
could be suggested that the target cell becomes more susceptible to malignant 
change.  With this, and the knowledge that postmenopausal women are exposed to 
transient increases in circulating androgens it could be hypothesised that the 
androgens increase the target cell’s capacity to undergo malignant change. 
The benefits of prophylactic salpingectomy have been considered in order to reduce 
the risk of females developing ovarian cancer.155  With the evidence in this thesis 
linking the postmenopausal tubal epithelia to the endometrial glandular epithelia 
and the current speculation that a stem cell population resides in the fimbria 
making the cells more vulnerable to malignant change, it may be clinically useful for 
females to undergo prophylactic salpingectomy at time of surgery.  Another angle 
to consider is that it could be of long-term benefit for women to have a 
laparoscopic salpingectomy at the time of endometrial ablation.  This could be of 
benefit for three reasons:  one being that this would reduce the patient’s long-term 
risk of ovarian cancer.  The other is that removal of the tubes could reduce the risk 
of ablation failure because one would be removing the other source of progenitor 
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cells in the reproductive tract (which could contribute to the endometrial mucosal 
re-growth that occurs after time). The final reason is that patients who may 
normally have had undergone a hysterectomy for menorrhagia, could have the less 
invasive procedure of ablation which reduces risk.     
7.6 Limitations 
This was a novel study on matched fallopian tubal and endometrial epithelia, thus it 
was not possible to pre-power the sample sizes.  A small sample population was 
selected in order to observe the trends of the selected markers and steroid 
receptors in both tissue populations.   To be thorough in the analysis of the fallopian 
tubal and endometrial mucosa, the samples were split into whether they were pre 
or postmenopausal and their menstrual cycle stage.  Naturally, this reduced the 
sample size in each of the groups.  Another limitation encountered was that ideally, 
each sample would have a full thickness section of endometrium, an isthmic tube 
and a fimbrial tube.  On collection of tissue it is not always possible to collect both 
the isthmic and fimbrial end of a fallopian tube therefore some sections only had 
one end or the other.  This also meant that there were slight discrepancies between 
the quantities of fimbrial or isthmic tubes in each group.  Another limitation to note 
was that this was a novel study in laboratories of The Women’s Hospital which 
meant that prior to the commencement of this project the collected fallopian tubal 
sample size was the sample-set available for staining at the time.  After the study 
began, more matched fallopian tubal samples were collected however; and are 
available for staining at a later date to increase the robustness of the trial. 
Due to the small sample number it was only possible to observe the trends 
occurring throughout the cycle stages and in the postmenopausal samples.  The 
trends were clearly evident but statistical significance could not be determined.  
Further work would be necessary to increase the sample numbers to determine if 
the trend observed would yield statistically significant differences between the 
tissue during each cycle stage and the fallopian tubal and endometrial mucosa.  In 
addition, the use of non-parametric tests on the data collected is more likely to 
produce non-significant P values.   
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Reverse transcriptase-polymerase chain reaction (RT-PCR) was performed on the 
sample population.  This technique is not quantitative.  It was only possible to 
determine the relative expression of mRNA between each of the samples in the set 
(i.e. postmenopausal eutopic endometrium against secretory phase eutopic 
endometrium).  In order to confirm the findings from the results and quantify the 
mRNA expression of the target gene in eutopic endometrium and fallopian tube it 
would be necessary to perform quantitative real time-PCR (qPCR).   
Two housekeeping genes were used in the RT-PCR experiments: YWHAZ and 
GAPDH.  These were used to normalise the expression of the target genes in the 
PCR experiment.  Both of the reference genes have been shown to be expressed in 
the endometrium and fallopian tube – but recent evidence suggests that Ubiquitin C 
(UBC) is the reference gene of choice for both the endometrium and fallopian 
tube.157  It could increase the robustness of the study to have UBC as the third 
reference gene.  Future work could include this. 
7.7 Future Work    
Future work would be needed in order to confirm the trends found during this 
study and thus prove the theories that have been discussed above as this was a 
short-term project over a 12 month period. 
First, the sample size would ideally be increased.  Therefore the markers and steroid 
receptors could continue to be analysed in these tissues, but on a larger scale to 
increase the robustness of the findings. 
The explant analysis of the fallopian tubal tissue produced novel findings.  It would 
however; be of benefit to treat matched fallopian tubal and endometrial mucosa 
with all of the steroid hormones.  In order to gain an insight into the function of all 
of the steroids on fallopian tubal mucosa; it could also be of benefit to combine 
hormonal treatment to see the effect they have on the tissue and then remove one 
of the hormones to see if any change occurs.  This work would help to gain an 
insight into the overall function of the fallopian tube in its normal state - in order to 
subsequently hypothesise further about changes that could occur in tubal 
pathology. 
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Another possible idea for further research would be to observe the effects of the 
treatment of androgens on normal and postmenopausal fallopian tubal and 
endometrial mucosa.  Serum levels of androgens could be measured in every 
patient to quantify the amount of exposure in both pre and postmenopausal 
women.  This would help to increase knowledge about cellular response to 
androgens in the normal postmenopausal woman and to determine whether the 
epithelia are vulnerable to changes in proliferative index under direct exposure to 
this hormone. 
7.8 Conclusions 
It can be concluded from this study that both eutopic endometrial and fallopian 
tubal epithelia uniformly express basalis markers after the menopause.  
Observations included strong SOX9 expression and an increase in SSEA-1 expression 
in the distal tubal epithelia and glands of the endometrium.  The trend indicates 
that there are phenotypical similarities between the tissues.  There is evidence to 
suggest that positive expression of these markers is seen in tissues that contain 
stem cell populations.  With the strong positive expression of these markers seen in 
both tubal and endometrial epithelia after menopause, it could be suggested that 
these regions are where progenitor cells reside.   
It is evident from the findings that dynamic changes in steroid hormone receptor 
expression occur throughout the menstrual cycle in the endometrial and fallopian 
tubal mucosa.  Research has shown that this happens in response to the changes of 
circulating steroid hormones during the monthly cycle.  This is important for the 
normal function of these organs.  There were some fundamental differences in 
receptor expression however; observed between the fallopian tubes and the 
endometrium which would indicate that there are differences in steroid hormone 
response in the premenopausal state.  It would appear that this would be beneficial 
because the endometrium undergoes growth and differentiation in order to 
promote embryo implantation and this is not the function of fallopian tubal mucosa 
in its normal state.   The fallopian tube functions to promote the transport of the 
fertilised embryo towards the implantation site: the uterus. 
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It was apparent that some differences in expression of steroid receptors occurred in 
the proximal and distal ends of the fallopian tube.  ER alpha and beta interaction 
was distinct at both ends.  ER alpha increased during the secretory phase of the 
menstrual cycle in the isthmic fallopian tubal epithelia whereas this receptor 
increased earlier, in the proliferative phase at the fimbrial end.  The expression at 
the distal end of the fallopian tube resembled the expression in the glandular 
epithelia of the endometrium.  The isthmic end did not.  This may be necessary for 
its normal function and could serve a purpose in separating the endometrial 
mucosa from the fallopian tubal mucosa in the premenopausal state.  The 
phenotypic and functional differences could be necessary, particularly at the 
proximal end of the fallopian tube because an embryo should not implant here.  
Any changes in receptor expression at the proximal end of the fallopian tubes (from 
the ampullary region to the isthmus) could increase the likelihood of an ectopic 
pregnancy therefore this particular portion of the fallopian tube would be 
recommended for use as a normal control in research of ectopic pregnancy. 
It can also be hypothesised that a lack of steroid hormone exposure in the 
postmenopausal state causes a change in steroid receptor expression indicating 
that the postmenopausal fallopian tubal and endometrial mucosa undergoes 
phenotypic change due to the sudden decline in the circulating ovarian steroid 
hormone concentrations.  A sudden exposure to a circulating steroid hormone after 
the menopause could alter the cell and make it more vulnerable to malignant 
change.   
It can be concluded that treatment of fallopian tubal and endometrial mucosa with 
the active androgen, DHT, causes an up-regulation of the androgen receptor.  High 
expression of androgen receptor is evident in fallopian tubal epithelia whilst 
androgen receptor expression is predominantly in the stroma of the endometrium.  
This indicates that androgens directly affect the epithelia of the tube whereas there 
appears to be an indirect effect in the endometrium.  The direct treatment of 
endometrial and fallopian tubal mucosa with androgen reduces the SOX9 
expression and increases the proliferative index of the tubal epithelia and 
endometrial stroma. This could be linked to cross-talk between SOX9 and the 
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Wnt/beta catenin pathway with the reduction of SOX9 promoting the activation of 
this pathway and thus increasing the proliferative ability of the cells.   
Further morphological assessment of the fallopian tube would be necessary to 
investigate its contribution towards high grade serous ovarian carcinoma and a 
possible link with endometrial cancer.  The study of changes in hormone receptor 
status would be necessary in order to gain an insight into the pathological 
involvement of the fallopian tube in ectopic pregnancy.  Further investigation into 
the presence of progenitor cells in the distal fallopian tube and their possible 
migratory abilities could assess potential tubal involvement in the pathogenesis of 
endometriosis and regeneration of the endometrium following the endometrial 
ablation procedure.    
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Appendix 
Appendix 1: RT-PCR data Normalised to YHWAZ 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 – Whisker graph representing relative expression of BCAM normalised to YWHAZ for N=3 
postmenopausal fallopian tube, N=3 postmenopausal eutopic endometrium, N=3 secretory phase fallopian tube 
and N=3 secretory eutopic endometrium.  
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Figure 2 - Whisker graph representing relative expression of SOX9 normalised to YWHAZ for N=3 
postmenopausal fallopian tube, N=3 postmenopausal eutopic endometrium, N=3 secretory phase fallopian tube 
and N=3 secretory eutopic endometrium. 
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Figure 3 - Whisker graph representing relative expression of AR normalised to YWHAZ for N=3 postmenopausal 
fallopian tube, N=3 postmenopausal eutopic endometrium, N=3 secretory phase fallopian tube and N=3 
secretory eutopic endometrium. 
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Figure 4 - Whisker graph representing relative expression of SOX9 normalised to YWHAZ for secretory phase N=3 
fallopian tube +DHT, N=3 fallopian tube -DHT, N=3 eutopic endometrium +DHT and N=3 eutopic endometrium - 
DHT. 
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Figure 5 - Whisker graph representing relative expression of AR normalised to YWHAZ for secretory phase N=3 
fallopian tube +DHT, N=3 fallopian tube -DHT, N=3 eutopic endometrium +DHT and N=3 eutopic endometrium - 
DHT. 
 
 
230 
 
Appendix 2:  Patient Information Sheets and Consent Forms 
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